Antigen binding proteins

ABSTRACT

The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.14/974,675 filed Dec. 18, 2015, which is a continuation of U.S.application Ser. No. 13/795,314 filed Mar. 12, 2013, now U.S. Pat. No.9,273,141, which is a continuation of International Application No.PCT/EP2012/059762, filed May 24, 2012, which claims priority to andbenefit of U.S. Provisional Application No. 61/490,732 filed on May 27,2011, which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

The present invention relates to antigen binding proteins and fragmentsthereof that specifically bind B cell maturation antigen (BCMA) and inparticular human BCMA (hBCMA).

The present invention also concerns methods of treating diseases ordisorders with said antigen binding fragments, pharmaceuticalcompositions comprising said antigen binding fragments and methods ofmanufacture. Other embodiments of the present invention will be apparentfrom the description below.

BACKGROUND OF THE INVENTION

BCMA (CD269 or TNFRSF17) is a member of the TNF receptor superfamily. Itis a non-glycosylated integral membrane receptor for the ligands BAFFand APRIL. BCMA's ligands can also bind additional receptors: TACI(Transmembrane Activator and Calcium modulator and cyclophilin ligandInteractor), which binds APRIL and BAFF; as well as BAFF-R (BAFFReceptor or BR3), which shows restricted but high affinity for BAFF.Together, these receptors and their corresponding ligands regulatedifferent aspects of humoral immunity, B-cell development andhomeostasis.

BCMA's expression is typically restricted to the B-cell lineage and isreported to increase in terminal B-cell differentiation. BCMA isexpressed by human plasma blasts, plasma cells from tonsils, spleen andbone marrow, but also by tonsillar memory B cells and by germinal centreB cells, which have a TACI-BAFFR low phenotype (Darce et al, 2007). BCMAis virtually absent on naïve and memory B-cells (Novak et al., 2004a andb). The BCMA antigen is expressed on the cell surface so is accessibleto the antibody, but is also expressed in the golgi. As suggested by itsexpression profile, BCMA signalling, typically linked with B-cellsurvival and proliferation, is important in the late stages of B-celldifferentiation, as well as the survival of long lived bone marrowplasma cells (O'Connor et al., 2004) and plasmablasts (Avery et al.,2003). Furthermore, as BCMA binds APRIL with high affinity, theBCMA-APRIL signalling axis is suggested to predominate at the laterstages of B-cell differentiation, perhaps being the most physiologicallyrelevant interaction.

Multiple Myeloma (MM) is a clonal B-cell malignancy that occurs inmultiple sites within the bone marrow before spreading to thecirculation; either de novo, or as a progression from monoclonalgammopathy of undetermined significance (MGUS). It is commonlycharacterised by increases in paraprotein and osteoclast activity, aswell as hypercalcaemia, cytopenia, renal dysfunction, hyperviscosity andperipheral neuropathy. Decreases in both normal antibody levels andnumbers of neutrophils are also common, leading to a life threateningsusceptibility to infection. BCMA has been implicated in the growth andsurvival of myeloma cell lines in vitro (Novak et al., 2004a and b;Moreaux et al., 2004).

BCMA expression (both transcript and protein) is reported to correlatewith disease progression in MM. Using Affymetrix microarrays, it wasdemonstrated that the TACI and BCMA genes were over-expressed inMultiple Myeloma Cells (MMC) compared with their normal counterparts(Moreaux et al, 2004). Gene expression analysis has been used to comparehuman myeloma cells with purified plasma cells from patients with MGUSand from normal bone marrow as well as with primary tumour cells fromB-cell lineage leukaemias (Bellucci et al, 2005). The BCMA gene washighly expressed in all myeloma samples. Although purified plasma cellsfrom patients with MGUS had lower expression of BCMA, there was nosignificant difference when compared with the expression found in normalplasma cells or myeloma cells. In contrast, BCMA expression wassignificantly lower in B-cell Chronic Lymphocytic Leukaemia (CLL), pre-BAcute Lymphocytic Leukaemia (ALL) and T-cell ALL (T-ALL).

Mouse models that transgenically over-express BAFF or APRIL have asignificant increase in B-cell lymphomas (Batten et al., 2004—BAFF;Planelles et al., 2004—APRIL). In humans, excess BAFF and APRIL havebeen detected in the sera and micro-environments of patients with anumber of B-cell malignancies, as well as other B-cell disorders.

All patent and literature references disclosed within the presentspecification are expressly and entirely incorporated herein byreference.

BRIEF DESCRIPTION OF FIGURES

FIG. 1: FMAT Binding Assay—Figure showing the results of the FMAT assayfor CA8 antibody binding to human and cyno BCMA expressing HEK293 cells.Human chimeric CA8 binds well to human and cyno BCMA expressing cells.

FIG. 2: ELISA Binding Assay—Figure showing the ELISA results for CA8antibodies binding to human and cyno BCMA recombinant proteins. Thisclearly shows that human chimeric CA8 antibodies bind to human and cynoBCMA proteins equally.

FIG. 3: BiaCore Binding Assay—Figure showing the binding of CA8 toBCMA-Fc, TACI-Fc and BAFF-R-Fc proteins in the Biacore experiment. CA8chimera antibody does not bind to TACI or BAFF-R proteins.

FIG. 4: Cell binding assay—Figure showing binding of murine S307118G03,S3222110D07, S332121F02 and S332126E04 to H929 multiple myeloma cellsand S3322110D07, S332121F02 and S332126E04 to the BCMA transfected ARH77cells as determined by FACS.

Multiple myeloma cell line H929 or ARH77-hBCMA 10B5 BCMA expressingtransfectant cells were stained with either murine anti BCMA antibodies(solid histogram) or murine IgG2a isotype control (open histograms).Cells were analysed by FACS to detect antibody bound to the cells.

FIG. 5: Cell binding assay—Figure showing binding of chimeric CA8 to apanel of multiple myeloma cell lines as determined by FACS. Binding toH929, OPM-2, JJN-3 and U266 was tested by flow cytometry and meanfluorescence intensity (MFI) values measured to determine binding.Synagis was used as an irrelevant isotype control.

FIG. 6A and FIG. 6B: Cell binding assay—FIG. 6A showing binding curvesof humanised CA8 variants to BCMA transfected ARH77 cells; and FIG. 6Bshowing multiple myeloma H929 cells as determined by FACS. Humanisedvariants J6M0, J6M1, J6M2, J9M0, J9M1 and J9M2 were tested by flowcytometry and mean fluorescence intensity (MFI) values measured todetermine binding compared to the CA8 chimera.

FIG. 7A, FIG. 7B, and FIG. 7C: Ligand neutralisation assays—FIG. 7A andFIG. 7B showing the ability of CA8 and J6M0 to neutralise binding ofrecombinant BAFF (FIG. 7A) or APRIL (FIG. 7B) to recombinant BCMA coatedon an ELISA plate. OD values were used to calculate the antibodymediated inhibition of the maximal signal achieved by the relevantligand alone binding to recombinant BCMA. Data is reported as percentageinhibition of the maximal signal. Antibodies tested were chimeric CA8and humanised CA8 version J6M0 in both wild type and afucosylated(Potelligent) form.

FIG. 7C showing the ability of J6M0 BCMA antibody in inhibition of BAFFor APRIL induced phosphorylation of NFKappaB in H929 cells. H-929 cellswere washed 3 times to remove any sBCMA and resuspended in serum freemedium. J6M0 potelligent antibody was added to a 96 well plate to give afinal well concentrations up to 100 ug/ml along with BAFF or APRILligand to give a final well concentration of 0.6 or 0.2 ug/mlrespectively. H-929 cells were then plated at 7.5×104 cells/well inserum free medium. 30 minutes later the cells were lysed andphosphorylated NFkappaB levels measured using a MSD pNFkappaB assay. MSDreader 502819. This data was from one independently generatedexperiments. Each data point is the mean/sd of two replicates.

FIG. 8A and FIG. 8B: ADCC assay—Figures showing ADCC activity ofchimeric CA8 and defucosylated (Fc enhanced) CA8 with target cellsexpressing BCMA.

Human NK cells were incubated with europium labelled ARH77 10B5 BCMAtransfected target cells in the presence of varying concentrations ofantibody. Europium release from the target cells was measured andspecific lysis calculated. FIG. 8A: ADCC dose response curves ofchimeric CA8 compared to isotype control. FIG. 8B: ADCC dose responsecurves for chimeric CA8 and defucosylated chimeric CA8 (Fc enhanced),against the BCMA expressing cell line ARH77 10B5.

FIG. 9: ADCC assay—Figure showing ADCC assay on CA8 humanised antibodiesusing ARH77 BCMA expressing target cells.

Human PBMC were incubated with europium labelled ARH77 BCMA transfectedtarget cells in the presence of a range of concentrations of the J5, J6,J7, J8 or J9 series of humanised CA8 antibodies. Europium release fromthe target cells was measured and specific lysis calculated. EC50 valuesare shown in ug/ml.

FIG. 10: ADCC assay—Figure showing ADCC activity of chimeric S322110F02chimeric S322110D07, chimeric S307118G03 and humanised S307118G03 H3L0against ARH7710B5 target cells with purified NK cells as effector cells.Human NK target cells were incubated with europium labelled ARH77 10B5BCMA transfected target cells in the presence of varying concentrationsof antibody. Europium release from the target cells was measured andspecific lysis calculated.

FIG. 11: Viability assay dose response curves—Figure showing doseresponse curves in a cell viability assay for chimeric CA8 antibody,chimeric CA8-vcMMAE and chimeric CA8-mcMMAF antibody-drug conjugates inhuman multiple myeloma cell lines NCI-H929, U266-B1, JJN3 and OPM2.Antibody was added to the cells and the number of viable cells after 96hours measured using CelltiterGlo. Data points represent the mean oftriplicate CellTiterGlo measurements. Error bars represent standarderror.

FIG. 12A, FIG. 12B and FIG. 12C: Impact of CA8 chimeric antibody on cellcycle. FIG. 12A: Cell cycle histograms of NCI-H929 cells treated withunconjugated chimeric CA8, chimeric CA8-vcMMAE ADC or chimericCA8-mcMMAF ADC at 50 ng/mL for the timepoints indicated. Pactitaxel (100nM) was used as a positive control for G2/M cell cycle arrest and celldeath. Control human IgG1 was used as a negative control. Cell cycleanalysis was carried out at the times shown on the graphs. FIG. 12B:Quantification of the 4N DNA cell population indicative of G2/M arrestand FIG. 12C: sub-2N DNA cell population indicative of cell death foreach of the treatments indicated. Cells were seeded in 12-well plates(2×10⁵ cells per well in 1 mL of RPMI+10% FBS). Antibody or ADC wasadded 6 hours after cell seeding.

FIG. 13A, and FIG. 13B: Impact of chimeric CA8 on phospho-histone H3.Chimeric CA8 ADC treatment results in increased phospho-Histone H3staining of NCI-H929 cells.

FIG. 13A and FIG. 13B: Dot plots of cells stained with propidium iodideto measure DNA content (FL3-H) x-axis and anti-phospho-Histone H3(Thr11) antibody (FL1-H) y-axis after treatment with either Control IgGFIG. 13A or chimeric CA8-mcMMAF FIG. 13B. Results show quantification ofphospho-Histone H3 positive NCI-H929 cells after a 48 hour treatmentwith the indicated concentrations of chimeric CA8 ADCs. Pactitaxel (100nM) was used as a positive control for mitotic arrest and controlchimera IgG1 was used as a negative control. Cells were seeded in12-well plates (2×10⁵ cells per well in 1 mL of RPMI+10% FBS). Antibodyor ADC was added 6 hours after cell seeding.

FIG. 14A, and FIG. 14B: Impact of chimeric CA8 on Annexin-V.

Chimeric CA8 ADC treatment results in increased Annexin-V staining ofNCI-H929 cells. FIG. 14A showing histograms of Annexin-V-FITC (FL1-H;top panels) and Live cell propidium iodide staining (FL3-H; bottompanels) after treatment with increasing concentrations of chimeric CA8ADCs. FIG. 14B of Annexin-V positive NCI-H929 cells after a 96 hourtreatment with the indicated showing quantification concentrations ofchimeric CA8 ADCs. Pactitaxel (100 nM) was used as a positive controlfor apoptosis and control chimera IgG1 was used as a negative control.Cells were seeded in 12-well plates (2×10⁵ cells per well in 1 mL ofRPMI+10% FBS). Antibody or ADC was added 6 hours after cell seeding.

FIG. 15: Viability assay dose response curves—Figure showing doseresponse curves for the unconjugated (Naked) and vcMMAE and mcMMAFantibody-drug conjugates of chimeric CA8 or humanized J6M0 antibodies.Antibody drug conjugates were tested against human multiple myeloma celllines NCI-H929 and OPM2.

FIG. 16: Viability assay dose response curves—Figure showing doseresponse curves for the unconjugated antibodies, vcMMAE and mcMMAFantibody-drug conjugates of murine anti-BCMA antibodies S332121F02,S322110D07, S332126E04 and S307118G03 in human multiple myeloma celllines NCI-H929 and U266-B1.

FIG. 17: ADCC activity of ADC J6M0 molecules—Figure showing ADCC assayon J6M0 antibodies using ARH77 BCMA expressing target cells. Human PBMCwere incubated with europium labelled ARH77 BCMA transfected targetcells in the presence of a range of concentrations of J6M0 WT andpotelligent BCMA antibodies conjugated to MMAE, MMAF, or unconjugatedEuropium release was monitored on the Victor 2 1420 multilabel reader.

FIG. 18: ADCC dose response curves of CA8 J6M0 Potelligent against apanel of 5 multiple myeloma lines—Human PBMC were incubated withmultiple myeloma target cells in the presence of varying concentrationsof CA8 J6M0 potelligent antibody at an E:T ratio of 50:1 for 18 hours.The percentage of target cells remaining in the effector plus targetmixture was then measured by FACS using a fluorescently labelledanti-CD138 antibody to detect the target cells and the percentcytotoxicity calculated. Example dose response curves for CA8 J6M0potelligent against the five multiple myeloma cell lines tested—H292,RPMI8226, JJN-3, OPM-2, and U266. Each data point is from a singlicatevalue.

FIG. 19: Effect of dose escalation of J6M0 and drug conjugated J6M0 onthe growth and establishment of NCI-H929 cells in CB.17 SCID mice.Calculated tumour volumes of NCI-H929 tumours in CB17 SCID micefollowing twice weekly intraperitoneal dosing of either 50 or 100 ugJ6M0 anti-BCMA or IgG1 isotype control unconjugated, or conjugated toMMAE or MMAF for 2 weeks. Data points represent mean tumour volume ofn=5 per group

FIG. 20: Determination of soluble BCMA levels in serum from healthyvolunteers and myeloma patients. Serum samples were collected from MMpatient samples were from a variety of stages (progressive disease,remission, relapsed, newly diagnosed, and others). The samples shown inthe figure are those from serum diluted 1/500 prior to the assay.

A Human BCMA/TNFRSF17 sandwich ELISA kit from R& D Systems whichmeasures soluble human BCMA levels was used to detect BCMA following thestandard protocol provided with the kit.

SUMMARY OF THE INVENTION

The present invention provides antigen binding proteins which bind tomembrane bound targets and wherein the antigen binding protein iscapable of internalisation. In a further embodiment there is provided animmunoconjugate comprising the antigen binding protein of the presentinvention and a cytotoxic agent. In a further embodiment the antigenbinding protein has ADCC effector function for example the antigenbinding protein has enhanced ADCC effector function.

The present invention provides antigen binding proteins whichspecifically bind to BCMA, for example antibodies which specificallybind to BCMA and which inhibit the binding of BAFF and/or APRIL to theBCMA receptor. The present invention also provides antigen bindingproteins which specifically bind to BCMA and which inhibits the bindingof BAFF and/or APRIL to BCMA wherein the antigen binding protein iscapable of binding to FcγRIIIA or is capable of FcγRIIIA mediatedeffector function.

The antigen binding proteins of the present invention specifically bindto BCMA and inhibit the binding of BAFF and/or APRIL to BCMA wherein theantigen binding protein has enhanced binding to FcγRIIIA or has enhancedFcγRIIIA mediated effector function. In one embodiment the antigenbinding protein is capable of internalisation.

In one aspect of the invention there is provided an antigen bindingprotein according to the invention as herein described which binds tonon-membrane bound BCMA, for example to serum BCMA.

In one embodiment of the present invention there is provided animmunoconjugate comprising the antigen binding protein of the presentinvention and a cytotoxic agent.

In a further embodiment the antigen binding proteins are conjugated to atoxin such as an auristatin. In yet a further embodiment the drugconjugate is vcMMAE or mcMMAF.

The antigen binding proteins of the present invention are related to, orderived from a murine monoclonal antibody CA8. The CA8 murine heavychain variable region amino acid sequence is provided as SEQ ID NO. 7and the CA8 murine light chain variable region amino acid sequence isprovided as SEQ ID NO. 9.

The antigen binding proteins of the present invention are related to, orderived from a murine monoclonal antibody S336105A07. The S336105A07murine heavy chain variable region amino acid sequence is provided asSEQ ID NO. 140 and the S336105A07 murine light chain variable regionamino acid sequence is provided as SEQ ID NO. 144.

Other murine monoclonal antibodies from which antigen binding proteinsof the present invention may also be derived are included in Table C.

The heavy chain variable regions (VH) of the present invention maycomprise the following CDRs or variants of these CDR's (as defined byKabat (Kabat et al; Sequences of proteins of Immunological Interest NIH,1987)):

CDRH1 is provided as SEQ ID NO. 1 or SEQ ID NO. 182CDRH2 is provided as SEQ ID NO. 2 or SEQ ID NO. 183CDRH3 is provided as SEQ ID NO. 3 or SEQ ID NO. 184

The light chain variable regions (VL) of the present invention maycomprise the following CDRs or variants of these CDR's (as defined byKabat (Kabat et al; Sequences of proteins of Immunological Interest NIH,1987)):

CDRL1 is provided as SEQ ID NO. 4 or SEQ ID NO. 185CDRL2 is provided as SEQ ID NO. 5 or SEQ ID NO. 186CDRL3 is provided as SEQ ID NO. 6 or SEQ ID NO. 187

The invention also provides a polynucleotide sequence encoding a heavychain variable region of any of the antigen-binding proteins describedherein, and a polynucleotide encoding a light chain variable region ofany of the antigen-binding proteins described herein.

The invention also provides a polynucleotide sequence encoding a heavychain of any of the antigen-binding proteins described herein, and apolynucleotide encoding a light chain of any of the antigen-bindingproteins described herein.

Such polynucleotides represent the coding sequence which corresponds tothe equivalent polypeptide sequences, however it will be understood thatsuch polynucleotide sequences could be cloned into an expression vectoralong with a start codon, an appropriate signal sequence and a stopcodon.

The invention also provides a recombinant transformed or transfectedhost cell comprising one or more polynucleotides encoding a heavy chainand/or a light chain of any of the antigen-binding proteins describedherein.

The invention further provides a method for the production of any of theantigen-binding proteins described herein which method comprises thestep of culturing a host cell comprising a first and second vector, saidfirst vector comprising a polynucleotide encoding a heavy chain of anyof the antigen-binding proteins described herein and said second vectorcomprising a polynucleotide encoding a light chain of any of theantigen-binding proteins described herein, in a suitable culture media,for example serum-free culture media.

The invention further provides a pharmaceutical composition comprisingan antigen-binding protein as described herein and a pharmaceuticallyacceptable carrier.

In a further aspect, the present invention provides a method oftreatment or prophylaxis of a disease or disorder responsive toinhibiting or blocking BCMA such as the modulation of the interactionbetween BCMA and its ligands, BAFF or APRIL which method comprises thestep of administering to said patient a therapeutically effective amountof the antigen binding protein thereof as described herein.

It is therefore an object of the present invention to provide atherapeutic approach to the treatment of B cell related disorders ordiseases such as antibody mediated or plasma cell mediated diseases orplasma cell malignancies such as for example Multiple Myeloma (MM). Inparticular it is an object of the present invention to provide antigenbinding proteins, especially antibodies that specifically bind BCMA(e.g. hBCMA) and modulate (i.e. inhibit or block) the interactionbetween BCMA and its ligands such as BAFF and/or APRIL in the treatmentof diseases and disorders responsive to modulation of that interaction.

In another aspect of the present invention there is provided a method oftreating a human patient afflicted with a B cell related disorders ordiseases such as antibody mediated or plasma cell mediated diseases orplasma cell malignancies such as for example Multiple Myeloma (MM) whichmethod comprises the step of administering to said patient atherapeutically effective amount of the antigen binding protein asdescribed herein.

In another aspect of the present invention there is provided a method oftreating a human patient afflicted with Rheumatoid Arthritis, Psoriasis,Type 1 Diabetes Mellitus or Multiple Sclerosis which method comprisesthe step of administering to said patient a therapeutically effectiveamount of the antigen binding protein as described herein.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides antigen binding proteins which bind tomembrane bound targets and wherein the antigen binding protein iscapable of internalisation. In a further embodiment there is provided animmunoconjugate comprising the antigen binding protein of the presentinvention and a cytotoxic agent. In a further embodiment the antigenbinding protein has ADCC effector function for example the antigenbinding protein has enhanced ADCC effector function.

In one such embodiment there is provided antigen binding proteins orfragments thereof which specifically bind to BCMA, for example whichspecifically binds human BCMA (hBCMA) and which inhibit the binding ofBAFF and/or APRIL to the BCMA receptor.

In a further embodiment the antigen binding proteins or fragments of thepresent invention specifically bind to BCMA and inhibit the binding ofBAFF and/or APRIL to BCMA wherein the antigen binding proteins orfragments thereof have the ability to bind to FcγRIIIA and mediateFcgRIIIA mediated effector functions, or have enhanced FcγRIIIA mediatedeffector function. In one embodiment of the invention as herein providedthe antigen binding proteins are capable of internalisation.

In one aspect of the invention there is provided an antigen bindingprotein according to the invention as herein described which binds tonon-membrane bound BCMA, for example to serum BCMA.

In one aspect of the invention there is provided an antigen bindingprotein as herein described wherein the antigen binding proteincomprises CDRH3 of SEQ ID NO. 3 or a variant of SEQ ID NO. 3.

In a further aspect of the invention there is provided an antigenbinding protein as herein described wherein the antigen binding proteinfurther comprises one or more of: CDR H1 of SEQ. ID. NO: 1, CDRH2: SEQ.ID. NO: 2: CDRL1: SEQ. ID. NO: 4, CDRL2: SEQ. ID. NO: 5 and/or CDRL3:SEQ. ID. NO: 6 and or variants thereof.

In one aspect of the invention there is provided an antigen bindingprotein as herein described wherein the antigen binding proteincomprises CDRH3 of SEQ ID NO. 184 or a variant of SEQ ID NO. 184.

In a further aspect of the invention there is provided an antigenbinding protein as herein described wherein the antigen binding proteinfurther comprises one or more of: CDR H1 of SEQ. ID. NO: 182, CDRH2:SEQ. ID. NO: 183: CDRL1: SEQ. ID. NO: 185, CDRL2: SEQ. ID. NO: 186and/or CDRL3: SEQ. ID. NO: 187 and or variants thereof.

In yet a further aspect the antigen binding protein comprises CDR H3 ofSEQ. ID. NO: 3: CDRH2: SEQ. ID. NO: 2: CDR H1 of SEQ. ID. NO:1: CDRL1:SEQ. ID. NO: 4: CDRL2: SEQ. ID. NO: 5 and CDRL3: SEQ. ID. NO: 6.

In yet a further aspect the antigen binding protein comprises CDR H3 ofSEQ. ID. NO: 184: CDRH2: SEQ. ID. NO: 183: CDR H1 of SEQ. ID. NO:182:CDRL1: SEQ. ID. NO: 185: CDRL2: SEQ. ID. NO: 186 and CDRL3: SEQ. ID. NO:187.

The antigen binding proteins of the present invention may comprise heavychain variable regions and light chain variable regions of the inventionwhich may be formatted into the structure of a natural antibody orfunctional fragment or equivalent thereof. An antigen binding protein ofthe invention may therefore comprise the VH regions of the inventionformatted into a full length antibody, a (Fab′)2 fragment, a Fabfragment, or equivalent thereof (such as scFV, bi- tri- or tetra-bodies,Tandabs etc.), when paired with an appropriate light chain. The antibodymay be an IgG1, IgG2, IgG3, or IgG4; or IgM; IgA, IgE or IgD or amodified variant thereof. The constant domain of the antibody heavychain may be selected accordingly. The light chain constant domain maybe a kappa or lambda constant domain. Furthermore, the antigen bindingprotein may comprise modifications of all classes e.g. IgG dimers, Fcmutants that no longer bind Fc receptors or mediate C1q binding. Theantigen binding protein may also be a chimeric antibody of the typedescribed in WO86/01533 which comprises an antigen binding region and anon-immunoglobulin region.

The constant region is selected according to any functionality requirede.g. an IgG1 may demonstrate lytic ability through binding to complementand/or will mediate ADCC (antibody dependent cell cytotoxicity).

The antigen binding proteins of the present invention are derived fromthe murine antibody having the variable regions as described in SEQ IDNO:7 and SEQ ID NO:9 or non-murine equivalents thereof, such as rat,human, chimeric or humanised variants thereof, for example they arederived from the antibody having the variable heavy chain sequences asdescribed in SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27 and SEQID NO:29 and/or the variable light chain sequences as described in SEQID NO:31, SEQ ID NO:33 and/or SEQ ID NO:35.

In another embodiment the antigen binding proteins of the presentinvention are derived from an antibody having the variable heavy chainsequences as described in SEQ ID NO:116 or SEQ ID NO:118 and/or thevariable light chain sequences as described in SEQ ID NO:120, or SEQ IDNO:122.

In another embodiment the antigen binding proteins of the presentinvention are derived from an antibody having the variable heavy chainsequences as described in SEQ ID NO:140 and/or the variable light chainsequences as described in SEQ ID NO: 144.

In one aspect of the invention there is provided an antigen bindingprotein comprising an isolated heavy chain variable domain selected fromany one of the following: SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ IDNO:27, SEQ ID NO:29, SEQ ID NO:116 or SEQ ID NO:118.

In another aspect of the invention there is provided an antigen bindingprotein comprising an isolated light chain variable domain selected fromany one of the following: SEQ ID NO:31, SEQ ID NO:33 or SEQ ID NO:35,SEQ ID NO:120 or SEQ ID NO:122.

In a further aspect of the invention there is provided an antigenbinding protein comprising an isolated heavy chain variable domainselected from any one of the following: SEQ ID NO:11, SEQ ID NO:13, SEQID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ IDNO:25, SEQ ID NO:27 and SEQ ID NO:29 and an isolated light chainvariable domain selected from any one of the following: SEQ ID NO:31,SEQ ID NO:33 and/or SEQ ID NO:35.

In one aspect the antigen binding protein of the present inventioncomprises a heavy chain variable region encoded by SEQ. ID. NO:23 and alight chain variable region encoded by SEQ. ID. NO:31

In one aspect the antigen binding protein of the present inventioncomprises a heavy chain variable region encoded by SEQ. ID. NO:27 and alight chain variable region encoded by SEQ. ID. NO:31.

In one aspect the antigen binding protein of the present inventioncomprises a heavy chain variable region encoded by SEQ. ID. NO:29 and alight chain variable region encoded by SEQ. ID. NO:31.

In one aspect the antigen binding protein of the present inventioncomprises a heavy chain variable region encoded by SEQ. ID. NO:116 and alight chain variable region encoded by SEQ. ID. NO:120

In one aspect the antigen binding protein of the present inventioncomprises a heavy chain variable region encoded by SEQ. ID. NO:118 and alight chain variable region encoded by SEQ. ID. NO:122

In one aspect there is provided a polynucleotide encoding an isolatedvariable heavy chain said polynucleotide comprising SEQ. ID. NO. 12, orSEQ. ID. NO. 14, or SEQ. ID. NO. 16, or SEQ. ID. NO. 18, or SEQ. ID. NO.20, or SEQ. ID. NO. 22, or SEQ. ID. NO. 24, or SEQ. ID. NO. 26, or SEQ.ID. NO. 28, or SEQ. ID. NO. 30 or SEQ. ID. NO. 117 or SEQ. ID. NO. 119or SEQ. ID. NO. 141.

In one aspect there is provided a polynucleotide encoding an isolatedvariable light chain said polynucleotide comprising SEQ. ID. NO. 32, orSEQ. ID. NO. 34, or SEQ. ID. NO. 36 or SEQ. ID. NO. 121 or SEQ. ID. NO.123 or SEQ. ID. NO. 145.

In a further aspect there is provided a polynucleotide encoding anisolated variable heavy chain said polynucleotide comprising SEQ. ID.NO. 24, or SEQ. ID. NO. 28 or SEQ. ID. NO. 30 and a polynucleotideencoding an isolated variable light chain said polynucleotide comprisingSEQ. ID. NO. 32, or SEQ. ID. NO. 34.

In yet a further aspect there is provided a polynucleotide encoding anisolated variable heavy chain said polynucleotide comprising SEQ. ID.NO. 24 and a polynucleotide encoding an isolated variable light chainsaid polynucleotide comprising SEQ. ID. NO. 32.

In yet a further aspect there is provided a polynucleotide encoding anisolated variable heavy chain said polynucleotide comprising SEQ. ID.NO. 117 and a polynucleotide encoding an isolated variable light chainsaid polynucleotide comprising SEQ. ID. NO. 121.

In yet a further aspect there is provided a polynucleotide encoding anisolated variable heavy chain said polynucleotide comprising SEQ. ID.NO. 119 and a polynucleotide encoding an isolated variable light chainsaid polynucleotide comprising SEQ. ID. NO. 123.

In yet a further aspect there is provided a polynucleotide encoding anisolated variable heavy chain said polynucleotide comprising SEQ. ID.NO. 141 and a polynucleotide encoding an isolated variable light chainsaid polynucleotide comprising SEQ. ID. NO. 145.

In a further aspect the antigen binding protein may comprise any one ofthe variable heavy chains as described herein in combination with anyone of the light chains as described herein.

In one aspect the antigen binding protein is an antibody or antigenbinding fragment thereof comprising one or more CDR's according to theinvention described herein, or one or both of the heavy or light chainvariable domains according to the invention described herein. In oneembodiment the antigen binding protein binds primate BCMA. In one suchembodiment the antigen binding protein additionally binds non-humanprimate BCMA, for example cynomolgus macaque monkey BCMA.

In another aspect the antigen binding protein is selected from the groupconsisting of a dAb, Fab, Fab′, F(ab′)₂, Fv, diabody, triabody,tetrabody, miniantibody, and a minibody.

In one aspect of the present invention the antigen binding protein is ahumanised or chimaeric antibody, in a further aspect the antibody ishumanised.

In one aspect the antibody is a monoclonal antibody.

In one aspect of the present invention there is provided an antibodywith the heavy chain sequence as set forth in SEQ ID NO: 55 or SEQ IDNO: 59 or SEQ ID NO: 61.

In one aspect of the present invention there is provided an antibodywith the light chain sequence as set forth in SEQ ID NO: 63 or SEQ IDNO: 65.

In a further aspect of the invention there is provided an antibody withthe heavy chain sequence of SEQ ID NO: 55 and a light chain sequence asset forth in SEQ ID NO: 63.

In one embodiment there is provided an antigen binding protein whichcompetes with an antigen binding protein of the invention as hereindescribed. In one such embodiment there is therefore provided an antigenbinding protein which competes with an antigen binding protein whichcomprises the heavy chain variable sequence of SEQ ID NO 23 and thelight chain variable region of SEQ ID NO 31.

In a further embodiment there is therefore provided an antigen bindingprotein which competes with an antigen binding protein which comprises aheavy chain variable sequence selected from one of SEQ ID NO 27, SEQ IDNO 29, SEQ ID NO 116, SEQ ID NO 118 and SEQ ID NO 140 and a light chainvariable region selected from one of SEQ ID NO 31, SEQ ID NO 120, SEQ IDNO 122 and SEQ ID NO 144.

In another aspect the antigen binding protein binds to human BCMA withhigh affinity for example when measured by Biacore the antigen bindingprotein binds to human BCMA with an affinity of 20 nM or less or anaffinity of 15 nM or less or an affinity of 5 nM or less or an affinityof 1000 pM or less or an affinity of 500 pM or less or an affinity of400 pM or less, or 300 pM or less or for example about 120 pM. In afurther embodiment the antigen binding protein binds to human BCMA whenmeasured by Biacore of between about 100 pM and about 500 pM or betweenabout 100 pM and about 400 pM, or between about 100 pM and about 300 pM.In one embodiment of the present invention the antigen binding proteinbinds BCMA with an affinity of less than 150 pm.

In one such embodiment, this is measured by Biacore, for example as setout in Example 4.

In another aspect the antigen binding protein binds to human BCMA andneutralises the binding of the ligands BAFF and/or APRIL to the BCMAreceptor in a cell neutralisation assay wherein the antigen bindingprotein has an IC50 of between about 1 nM and about 500 nM, or betweenabout 1 nM and about 100 nM, or between about 1 nM and about 50 nM, orbetween about 1 nM and about 25 nM, or between about 5 nM and about 15nM. In a further embodiment of the present invention the antigen bindingprotein binds BCMA and neutralises BCMA in a cell neutralisation assaywherein the antigen binding protein has an IC50 of about 10 nM.

In one such embodiment, this is measured by a cell neutralisation assay,for example as set out in Example 4.6.

The antigen binding proteins, for example antibodies of the presentinvention may be produced by transfection of a host cell with anexpression vector comprising the coding sequence for the antigen bindingprotein of the invention. An expression vector or recombinant plasmid isproduced by placing these coding sequences for the antigen bindingprotein in operative association with conventional regulatory controlsequences capable of controlling the replication and expression in,and/or secretion from, a host cell. Regulatory sequences includepromoter sequences, e.g., CMV promoter, and signal sequences which canbe derived from other known antibodies. Similarly, a second expressionvector can be produced having a DNA sequence which encodes acomplementary antigen binding protein light or heavy chain. In certainembodiments this second expression vector is identical to the firstexcept insofar as the coding sequences and selectable markers areconcerned, so to ensure as far as possible that each polypeptide chainis functionally expressed. Alternatively, the heavy and light chaincoding sequences for the antigen binding protein may reside on a singlevector.

A selected host cell is co-transfected by conventional techniques withboth the first and second vectors (or simply transfected by a singlevector) to create the transfected host cell of the invention comprisingboth the recombinant or synthetic light and heavy chains. Thetransfected cell is then cultured by conventional techniques to producethe engineered antigen binding protein of the invention. The antigenbinding protein which includes the association of both the recombinantheavy chain and/or light chain is screened from culture by appropriateassay, such as ELISA or RIA. Similar conventional techniques may beemployed to construct other antigen binding proteins.

Suitable vectors for the cloning and subcloning steps employed in themethods and construction of the compositions of this invention may beselected by one of skill in the art.

For example, the conventional pUC series of cloning vectors may be used.One vector, pUC19, is commercially available from supply houses, such asAmersham (Buckinghamshire, United Kingdom) or Pharmacia (Uppsala,Sweden). Additionally, any vector which is capable of replicatingreadily, has an abundance of cloning sites and selectable genes (e.g.,antibiotic resistance), and is easily manipulated may be used forcloning. Thus, the selection of the cloning vector is not a limitingfactor in this invention. The expression vectors may also becharacterized by genes suitable for amplifying expression of theheterologous DNA sequences, e.g., the mammalian dihydrofolate reductasegene (DHFR). Other vector sequences include a poly A signal sequence,such as from bovine growth hormone (BGH) and the betaglobin promotersequence (betaglopro). The expression vectors useful herein may besynthesized by techniques well known to those skilled in this art.

The components of such vectors, e.g. replicons, selection genes,enhancers, promoters, signal sequences and the like, may be obtainedfrom commercial or natural sources or synthesized by known proceduresfor use in directing the expression and/or secretion of the product ofthe recombinant DNA in a selected host. Other appropriate expressionvectors of which numerous types are known in the art for mammalian,bacterial, insect, yeast, and fungal expression may also be selected forthis purpose.

The present invention also encompasses a cell line transfected with arecombinant plasmid containing the coding sequences of the antigenbinding proteins of the present invention. Host cells useful for thecloning and other manipulations of these cloning vectors are alsoconventional. However, cells from various strains of E. Coli may be usedfor replication of the cloning vectors and other steps in theconstruction of antigen binding proteins of this invention.

Suitable host cells or cell lines for the expression of the antigenbinding proteins of the invention include mammalian cells such as NS0,Sp2/0, CHO (e.g. DG44), COS, HEK, a fibroblast cell (e.g., 3T3), andmyeloma cells, for example it may be expressed in a CHO or a myelomacell. Human cells may be used, thus enabling the molecule to be modifiedwith human glycosylation patterns. Alternatively, other eukaryotic celllines may be employed. The selection of suitable mammalian host cellsand methods for transformation, culture, amplification, screening andproduct production and purification are known in the art. See, e.g.,Sambrook et al., cited above.

Bacterial cells may prove useful as host cells suitable for theexpression of the recombinant Fabs or other embodiments of the presentinvention (see, e.g., Pltickthun, A., Immunol. Rev., 130:151-188(1992)). However, due to the tendency of proteins expressed in bacterialcells to be in an unfolded or improperly folded form or in anon-glycosylated form, any recombinant Fab produced in a bacterial cellwould have to be screened for retention of antigen binding ability. Ifthe molecule expressed by the bacterial cell was produced in a properlyfolded form, that bacterial cell would be a desirable host, or inalternative embodiments the molecule may express in the bacterial hostand then be subsequently re-folded. For example, various strains of E.Coli used for expression are well-known as host cells in the field ofbiotechnology. Various strains of B. Subtilis, Streptomyces, otherbacilli and the like may also be employed in this method.

Where desired, strains of yeast cells known to those skilled in the artare also available as host cells, as well as insect cells, e.g.Drosophila and Lepidoptera and viral expression systems. See, e.g.Miller et al., Genetic Engineering, 8:277-298, Plenum Press (1986) andreferences cited therein.

The general methods by which the vectors may be constructed, thetransfection methods required to produce the host cells of theinvention, and culture methods necessary to produce the antigen bindingprotein of the invention from such host cell may all be conventionaltechniques. Typically, the culture method of the present invention is aserum-free culture method, usually by culturing cells serum-free insuspension. Likewise, once produced, the antigen binding proteins of theinvention may be purified from the cell culture contents according tostandard procedures of the art, including ammonium 20eroxidiprecipitation, affinity columns, column chromatography, gelelectrophoresis and the like. Such techniques are within the skill ofthe art and do not limit this invention. For example, preparations ofaltered antibodies are described in WO 99/58679 and WO 96/16990.

Yet another method of expression of the antigen binding proteins mayutilize expression in a transgenic animal, such as described in U.S.Pat. No. 4,873,316. This relates to an expression system using theanimals casein promoter which when transgenically incorporated into amammal permits the female to produce the desired recombinant protein inits milk.

In a further embodiment of the invention there is provided a method ofproducing an antibody of the invention which method comprises the stepof culturing a host cell transformed or transfected with a vectorencoding the light and/or heavy chain of the antibody of the inventionand recovering the antibody thereby produced.

In accordance with the present invention there is provided a method ofproducing an anti-BCMA antibody of the present invention which binds toand neutralises the activity of human BCMA which method comprises thesteps of;

providing a first vector encoding a heavy chain of the antibody;providing a second vector encoding a light chain of the antibody;transforming a mammalian host cell (e.g. CHO) with said first and secondvectors;culturing the host cell of step (c) under conditions conducive to thesecretion of the antibody from said host cell into said culture media;recovering the secreted antibody of step (d).

Once expressed by the desired method, the antibody is then examined forin vitro activity by use of an appropriate assay. Presently conventionalELISA assay formats are employed to assess qualitative and quantitativebinding of the antibody to BCMA. Additionally, other in vitro assays mayalso be used to verify neutralizing efficacy prior to subsequent humanclinical studies performed to evaluate the persistence of the antibodyin the body despite the usual clearance mechanisms.

The dose and duration of treatment relates to the relative duration ofthe molecules of the present invention in the human circulation, and canbe adjusted by one of skill in the art depending upon the conditionbeing treated and the general health of the patient. It is envisagedthat repeated dosing (e.g. once a week or once every two weeks or onceevery 3 weeks) over an extended time period (e.g. four to six months)maybe required to achieve maximal therapeutic efficacy.

In one embodiment of the present invention there is provided arecombinant transformed, transfected or transduced host cell comprisingat least one expression cassette, for example where the expressioncassette comprises a polynucleotide encoding a heavy chain of an antigenbinding protein according to the invention described herein and furthercomprises a polynucleotide encoding a light chain of an antigen bindingprotein according to the invention described herein or where there aretwo expression cassettes and the 1^(st) encodes the light chain and thesecond encodes the heavy chain. For example in one embodiment the firstexpression cassette comprises a polynucleotide encoding a heavy chain ofan antigen binding protein comprising a constant region or antigenbinding fragment thereof which is linked to a constant region accordingto the invention described herein and further comprises a secondcassette comprising a polynucleotide encoding a light chain of anantigen binding protein comprising a constant region or antigen bindingfragment thereof which is linked to a constant region according to theinvention described herein for example the first expression cassettecomprises a polynucleotide encoding a heavy chain selected from SEQ. ID.NO:56, or SEQ. ID. NO: 60 or SEQ. ID. NO: 62 and a second expressioncassette comprising a polynucleotide encoding a light chain selectedfrom SEQ. ID. NO: 64 or SEQ. ID. NO: 66.

In another embodiment of the invention there is provided a stablytransformed host cell comprising a vector comprising one or moreexpression cassettes encoding a heavy chain and/or a light chain of theantibody comprising a constant region or antigen binding fragmentthereof which is linked to a constant region as described herein. Forexample such host cells may comprise a first vector encoding the lightchain and a second vector encoding the heavy chain, for example thefirst vector encodes a heavy chain selected from SEQ. ID. NO: 55, orSEQ. ID. NO: 59 or SEQ. ID. NO: 61 and a second vector encoding a lightchain for example the light chain of SEQ ID NO: 63 or SEQ. ID. NO: 65.In one such example the first vector encodes a heavy chain selected fromSEQ. ID. NO: 55 and a second vector encoding a light chain for examplethe light chain of SEQ ID NO: 63.

In another embodiment of the present invention there is provided a hostcell according to the invention described herein wherein the cell iseukaryotic, for example where the cell is mammalian. Examples of suchcell lines include CHO or NS0.

In another embodiment of the present invention there is provided amethod for the production of an antibody comprising a constant region orantigen binding fragment thereof which is linked to a constant regionaccording to the invention described herein which method comprises thestep of culturing a host cell in a culture media, for example serum-freeculture media.

In another embodiment of the present invention there is provided amethod according to the invention described herein wherein said antibodyis further purified to at least 95% or greater (e.g. 98% or greater)with respect to said antibody containing serum-free culture media.

In yet another embodiment there is provided a pharmaceutical compositioncomprising an antigen binding protein and a pharmaceutically acceptablecarrier.

In another embodiment of the present invention there is provided akit-of-parts comprising the composition according to the inventiondescribed herein described together with instructions for use.

The mode of administration of the therapeutic agent of the invention maybe any suitable route which delivers the agent to the host. The antigenbinding proteins, and pharmaceutical compositions of the invention areparticularly useful for parenteral administration, i.e., subcutaneously(s.c.), intrathecally, intraperitoneally, intramuscularly (i.m.) orintravenously (i.v.). In one such embodiment the antigen bindingproteins of the present invention are administered intravenously orsubcutaneously.

Therapeutic agents of the invention may be prepared as pharmaceuticalcompositions containing an effective amount of the antigen bindingprotein of the invention as an active ingredient in a pharmaceuticallyacceptable carrier. In one embodiment the prophylactic agent of theinvention is an aqueous suspension or solution containing the antigenbinding protein in a form ready for injection. In one embodiment thesuspension or solution is buffered at physiological pH. In oneembodiment the compositions for parenteral administration will comprisea solution of the antigen binding protein of the invention or a cocktailthereof dissolved in a pharmaceutically acceptable carrier. In oneembodiment the carrier is an aqueous carrier. A variety of aqueouscarriers may be employed, e.g., 0.9% saline, 0.3% glycine, and the like.These solutions may be made sterile and generally free of particulatematter. These solutions may be sterilized by conventional, well knownsterilization techniques (e.g., filtration). The compositions maycontain pharmaceutically acceptable auxiliary substances as required toapproximate physiological conditions such as pH adjusting and bufferingagents, etc. The concentration of the antigen binding protein of theinvention in such pharmaceutical formulation can vary widely, i.e., fromless than about 0.5%, usually at or at least about 1% to as much asabout 15 or 20% by weight and will be selected primarily based on fluidvolumes, viscosities, etc., according to the particular mode ofadministration selected.

Thus, a pharmaceutical composition of the invention for intravenousinfusion could be made up to contain about 250 ml of sterile Ringer'ssolution, and about 1 to about 30 or 5 mg to about 25 mg of an antigenbinding protein of the invention per ml of Ringer's solution.

Actual methods for preparing parenterally administrable compositions arewell known or will be apparent to those skilled in the art and aredescribed in more detail in, for example, Remington's PharmaceuticalScience, 15^(th) ed., Mack Publishing Company, Easton, Pa. For thepreparation of intravenously administrable antigen binding proteinformulations of the invention see Lasmar U and Parkins D “Theformulation of Biopharmaceutical products”, Pharma. Sci. Tech. today,page 129-137, Vol. 3 (3 Apr. 2000); Wang, W “Instability, stabilisationand formulation of liquid protein pharmaceuticals”, Int. J. Pharm 185(1999) 129-188; Stability of Protein Pharmaceuticals Part A and B edAhern T. J., Manning M. C., New York, N.Y.: Plenum Press (1992); Akers,M. J. “Excipient-Drug interactions in Parenteral Formulations”, J. PharmSci 91 (2002) 2283-2300; Imamura, K et al “Effects of types of sugar onstabilization of Protein in the dried state”, J Pharm Sci 92 (2003)266-274; Izutsu, Kkojima, S. “Excipient crystallinity and itsprotein-structure-stabilizing effect during freeze-drying”, J Pharm.Pharmacol, 54 (2002) 1033-1039; Johnson, R, “Mannitol-sucrosemixtures-versatile formulations for protein peroxidise23g23n”, J. Pharm.Sci, 91 (2002) 914-922; and Ha, E Wang W, Wang Y. j. “Peroxide formationin polysorbate 80 and protein stability”, J. Pharm Sci, 91, 2252-2264,(2002) the entire contents of which are incorporated herein by referenceand to which the reader is specifically referred.

In one embodiment the therapeutic agent of the invention, when in apharmaceutical preparation, is present in unit dose forms. Theappropriate therapeutically effective dose will be determined readily bythose of skill in the art. Suitable doses may be calculated for patientsaccording to their weight, for example suitable doses may be in therange of about 0.1 to about 20 mg/kg, for example about 1 to about 20mg/kg, for example about 10 to about 20 mg/kg or for example about 1 toabout 15 mg/kg, for example about 10 to about 15 mg/kg. To effectivelytreat conditions such as Multiple myeloma, SLE or IPT in a human,suitable doses may be within the range of about 0.1 to about 1000 mg,for example about 0.1 to about 500 mg, for example about 500 mg, forexample about 0.1 to about 100 mg, or about 0.1 to about 80 mg, or about0.1 to about 60 mg, or about 0.1 to about 40 mg, or for example about 1to about 100 mg, or about 1 to about 50 mg, of an antigen bindingprotein of this invention, which may be administered parenterally, forexample subcutaneously, intravenously or intramuscularly. Such dose may,if necessary, be repeated at appropriate time intervals selected asappropriate by a physician.

The antigen binding proteins described herein can be lyophilized forstorage and reconstituted in a suitable carrier prior to use. Thistechnique has been shown to be effective with conventionalimmunoglobulins and art-known peroxidise and reconstitution techniquescan be employed.

In another aspect of the invention there is provided an antigen bindingprotein as herein described for use in a medicament.

In one aspect of the present invention there is provided an antigenbinding protein according to the invention as herein described for usein the treatment of rheumatoid arthritis, Type 1 Diabetes Mellitus,multiple sclerosis or psoriasis wherein said method comprises the stepof administering to said patient a therapeutically effective amount ofthe antigen binding protein as described herein.

In one embodiment of the present invention, methods are provided fortreating cancer in a human comprising administering to said human anantigen binding protein that specifically binds to BCMA. In someinstances the antigen binding protein is part of an immunoconjugate.

In another aspect of the present invention there is provided an antigenbinding protein according to the invention as herein described for usein the treatment of a B-cell mediated or plasma cell mediated disease orantibody mediated disease or disorder selected from Multiple Myeloma(MM), chronic lymphocytic leukemia (CLL), Non-secretory multiplemyeloma, Smoldering multiple myeloma, Monoclonal gammopathy ofundetermined significance (MGUS), Solitary plasmacytoma (Bone,Extramedullary), Lymphoplasmacytic lymphoma (LPL), Waldenström'sMacroglobulinemia, Plasma cell leukemia, Primary Amyloidosis (AL), Heavychain disease, Systemic lupus erythematosus (SLE), POEMSsyndrome/osteosclerotic myeloma, Type I and II cryoglobulinemia, Lightchain deposition disease, Goodpasture's syndrome, Idiopathicthrombocytopenic purpura (ITP), Acute glomerulonephritis, Pemphigus andPemphigoid disorders, and Epidermolysis bullosa acquisita; or anyNon-Hodgkin's Lymphoma B-cell leukemia or Hodgkin's lymphoma (HL) withBCMA expression or any diseases in which patients develop neutralisingantibodies to recombinant protein replacement therapy wherein saidmethod comprises the step of administering to said patient atherapeutically effective amount of the antigen binding protein asdescribed herein.

B-cell disorders can be divided into defects of B-celldevelopment/immunoglobulin production (immunodeficiencies) andexcessive/uncontrolled proliferation (lymphomas, leukemias). As usedherein, B-cell disorder refers to both types of diseases, and methodsare provided for treating B-cell disorders with an antigen bindingprotein.

In a particular aspect, the disease or disorder is selected from thegroup consisting of Multiple Myeloma (MM), Chronic Lymphocytic Leukaemia(CLL), Solitary Plasmacytoma (Bone, Extramedullary), Waldenström'sMacroglobulinemia.

In one aspect of the present invention the disease is Multiple Myeloma,Smoldering Multiple Myeloma (SMM) or Solitary Plasmacytoma (Bone,Extramedullary).

In one aspect of the present invention the disease is Multiple Myeloma.

In one aspect of the present invention the disease is Systemic lupuserythematosus (SLE) In one aspect of the present invention the diseaseis Idiopathic thrombocytopenic purpura (ITP) Use of the antigen bindingprotein as described herein in the manufacture of a medicament for thetreatment of diseases and disorders as described herein is alsoprovided.

For example in one aspect of the invention there is provided the use ofthe antigen binding protein as described herein for use in the treatmentor prophylaxis of diseases and disorders responsive to modulation (suchas inhibiting or blocking) of the interaction between BCMA and theligands BAFF and APRIL.

In another aspect of the invention there is provided the use of theantigen binding protein as described herein for use in the treatment orprophylaxis of an antibody mediated or plasma cell mediated disease ordisorder selected from rheumatoid arthritis, Type 1 Diabeted Mellitus,multiple sclerosis or psoriasis.

In another aspect of the invention there is provided the use of theantigen binding protein as described herein for use in the treatment orprophylaxis of an antibody mediated or plasma cell mediated disease ordisorder selected from Multiple Myeloma (MM), chronic lymphocyticleukemia (CLL), Monoclonal gammopathy of undetermined significance(MGUS), Smoldering multiple myeloma (SMM), Solitary Plasmacytoma (Bone,Extramedullary), Waldenström's Macroglobulinemia, Primary Amyloidosis(AL), Heavy chain disease, Systemic lupus erythematosus (SLE), POEMSsyndrome/osteosclerotic myeloma, Type I and II cryoglobulinemia, Lightchain deposition disease, Goodpastures syndrome, Idiopathicthrombocytopenic purpura (ITP), Acute glomerulonephritis, Pemphigus andPemphigoid disorders and Epidermolysis bullosa acquisita, anyNon-Hodgkin Lymphoma and Leukemia with BCMA expression or any diseasesin which patients develop neutralising antibodies to recombinant proteinreplacement therapy wherein said method comprises the step ofadministering to said patient a therapeutically effective amount of theantigen binding protein as described herein.

In one aspect, the invention provides a pharmaceutical compositioncomprising an antigen binding protein of the present invention or afunctional fragment thereof and a pharmaceutically acceptable carrierfor treatment or prophylaxis of rheumatoid arthritis, Type 1 DiabetesMellitus, multiple sclerosis or psoriasis or an antibody mediated orplasma cell mediated disease or disorder selected from selected fromMultiple Myeloma (MM), chronic lymphocytic leukemia (CLL), Monoclonalgammopathy of undetermined significance (MGUS), Smoldering multiplemyeloma (SMM), Solitary Plasmacytoma (Bone, Extramedullary),Waldenström's Macroglobulinemia, Primary Amyloidosis (AL), Heavy chaindisease, Systemic lupus erythematosus (SLE), POEMSsyndrome/osteosclerotic myeloma, Type I and II cryoglobulinemia, Lightchain deposition disease, Goodpastures syndrome, Idiopathicthrombocytopenic purpura (ITP), Acute glomerulonephritis, Pemphigus andPemphigoid disorders and Epidermolysis bullosa acquisita, anyNon-Hodgkin Lymphoma and Leukemia with BCMA expression or any diseasesin which patients develop neutralising antibodies to recombinant proteinreplacement therapy wherein said method comprises the step ofadministering to said patient a therapeutically effective amount of theantigen binding protein as described herein.

In another embodiment of the present invention there is provided amethod of treating a human patient afflicted with rheumatoid arthritis,Type 1 Diabetes Mellitus, multiple sclerosis or psoriasis or an antibodymediated or plasma cell mediated disorder or disease which methodcomprises the step of administering a therapeutically effective amountof the antigen binding protein according to the invention as describedherein, for example there is provided a method of treating a humanpatient afflicted with an antibody mediated or plasma cell mediateddisease or disorder selected from In another aspect of the presentinvention there is provided an antigen binding protein according to theinvention as herein described for use in the treatment of an antibodymediated or plasma cell mediated disease or disorder selected fromMultiple Myeloma (MM), Chronic Lymphocytic Leukaemia (CLL) Monoclonalgammopathy of undetermined significance (MGUS), Smoldering multiplemyeloma (SMM), Solitary Plasmacytoma (Bone, Extramedullary),Waldenström's Macroglobulinemia, Primary Amyloidosis (AL), Heavy chaindisease, Systemic lupus erythematosus (SLE), POEMSsyndrome/osteosclerotic myeloma, Type I and II cryoglobulinemia, Lightchain deposition disease, Goodpastures syndrome, Idiopathicthrombocytopenic purpura (ITP), Acute glomerulonephritis, Pemphigus andPemphigoid disorders and Epidermolysis bullosa acquisita, anyNon-Hodgkin Lymphoma and Leukemia with BCMA expression or any diseasesin which patients develop neutralising antibodies to recombinant proteinreplacement therapy wherein said method comprises the step ofadministering a pharmaceutical composition comprising an antigen bindingprotein according to the invention herein in combination with apharmaceutically acceptable carrier.

In a further embodiment there is provided a method of treating a humanpatient afflicted with Multiple Myeloma (MM).

Definitions

As used herein, the terms “cancer,” “neoplasm,” and “tumor” are usedinterchangeably and, in either the singular or plural form, refer tocells that have undergone a malignant transformation that makes thempathological to the host organism. Primary cancer cells can be readilydistinguished from non-cancerous cells by well-established techniques,particularly histological examination. The definition of a cancer cell,as used herein, includes not only a primary cancer cell, but any cellderived from a cancer cell ancestor. This includes metastasized cancercells, and in vitro cultures and cell lines derived from cancer cells.

When referring to a type of cancer that normally manifests as a solidtumor, a “clinically detectable” tumor is one that is detectable on thebasis of tumor mass; e.g., by procedures such as computed tomography(CT) scan, magnetic resonance imaging (MRI), X-ray, ultrasound orpalpation on physical examination, and/or which is detectable because ofthe expression of one or more cancer-specific antigens in a sampleobtainable from a patient. Tumors may be a hematopoietic (or hematologicor hematological or blood-related) cancer, for example, cancers derivedfrom blood cells or immune cells, which may be referred to as “liquidtumors.” Specific examples of clinical conditions based on hematologictumors include leukemias such as chronic myelocytic leukemia, acutemyelocytic leukemia, chronic lymphocytic leukemia and acute lymphocyticleukemia; plasma cell malignancies such as multiple myeloma, MGUS andWaldenstrom's macroglobulinemia; lymphomas such as non-Hodgkin'slymphoma, Hodgkin's lymphoma; and the like.

The cancer may be any cancer in which an abnormal number of blast cellsor unwanted cell proliferation is present or that is diagnosed as ahematological cancer, including both lymphoid and myeloid malignancies.Myeloid malignancies include, but are not limited to, acute myeloid (ormyelocytic or myelogenous or myeloblastic) leukemia (undifferentiated ordifferentiated), acute promyeloid (or promyelocytic or promyelogenous orpromyeloblastic) leukemia, acute myelomonocytic (or myelomonoblastic)leukemia, acute monocytic (or monoblastic) leukemia, erythroleukemia andmegakaryocytic (or megakaryoblastic) leukemia. These leukemias may bereferred together as acute myeloid (or myelocytic or myelogenous)leukemia (AML). Myeloid malignancies also include myeloproliferativedisorders (MPD) which include, but are not limited to, chronicmyelogenous (or myeloid) leukemia (CML), chronic myelomonocytic leukemia(CMML), essential thrombocythemia (or thrombocytosis), and polcythemiavera (PCV). Myeloid malignancies also include myelodysplasia (ormyelodysplastic syndrome or MDS), which may be referred to as refractoryanemia (RA), refractory anemia with excess blasts (RAEB), and refractoryanemia with excess blasts in transformation (RAEBT); as well asmyelofibrosis (MFS) with or without agnogenic myeloid metaplasia.

Hematopoietic cancers also include lymphoid malignancies, which mayaffect the lymph nodes, spleens, bone marrow, peripheral blood, and/orextranodal sites. Lymphoid cancers include B-cell malignancies, whichinclude, but are not limited to, B-cell non-Hodgkin's lymphomas(B-NHLs). B-NHLs may be indolent (or low-grade), intermediate-grade (oraggressive) or high-grade (very aggressive). Indolent Bcell lymphomasinclude follicular lymphoma (FL); small lymphocytic lymphoma (SLL);marginal zone lymphoma (MZL) including nodal MZL, extranodal MZL,splenic MZL and splenic MZL with villous lymphocytes; lymphoplasmacyticlymphoma (LPL); and mucosa-associated-lymphoid tissue (MALT orextranodal marginal zone) lymphoma. Intermediate-grade B-NHLs includemantle cell lymphoma (MCL) with or without leukemic involvement, diffuselarge cell lymphoma (DLBCL), follicular large cell (or grade 3 or grade3B) lymphoma, and primary mediastinal lymphoma (PML). High-grade B-NHLsinclude Burkitt's lymphoma (BL), Burkitt-like lymphoma, smallnon-cleaved cell lymphoma (SNCCL) and lymphoblastic lymphoma. OtherB-NHLs include immunoblastic lymphoma (or immunocytoma), primaryeffusion lymphoma, HIV associated (or AIDS related) lymphomas, andpost-transplant lymphoproliferative disorder (PTLD) or lymphoma. B-cellmalignancies also include, but are not limited to, chronic lymphocyticleukemia (CLL), prolymphocytic leukemia (PLL), Waldenstrom'smacroglobulinemia (WM), hairy cell leukemia (HCL), large granularlymphocyte (LGL) leukemia, acute lymphoid (or lymphocytic orlymphoblastic) leukemia, and Castleman's disease. NHL may also includeT-cell non-Hodgkin's lymphoma s (T-NHLs), which include, but are notlimited to T-cell non-Hodgkin's lymphoma not otherwise specified (NOS),peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma(ALCL), angioimmunoblastic lymphoid disorder (AILD), nasal naturalkiller (NK) cell/T-cell lymphoma, gamma/delta lymphoma, cutaneous T celllymphoma, mycosis fungoides, and Sezary syndrome.

Hematopoietic cancers also include Hodgkin's lymphoma (or disease)including classical Hodgkin's lymphoma, nodular sclerosing Hodgkin'slymphoma, mixed cellularity Hodgkin's lymphoma, lymphocyte predominant(LP) Hodgkin's lymphoma, nodular LP Hodgkin's lymphoma, and lymphocytedepleted Hodgkin's lymphoma. Hematopoietic cancers also include plasmacell diseases or cancers such as multiple myeloma (MM) includingsmoldering MM, monoclonal gammopathy of undetermined (or unknown orunclear) significance (MGUS), plasmacytoma (bone, extramedullary),lymphoplasmacytic lymphoma (LPL), Waldenström's Macroglobulinemia,plasma cell leukemia, and primary amyloidosis (AL). Hematopoieticcancers may also include other cancers of additional hematopoieticcells, including polymorphonuclear leukocytes (or neutrophils),basophils, eosinophils, dendritic cells, platelets, erythrocytes andnatural killer cells. Tissues which include hematopoietic cells referredherein to as “hematopoietic cell tissues” include bone marrow;peripheral blood; thymus; and peripheral lymphoid tissues, such asspleen, lymph nodes, lymphoid tissues associated with mucosa (such asthe gut-associated lymphoid tissues), tonsils, Peyer's patches andappendix, and lymphoid tissues associated with other mucosa, forexample, the bronchial linings.

The term “antigen binding protein” as used herein refers to antibodies,antibody fragments and other protein constructs which are capable ofbinding to and neutralising human BCMA.

The terms Fv, Fc, Fd, Fab, or F(ab)2 are used with their standardmeanings (see, e.g., Harlow et al., Antibodies A Laboratory Manual, ColdSpring Harbor Laboratory, (1988)).

The term “antibody” is used herein in the broadest sense andspecifically covers monoclonal antibodies (including full lengthmonoclonal antibodies), polyclonal antibodies, multispecific antibodies(e.g. bispecific antibodies)

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogenous antibodies i.e.the individual antibodies comprising the population are identical exceptfor possible naturally occurring mutations that may be present in minoramounts. Monoclonal antibodies are highly specific being directedagainst a single antigenic binding site. Furthermore, in contrast topolyclonal antibody preparations which typically include differentantibodies directed against different determinants (epitopes), eachmonoclonal antibody is directed against a single determinant on theantigen.

A “chimeric antibody” refers to a type of engineered antibody in which aportion of the heavy and/or light chain is identical with or homologousto corresponding sequences in antibodies derived from a particular donorantibody class or subclass, while the remainder of the chain(s) isidentical with or homologous to corresponding sequences in antibodiesderived from another species or belonging to another antibody class orsubclass, as well as fragments of such antibodies, so long as theyexhibit the desired biological activity (U.S. Pat. No. 4,816,567 andMorrison et al. Proc. Natl. Acad. Sci. USA 81:6851-6855) (1984)).

A “humanised antibody” refers to a type of engineered antibody havingits CDRs derived from a non-human donor immunoglobulin, the remainingimmunoglobulin-derived parts of the molecule being derived from one (ormore) human immunoglobulin(s). In addition, framework support residuesmay be altered to preserve binding affinity (see, e.g., Queen et al.,Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al.,Bio/Technology, 9:421 (1991)). A suitable human acceptor antibody may beone selected from a conventional database, e.g., the KABAT® database,Los Alamos database, and Swiss Protein database, by homology to thenucleotide and amino acid sequences of the donor antibody. A humanantibody characterized by a homology to the framework regions of thedonor antibody (on an amino acid basis) may be suitable to provide aheavy chain constant region and/or a heavy chain variable frameworkregion for insertion of the donor CDRs. A suitable acceptor antibodycapable of donating light chain constant or variable framework regionsmay be selected in a similar manner. It should be noted that theacceptor antibody heavy and light chains are not required to originatefrom the same acceptor antibody. The prior art describes several ways ofproducing such humanised antibodies—see for example EP-A-0239400 andEP-A-054951.

For nucleic acids, the term “substantial identity” indicates that twonucleic acids, or designated sequences thereof, when optimally alignedand compared, are identical, with appropriate nucleotide insertions ordeletions, in at least about 80% of the nucleotides, at least about 90%to about 95%, or at least about 98% to about 99.5% of the nucleotides.

Alternatively, substantial identity exists when the segments willhybridize under selective hybridization conditions, to the complement ofthe strand.

“Identity,” means, for polynucleotides and polypeptides, as the case maybe, the comparison calculated using an algorithm provided in (1) and (2)below:

(1) Identity for polynucleotides is calculated by multiplying the totalnumber of nucleotides in a given sequence by the integer defining thepercent identity divided by 100 and then subtracting that product fromsaid total number of nucleotides in said sequence, or:

nn≤xn−(xn·y),

wherein nn is the number of nucleotide alterations, xn is the totalnumber of nucleotides in a given sequence, y is 0.95 for 95%, 0.97 for97% or 1.00 for 100%, and · is the symbol for the multiplicationoperator, and wherein any non-integer product of xn and y is roundeddown to the nearest integer prior to subtracting it from xn. Alterationsof a polynucleotide sequence encoding a polypeptide may create nonsense,missense or frameshift mutations in this coding sequence and therebyalter the polypeptide encoded by the polynucleotide following suchalterations.

(2) Identity for polypeptides is calculated by multiplying the totalnumber of amino acids by the integer defining the percent identitydivided by 100 and then subtracting that product from said total numberof amino acids, or:

na≤xa−(xa·y),

wherein na is the number of amino acid alterations, xa is the totalnumber of amino acids in the sequence, y is 0.95 for 95%, 0.97 for 97%or 1.00 for 100%, and · is the symbol for the multiplication operator,and wherein any non-integer product of xa and y is rounded down to thenearest integer prior to subtracting it from xa

For nucleotide and amino acid sequences, the term “identical” indicatesthe degree of identity between two nucleic acid or amino acid sequenceswhen optimally aligned and compared with appropriate insertions ordeletions.

“Isolated” means altered “by the hand of man” from its natural state,has been changed or removed from its original environment, or both. Forexample, a polynucleotide or a polypeptide naturally present in a livingorganism is not “isolated,” but the same polynucleotide or polypeptideseparated from the coexisting materials of its natural state is“isolated”, including but not limited to when such polynucleotide orpolypeptide is introduced back into a cell, even if the cell is of thesame species or type as that from which the polynucleotide orpolypeptide was separated.

Throughout the present specification and the accompanying claims theterm “comprising” and “comprises” incorporates “consisting of” and“consists of”. That is, these words are intended to convey the possibleinclusion of other elements or integers not specifically recited, wherethe context allows.

The term “specifically binds” as used throughout the presentspecification in relation to antigen binding proteins of the inventionmeans that the antigen binding protein binds human BCMA (hBCMA) with noor insignificant binding to other human proteins. The term however doesnot exclude the fact that antigen binding proteins of the invention mayalso be cross-reactive with other forms of BCMA, for example primateBCMA. For example in one embodiment the antigen binding protein does notbind to TACI or BAFF-R.

The term “inhibits” as used throughout the present specification inrelation to antigen binding proteins of the invention means that thebiological activity of BCMA is reduced in the presence of the antigenbinding proteins of the present invention in comparison to the activityof BCMA in the absence of such antigen binding proteins. Inhibition maybe due but not limited to one or more of blocking ligand binding,preventing the ligand activating the receptor, and/or down regulatingthe BCMA. Inhibits can also refer to an antigen binding protein bindingto BCMA and causing cell apoptosis or ADCC. The antibodies of theinvention may neutralise the activity of the BCMA ligands BAFF and/orAPRIL binding to BCMA. Levels of neutralisation can be measured inseveral ways, for example by use of the assays as set out in theexamples below, for example in 4.4 in an H929 cell NFkB signallingassay. The BCMA ligands BAFF and APRIL are able to induce NFkBsignalling and downstream events following binding to BCMA. Theneutralisation of BCMA in this assay is measured by assessing theability of anti-BCMA monoclonal antibodies to inhibit BAFF or APRILdriven NFkB induction.

If an antibody or antigen binding fragment thereof is capable ofneutralisation then this is indicative of inhibition of the interactionbetween human BAFF or APRIL and BCMA. Antibodies which are considered tohave neutralising activity against human BCMA would have an IC50 of lessthan 30 micrograms/ml, or less than 20 micrograms/ml, or less than 10micrograms/ml, or less than 5 micrograms/ml or less than 1 micrograms/mlor less than 0.1 micrograms/ml in the H929 stimulation assay as set outin Example 4.4

“CDRs” are defined as the complementarity determining region amino acidsequences of an antibody which are the hypervariable domains ofimmunoglobulin heavy and light chains. There are three heavy chain andthree light chain CDRs (or CDR regions) in the variable portion of animmunoglobulin. Thus, “CDRs” as used herein may refer to all three heavychain CDRs, or all three light chain CDRs (or both all heavy and alllight chain CDRs, if appropriate).

CDRs provide the majority of contact residues for the binding of theantibody to the antigen or epitope. CDRs of interest in this inventionare derived from donor antibody variable heavy and light chainsequences, and include analogs of the naturally occurring CDRs, whichanalogs also share or retain the same antigen binding specificity and/orneutralizing ability as the donor antibody from which they were derived.

The CDR sequences of antibodies can be determined by the Kabat numberingsystem (Kabat et al; (Sequences of proteins of Immunological InterestNIH, 1987), alternatively they can be determined using the Chothianumbering system (Al-Lazikani et al., (1997) JMB 273,927-948), thecontact definition method (MacCallum R. M., and Martin A. C. R. andThornton J. M, (1996), Journal of Molecular Biology, 262 (5), 732-745)or any other established method for numbering the residues in anantibody and determining CDRs known to the skilled man in the art

Other numbering conventions for CDR sequences available to a skilledperson include “AbM” (University of Bath) and “contact” (UniversityCollege London) methods. The minimum overlapping region using at leasttwo of the Kabat, Chothia, AbM and contact methods can be determined toprovide the “minimum binding unit”. The minimum binding unit may be asub-portion of a CDR.

Table A below represents one definition using each numbering conventionfor each CDR or binding unit. The Kabat numbering scheme is used inTable X to number the variable domain amino acid sequence. It should benoted that some of the CDR definitions may vary depending on theindividual publication used.

TABLE A Minimum Chothia binding Kabat CDR CDR AbM CDR Contact CDR unitH1 31-35/ 26-32/ 26-35/ 30-35B/ 31-32 35A/35B 33/34 35A/35B 35A/35 H250-65 52-56 50-58 47-58 52-56 H3  95-102  95-102  95-102  93-101  95-101L1 24-34 24-34 24-34 30-36 30-34 L2 50-56 50-56 50-56 46-55 50-55 L389-97 89-97 89-97 89-96 89-96 .

Throughout this specification, amino acid residues in antibody sequencesare numbered according to the Kabat scheme. Similarly, the terms “CDR”,“CDRL”, “CDRL2”, “CDRL3”, “CDRH1”, “CDRH2”, “CDRH3” follow the Kabatnumbering system as set forth in Kabat et al; Sequences of proteins ofImmunological Interest NIH, 1987.

The terms “Variant” refers to at least one, two or three amino acidchanges in the sequence. These amino acid changes may be deletion,substitution or addition but are preferably substitution. In one suchembodiment the substitutions are conservative substitutions.

In an alternative embodiment the variant sequence contains at least onesubstitution whilst retaining the canonical of the antigen bindingprotein.

The complementarity determining regions (CDRs) L1, L2, L3, H1 and H2tend to structurally exhibit one of a finite number of main chainconformations. The particular canonical structure class of a CDR isdefined by both the length of the CDR and by the loop packing,determined by residues located at key positions in both the CDRs and theframework regions (structurally determining residues or SDRs). Martinand Thornton (1996; J Mol Biol 263:800-815) have generated an automaticmethod to define the “key residue” canonical templates. Cluster analysisis used to define the canonical classes for sets of CDRs, and canonicaltemplates are then identified by analysing buried hydrophobics,hydrogen-bonding residues, and e.g. conserved glycines. The CDRs ofantibody sequences can be assigned to canonical classes by comparing thesequences to the key residue templates and scoring each template usingidentity or similarity matrices.

The terms “VH” and “VL” are used herein to refer to the heavy chainvariable domain and light chain variable domain respectively of anantibody.

As used herein the term “domain” refers to a folded protein structurewhich has tertiary structure independent of the rest of the protein.Generally, domains are responsible for discrete functional properties ofproteins and in many cases may be added, removed or transferred to otherproteins without loss of function of the remainder of the protein and/orof the domain. An “antibody single variable domain” is a foldedpolypeptide domain comprising sequences characteristic of antibodyvariable domains. It therefore includes complete antibody variabledomains and modified variable domains, for example, in which one or moreloops have been replaced by sequences which are not characteristic ofantibody variable domains, or antibody variable domains which have beentruncated or comprise N- or C-terminal extensions, as well as foldedfragments of variable domains which retain at least the binding activityand specificity of the full-length domain.

The phrase “immunoglobulin single variable domain” refers to an antibodyvariable domain (VH, VHH, VL) that specifically binds an antigen orepitope independently of a different V region or domain. Animmunoglobulin single variable domain can be present in a format (e.g.,homo- or hetero-multimer) with other, different variable regions orvariable domains where the other regions or domains are not required forantigen binding by the single immunoglobulin variable domain (i.e.,where the immunoglobulin single variable domain binds antigenindependently of the additional variable domains). A “domain antibody”or “dAb” is the same as an “immunoglobulin single variable domain” whichis capable of binding to an antigen as the term is used herein. Animmunoglobulin single variable domain may be a human antibody variabledomain, but also includes single antibody variable domains from otherspecies such as rodent (for example, as disclosed in WO 00/29004), nurseshark and Camelid VHH dAbs. Camelid VHH are immunoglobulin singlevariable domain polypeptides that are derived from species includingcamel, llama, alpaca, dromedary, and guanaco, which produce heavy chainantibodies naturally devoid of light chains. Such VHH domains may behumanised according to standard techniques available in the art, andsuch domains are still considered to be “domain antibodies” according tothe invention. As used herein “VH includes camelid VHH domains. NARV areanother type of immunoglobulin single variable domain which wereidentified in cartilaginous fish including the nurse shark. Thesedomains are also known as Novel Antigen Receptor variable region(commonly abbreviated to V(NAR) or NARV). For further details see Mol.Immunol. 44, 656-665 (2006) and US20050043519A.

The term “Epitope-binding domain” refers to a domain that specificallybinds an antigen or epitope independently of a different V region ordomain, this may be a domain antibody (dAb), for example a human,camelid or shark immunoglobulin single variable domain or it may be adomain which is a derivative of a scaffold selected from the groupconsisting of CTLA-4 (Evibody); lipocalin; Protein A derived moleculessuch as Z-domain of Protein A (Affibody, SpA), A-domain(Avimer/Maxibody); Heat shock proteins such as GroEl and GroES;37eroxidise37g (trans-body); ankyrin repeat protein (DARPin); peptideaptamer; C-type lectin domain (Tetranectin); human γ-crystallin andhuman ubiquitin (affilins); PDZ domains; scorpion toxinkunitz typedomains of human protease inhibitors; and fibronectin (adnectin); whichhas been subjected to protein engineering in order to obtain binding toa ligand other than the natural ligand.

CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-familyreceptor expressed on mainly CD4+ T-cells. Its extracellular domain hasa variable domain-like Ig fold. Loops corresponding to CDRs ofantibodies can be substituted with heterologous sequence to conferdifferent binding properties. CTLA-4 molecules engineered to havedifferent binding specificities are also known as Evibodies. For furtherdetails see Journal of Immunological Methods 248 (1-2), 31-45 (2001)Lipocalins are a family of extracellular proteins which transport smallhydrophobic molecules such as steroids, bilins, retinoids and lipids.They have a rigid β-sheet secondary structure with a number of loops atthe open end of the conical structure which can be engineered to bind todifferent target antigens. Anticalins are between 160-180 amino acids insize, and are derived from lipocalins. For further details see BiochimBiophys Acta 1482: 337-350 (2000), U.S. Pat. No. 7,250,297B1 andUS20070224633

An affibody is a scaffold derived from Protein A of Staphylococcusaureus which can be engineered to bind to antigen. The domain consistsof a three-helical bundle of approximately 58 amino acids. Librarieshave been generated by randomisation of surface residues. For furtherdetails see Protein Eng. Des. Sel. 17, 455-462 (2004) and EP1641818A1

Avimers are multidomain proteins derived from the A-domain scaffoldfamily. The native domains of approximately 35 amino acids adopt adefined disulphide bonded structure. Diversity is generated by shufflingof the natural variation exhibited by the family of A-domains. Forfurther details see Nature Biotechnology 23(12), 1556-1561 (2005) andExpert Opinion on Investigational Drugs 16(6), 909-917 (June 2007)

A Transferrin is a monomeric serum transport glycoprotein. Transferrinscan be engineered to bind different target antigens by insertion ofpeptide sequences in a permissive surface loop. Examples of engineeredtransferrins scaffolds include the Trans-body. For further details seeJ. Biol. Chem 274, 24066-24073 (1999).

Designed Ankyrin Repeat Proteins (DARPins) are derived from Ankyrinwhich is a family of proteins that mediate attachment of integralmembrane proteins to the cytoskeleton. A single ankyrin repeat is a 33residue motif consisting of two α-helices and a β-turn. They can beengineered to bind different target antigens by randomising residues inthe first α-helix and a β-turn of each repeat. Their binding interfacecan be increased by increasing the number of modules (a method ofaffinity maturation). For further details see J. Mol. Biol. 332, 489-503(2003), PNAS 100(4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028(2007) and US20040132028A1.

Fibronectin is a scaffold which can be engineered to bind to antigen.Adnectins consists of a backbone of the natural amino acid sequence ofthe 10^(th) domain of the 15 repeating units of human fibronectin typeIII (FN3). Three loops at one end of the β-sandwich can be engineered toenable an Adnectin to specifically recognize a therapeutic target ofinterest. For further details see Protein Eng. Des. Sel. 18, 435-444(2005), US20080139791, WO2005056764 and U.S. Pat. No. 6,818,418B1.

Peptide aptamers are combinatorial recognition molecules that consist ofa constant scaffold protein, typically thioredoxin (TrxA) which containsa constrained variable peptide loop inserted at the active site. Forfurther details see Expert Opin. Biol. Ther. 5, 783-797 (2005).

Microbodies are derived from naturally occurring microproteins of 25-50amino acids in length which contain 3-4 cysteine bridges—examples ofmicroproteins include KalataB 1 and conotoxin and knottins. Themicroproteins have a loop which can be engineered to include upto 25amino acids without affecting the overall fold of the microprotein. Forfurther details of engineered knottin domains, see WO2008098796.

Other epitope binding domains include proteins which have been used as ascaffold to engineer different target antigen binding properties includehuman γ-crystallin and human ubiquitin (affilins), kunitz type domainsof human protease inhibitors, PDZ-domains of the Ras-binding proteinAF-6, scorpion toxins (charybdotoxin), C-type lectin domain(tetranectins) are reviewed in Chapter 7—Non-Antibody Scaffolds fromHandbook of Therapeutic Antibodies (2007, edited by Stefan Dubel) andProtein Science 15:14-27 (2006). Epitope binding domains of the presentinvention could be derived from any of these alternative proteindomains.

As used herein, the term “antigen-binding site” refers to a site on aprotein which is capable of specifically binding to antigen, this may bea single domain, for example an epitope-binding domain, or it may bepaired VH/VL domains as can be found on a standard antibody. In someembodiments of the invention single-chain Fv (ScFv) domains can provideantigen-binding sites.

The terms “mAbdAb” and dAbmAb” are used herein to refer toantigen-binding proteins of the present invention. The two terms can beused interchangeably, and are intended to have the same meaning as usedherein.

The term “antigen binding protein” as used herein refers to antibodies,antibody fragments for example a domain antibody (dAb), ScFv, Fab, Fab2,and other protein constructs. Antigen binding molecules may comprise atleast one Ig variable domain, for example antibodies, domain antibodies(dAbs), Fab, Fab′, F(ab′)2, Fv, ScFv, diabodies, mAbdAbs, affibodies,heteroconjugate antibodies or bispecific antibodies. In one embodimentthe antigen binding molecule is an antibody. In another embodiment theantigen binding molecule is a dAb, i.e. an immunoglobulin singlevariable domain such as a VH, VHH or VL that specifically binds anantigen or epitope independently of a different V region or domain.Antigen binding molecules may be capable of binding to two targets, i.e.they may be dual targeting proteins. Antigen binding molecules may be acombination of antibodies and antigen binding fragments such as forexample, one or more domain antibodies and/or one or more ScFvs linkedto a monoclonal antibody. Antigen binding molecules may also comprise anon-Ig domain for example a domain which is a derivative of a scaffoldselected from the group consisting of CTLA-4 (Evibody); lipocalin;Protein A derived molecules such as Z-domain of Protein A (Affibody,SpA), A-domain (Avimer/Maxibody); Heat shock proteins such as GroEl andGroES; 40eroxidise40g (trans-body); ankyrin repeat protein (DARPin);peptide aptamer; C-type lectin domain (Tetranectin); human γ-crystallinand human ubiquitin (affilins); PDZ domains; scorpion toxinkunitz typedomains of human protease inhibitors; and fibronectin (adnectin); whichhas been subjected to protein engineering in order to obtain binding toOSM. As used herein “antigen binding protein” will be capable ofantagonising and/or neutralising human OSM. In addition, an antigenbinding protein may inhibit and or block OSM activity by binding to OSMand preventing a natural ligand from binding and/or activating the gp130receptor.

The term “Effector Function” as used herein is meant to refer to one ormore of Antibody dependant cell mediated cytotoxic activity (ADCC),Complement-dependant cytotoxic activity (CDC) mediated responses,Fc-mediated phagocytosis and antibody recycling via the FcRn receptor.For IgG antibodies, effector functionalities including ADCC and ADCP aremediated by the interaction of the heavy chain constant region with afamily of Fcγ receptors present on the surface of immune cells. Inhumans these include FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16).Interaction between the antigen binding protein bound to antigen and theformation of the Fc/Fcγ complex induces a range of effects includingcytotoxicity, immune cell activation, phagocytosis and release ofinflammatory cytokines. The interaction between the constant region ofan antigen binding protein and various Fc receptors (FcR) is believed tomediate the effector functions of the antigen binding protein.Significant biological effects can be a consequence of effectorfunctionality, in particular, antibody-dependent cellular cytotoxicity(ADCC), fixation of complement (complement dependent cytotoxicity orCDC), and half-life/clearance of the antigen binding protein. Usually,the ability to mediate effector function requires binding of the antigenbinding protein to an antigen and not all antigen binding proteins willmediate every effector function. Effector function can be measured in anumber of ways including for example via binding of the FcγRIII toNatural Killer cells or via FcγRI to monocytes/macrophages to measurefor ADCC effector function. For example an antigen binding protein ofthe present invention can be assessed for ADCC effector function in aNatural Killer cell assay. Examples of such assays can be found inShields et al, 2001 The Journal of Biological Chemistry, Vol. 276, p6591-6604; Chappel et al, 1993 The Journal of Biological Chemistry, Vol268, p 25124-25131; Lazar et al, 2006 PNAS, 103; 4005-4010.

Examples of assays to determine CDC function include that described in1995 J Imm Meth 184:29-38.

Some isotypes of human constant regions, in particular IgG4 and IgG2isotypes, essentially lack the functions of a) activation of complementby the classical pathway; and b) antibody-dependent cellularcytotoxicity. Various modifications to the heavy chain constant regionof antigen binding proteins may be carried out depending on the desiredeffector property. IgG1 constant regions containing specific mutationshave separately been described to reduce binding to Fc receptors andtherefore reduce ADCC and CDC (Duncan et al. Nature 1988, 332; 563-564;Lund et al. J. Immunol. 1991, 147; 2657-2662; Chappel et al. PNAS 1991,88; 9036-9040; Burton and Woof, Adv. Immunol. 1992, 51; 1-84; Morgan etal., Immunology 1995, 86; 319-324; Hezareh et al., J. Virol. 2001, 75(24); 12161-12168).

In one embodiment of the present invention there is provided an antigenbinding protein comprising a constant region such that the antigenbinding protein has reduced ADCC and/or complement activation oreffector functionality. In one such embodiment the heavy chain constantregion may comprise a naturally disabled constant region of IgG2 or IgG4isotype or a mutated IgG1 constant region. Examples of suitablemodifications are described in EP0307434. One example comprises thesubstitutions of alanine residues at positions 235 and 237 (EU indexnumbering).

Human IgG1 constant regions containing specific mutations or alteredglycosylation on residue Asn297 have also been described to enhancebinding to Fc receptors. In some cases these mutations have also beenshown to enhance ADCC and CDC (Lazar et al. PNAS 2006, 103; 4005-4010;Shields et al. J Biol Chem 2001, 276; 6591-6604; Nechansky et al. MolImmunol, 2007, 44; 1815-1817).

In one embodiment of the present invention, such mutations are in one ormore of positions selected from 239, 332 and 330 (IgG1), or theequivalent positions in other IgG isotypes. Examples of suitablemutations are S239D and I332E and A330L. In one embodiment the antigenbinding protein of the invention herein described is mutated atpositions 239 and 332, for example S239D and I332E or in a furtherembodiment it is mutated at three or more positions selected from 239and 332 and 330, for example S239D and I332E and A330L. (EU indexnumbering).

In an alternative embodiment of the present invention, there is providedan antigen binding protein comprising a heavy chain constant region withan altered glycosylation profile such that the antigen binding proteinhas enhanced effector function. For example, wherein the antigen bindingprotein has enhanced ADCC or enhanced CDC or wherein it has bothenhanced ADCC and CDC effector function. Examples of suitablemethodologies to produce antigen binding proteins with an alteredglycosylation profile are described in WO2003011878, WO2006014679 andEP1229125, all of which can be applied to the antigen binding proteinsof the present invention.

The present invention also provides a method for the production of anantigen binding protein according to the invention comprising the stepsof:

a) culturing a recombinant host cell comprising an expression vectorcomprising the isolated nucleic acid as described herein, wherein theFUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated inthe recombinant host cell; andb) recovering the antigen binding protein.

Such methods for the production of antigen binding proteins can beperformed, for example, using the POTELLIGENT™ technology systemavailable from BioWa, Inc. (Princeton, N.J.) in which CHOK1SV cellslacking a functional copy of the FUT8 gene produce monoclonal antibodieshaving enhanced antibody dependent cell mediated cytotoxicity (ADCC)activity that is increased relative to an identical monoclonal antibodyproduced in a cell with a functional FUT8 gene. Aspects of thePOTELLIGENT™ technology system are described in U.S. Pat. No. 7,214,775,U.S. Pat. No. 6,946,292, WO0061739 and WO0231240 all of which areincorporated herein by reference. Those of ordinary skill in the artwill also recognize other appropriate systems.

In one embodiment of the present invention there is provided an antigenbinding protein comprising a chimaeric heavy chain constant region forexample an antigen binding protein comprising a chimaeric heavy chainconstant region with at least one CH2 domain from IgG3 such that theantigen binding protein has enhanced effector function, for examplewherein it has enhanced ADCC or enhanced CDC, or enhanced ADCC and CDCfunctions. In one such embodiment, the antigen binding protein maycomprise one CH2 domain from IgG3 or both CH2 domains may be from IgG3.

Also provided is a method of producing an antigen binding proteinaccording to the invention comprising the steps of:

a) culturing a recombinant host cell comprising an expression vectorcomprising an isolated nucleic acid as described herein wherein theexpression vector comprises a nucleic acid sequence encoding an Fcdomain having both IgG1 and IgG3 Fc domain amino acid residues; andb) recovering the antigen binding protein.

Such methods for the production of antigen binding proteins can beperformed, for example, using the COMPLEGENT™ technology systemavailable from BioWa, Inc. (Princeton, N.J.) and Kyowa Hakko Kogyo (now,Kyowa Hakko Kirin Co., Ltd.) Co., Ltd. In which a recombinant host cellcomprising an expression vector in which a nucleic acid sequenceencoding a chimeric Fc domain having both IgG1 and IgG3 Fc domain aminoacid residues is expressed to produce an antigen binding protein havingenhanced complement dependent cytotoxicity (CDC) activity that isincreased relative to an otherwise identical antigen binding proteinlacking such a chimeric Fc domain. Aspects of the COMPLEGENT™ technologysystem are described in WO2007011041 and US20070148165 each of which areincorporated herein by reference. In an alternative embodiment CDCactivity may be increased by introducing sequence specific mutationsinto the Fc region of an IgG chain. Those of ordinary skill in the artwill also recognize other appropriate systems.

It will be apparent to those skilled in the art that such modificationsmay not only be used alone but may be used in combination with eachother in order to further enhance effector function.

In one such embodiment of the present invention there is provided anantigen binding protein comprising a heavy chain constant region whichcomprises a mutated and chimaeric heavy chain constant region forexample wherein an antigen binding protein comprising at least one CH2domain from IgG3 and one CH2 domain from IgG1, wherein the IgG1 CH2domain has one or more mutations at positions selected from 239 and 332and 330 (for example the mutations may be selected from S239D and I332Eand A330L) such that the antigen binding protein has enhanced effectorfunction, for example wherein it has one or more of the followingfunctions, enhanced ADCC or enhanced CDC, for example wherein it hasenhanced ADCC and enhanced CDC. In one embodiment the IgG1 CH2 domainhas the mutations S239D and I332E.

In an alternative embodiment of the present invention there is providedan antigen binding protein comprising a chimaeric heavy chain constantregion and which has an altered glycosylation profile. In one suchembodiment the heavy chain constant region comprises at least one CH2domain from IgG3 and one CH2 domain from IgG1 and has an alteredglycosylation profile such that the ratio of fucose to mannose is 0.8:3or less, for example wherein the antigen binding protein isdefucosylated so that said antigen binding protein has an enhancedeffector function in comparison with an equivalent antigen bindingprotein with an immunoglobulin heavy chain constant region lacking saidmutations and altered glycosylation profile, for example wherein it hasone or more of the following functions, enhanced ADCC or enhanced CDC,for example wherein it has enhanced ADCC and enhanced CDC.

In an alternative embodiment the antigen binding protein has at leastone IgG3 CH2 domain and at least one heavy chain constant domain fromIgG1 wherein both IgG CH2 domains are mutated in accordance with thelimitations described herein.

In one aspect of the invention there is provided a method of producingan antigen binding protein according to the invention described hereincomprising the steps of:

a) culturing a recombinant host cell containing an expression vectorcontaining an isolated nucleic acid as described herein, said expressionvector further comprising a Fc nucleic acid sequence encoding a chimericFc domain having both IgG1 and IgG3 Fc domain amino acid residues, andwherein the FUT8 gene encoding alpha-1,6-fucosyltransferase has beeninactivated in the recombinant host cell; andb) recovering the antigen binding protein.

Such methods for the production of antigen binding proteins can beperformed, for example, using the ACCRETAMAB™ technology systemavailable from BioWa, Inc. (Princeton, N.J.) which combines thePOTELLIGENT™ and COMPLEGENT™ technology systems to produce an antigenbinding protein having both ADCC and CDC enhanced activity that isincreased relative to an otherwise identical monoclonal antibody lackinga chimeric Fc domain and which has fucose on the oligosaccharide.

In yet another embodiment of the present invention there is provided anantigen binding protein comprising a mutated and chimeric heavy chainconstant region wherein said antigen binding protein has an alteredglycosylation profile such that the antigen binding protein has enhancedeffector function, for example wherein it has one or more of thefollowing functions, enhanced ADCC or enhanced CDC. In one embodimentthe mutations are selected from positions 239 and 332 and 330, forexample the mutations are selected from S239D and I332E and A330L. In afurther embodiment the heavy chain constant region comprises at leastone CH2 domain from IgG3 and one Ch2 domain from IgG1. In one embodimentthe heavy chain constant region has an altered glycosylation profilesuch that the ratio of fucose to mannose is 0.8:3 or less for examplethe antigen binding protein is defucosylated, so that said antigenbinding protein has an enhanced effector function in comparison with anequivalent non-chimaeric antigen binding protein or with animmunoglobulin heavy chain constant region lacking said mutations andaltered glycosylation profile.

Immunoconjugates

Also provided is an immunoconjugate (interchangeably referred to as“antibody-drug conjugates,” or “ADCs”) comprising an antigen bindingprotein according to the invention as herein described including, butnot limited to, an antibody conjugated to one or more cytotoxic agents,such as a chemotherapeutic agent, a drug, a growth inhibitory agent, atoxin (e.g., a protein toxin, an enzymatically active toxin ofbacterial, fungal, plant, or animal origin, or fragments thereof), or aradioactive isotope (i.e., a radioconjugate).

Immunoconjugates have been used for the local delivery of cytotoxicagents, i.e., drugs that kill or inhibit the growth or proliferation ofcells, in the treatment of cancer (Lambert, J. (2005) Curr. Opinion inPharmacology 5:543-549; Wu et al. (2005) Nature Biotechnology23(9):1137-1146; Payne, G. (2003) i 3:207-212; Syrigos and Epenetos(1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer(1997) Adv. Drug Deliv. Rev. 26:151-172; U.S. Pat. No. 4,975,278).Immunoconjugates allow for the targeted delivery of a drug moiety to atumor, and intracellular accumulation therein, where systemicadministration of unconjugated drugs may result in unacceptable levelsof toxicity to normal cells as well as the tumor cells sought to beeliminated (Baldwin et al., Lancet (Mar. 15, 1986) pp. 603-05; Thorpe(1985) “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: AReview,” in Monoclonal Antibodies '84: Biological And ClinicalApplications (A. Pinchera et al., eds) pp. 475-506. Both polyclonalantibodies and monoclonal antibodies have been reported as useful inthese strategies (Rowland et al., (1986) Cancer Immunol. Immunother.21:183-87). Drugs used in these methods include daunomycin, doxorubicin,methotrexate, and vindesine (Rowland et al., (1986) supra). Toxins usedin antibody-toxin conjugates include bacterial toxins such as diphtheriatoxin, plant toxins such as ricin, small molecule toxins such asgeldanamycin (Mandler et al (2000) J. Nat. Cancer Inst.92(19):1573-1581; Mandler et al (2000) Bioorganic & Med. Chem. Letters10:1025-1028; Mandler et al (2002) Bioconjugate Chem. 13:786-791),maytansinoids (EP 1391213; Liu et al., (1996) Proc. Natl. Acad. Sci. USA93:8618-8623), and calicheamicin (Lode et al (1998) Cancer Res. 58:2928;Hinman et al (1993) Cancer Res. 53:3336-3342).

In one embodiment, the present invention includes immunoconjugateshaving the following general structure:

ABP-((Linker)_(n)-Ctx)_(m)

Wherein ABP is an antigen binding proteinLinker is either absent or any a cleavable or non-cleavable linkerdescribed hereinCtx is any cytotoxic agent described hereinn is 0, 1, 2, or 3 andm is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

Examples of antibodies linked by an MC linker with auristatins such asMMAE and MMAF are depicted in the following structures:

In certain embodiments, an immunoconjugate comprises an antigen bindingprotein, including but not limited to, an antibody and achemotherapeutic agent or other toxin. Chemotherapeutic agents useful inthe generation of immunoconjugates are described herein. Enzymaticallyactive toxins and fragments thereof that can be used include diphtheriaA chain, nonbinding active fragments of diphtheria toxin, exotoxin Achain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain,modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthinproteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S),momordica charantia inhibitor, curcin, crotin, sapaonaria officinalisinhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, andthe tricothecenes. See, e.g., WO 93/21232 published Oct. 28, 1993. Avariety of radionuclides are available for the production ofradioconjugated antibodies. Examples include ²¹¹At, ²¹²Bi, ¹³¹I, ¹³¹In,⁹⁰Y, and ¹⁸⁶Re.

Antigen binding proteins of the present invention may also be conjugatedto one or more toxins, including, but not limited to, a calicheamicin,maytansinoids, dolastatins, aurostatins, a trichothecene, and CC1065,and the derivatives of these toxins that have toxin activity. Suitablecytotoxic agents include, but are not limited to, an auristatinincluding dovaline-valine-dolaisoleunine-dolaproine-phenylalanine (MMAF)and monomethyl auristatin E (MMAE) as well as ester forms of MMAE, a DNAminor groove binding agent, a DNA minor groove alkylating agent, anenediyne, a lexitropsin, a duocarmycin, a taxane, including paclitaxeland docetaxel, a puromycin, a dolastatin, a maytansinoid, and a vincaalkaloid. Specific cytotoxic agents include topotecan,morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin,dolastatin-10, echinomycin, combretatstatin, chalicheamicin, maytansine,DM-1, DM-4, netropsin. Other suitable cytotoxic agents includeanti-tubulin agents, such as an auristatin, a vinca alkaloid, apodophyllotoxin, a taxane, a baccatin derivative, a cryptophysin, amaytansinoid, a combretastatin, or a dolastatin. Antitubulin agentincludedimethylvaline-valine-dolaisoleuine-dolaproine-phenylalanine-p-phenylened-iamine(AFP), MMAF, MMAE, auristatin E, vincristine, vinblastine, vindesine,vinorelbine, VP-16, camptothecin, paclitaxel, docetaxel, epothilone A,epothilone B, nocodazole, colchicines, colcimid, estramustine,cemadotin, discodermolide, maytansine, DM-1, DM-4 or eleutherobin.

Antibody drug conjugates were produced by conjugating the small moleculeanti-tubulin agent monomethylauristatin E (MMAE) or monomethylauristatinF (MMAF) to the antibodies. In the case of MMAE the linker consists of athiol-reactive maleimide, a caproyl spacer, the dipeptidevaline-citrulline, and p-aminobenzyloxycarbonyl, a self-immolativefragmenting group. In the case of MMAF a protease-resistantmaleimidocaproyl linker is used. The conjugation process leads toheterogeneity in drug-antibody attachment, varying in both the number ofdrugs bound to each antibody molecule (mole ratio [MR]), and the site ofattachment. The most prevalent species is the material with an MR=4;less prevalent are materials with MR of 0, 2, 6, and 8. The overallaverage drug-to-antibody MR is approximately 4.

Production of Immunoconjugates

The points of attachment are cysteines produced by mild reduction of theinterchain disulfides of the antibody which is carried out whilstantibodies are immobilised on Protein G affinity resin (thus enablingthe use of large reagent excesses without intermediate purifications).While immobilized, a large excess of TCEP will fully reduce theinterchain disulfides but has no impact upon the binding of the antibodyto the resin.

The number of thiols per antibody generated by this procedure dependsupon the source and isotype of the antibodies. For example, human (andmouse-human chimeric) IgG1s have 4 reducible disulfides, and thusgenerate 8 thiols upon full reduction, whereas murine IgG1s have 5reducible disulfides and produce 10 thiols. If ADCs with the maximaldrug loading (e.g., 10 drugs per antibody for the murine IgG1s) aredesired, then the maleimido-drug-linker can simply be added to theimmobilized antibodies in sufficient excess to ensure completeconjugation. However, ADCs with fewer drugs per antibody can also beprepared from fully reduced antibodies by including a biologically inertcapping agent such as N-ethyl maleimide (NEM) which occupies some of theavailable thiols on the antibody. When the maleimido-drug-linker and thecapping agent are added simultaneously to the fully reduced antibody andin large excess (at least 3-fold), the two maleimide electrophilescompete for the limiting number of available thiols. In this fashion,the drug loading is determined by the relative thiol reaction rates ofthe drug-linker and capping agent, and thus can be considered to beunder kinetic control. The relative reaction rates ofmaleimido-drug-linkers do vary significantly, and thus the molar ratioof drug-linker to NEM present in a reaction mix must be determinedempirically to arrive at a panel of ADCs with a desired level of drugloading. The mole fraction of the drug linkers SGD-1006 (vcMMAE) andSGD-1269 (mcMMAF) in NEM mixtures which yield ADCs with approximately 4drugs per antibody are summarized in Table 2 for common human and murineIgG isotypes.

Auristatins and Dolastatins

In some embodiments, the immunoconjugate comprises an antigen bindingprotein or antibody conjugated to dolastatins or dolostatin peptidicanalogs and derivatives, the auristatins (U.S. Pat. Nos. 5,635,483;5,780,588). Dolastatins and auristatins have been shown to interferewith microtubule dynamics, GTP hydrolysis, and nuclear and cellulardivision (Woyke et al. (2001) Antimicrob. Agents and Chemother.45(12):3580-3584) and have anticancer (U.S. Pat. No. 5,663,149) andantifungal activity (Pettit et al. (1998) Antimicrob. Agents Chemother.42:2961-2965). The dolastatin or auristatin (which are pentapeptidederivatives of dolastatins) drug moiety may be attached to the antibodythrough the N (amino) terminus or the C (carboxyl) terminus of thepeptidic drug moiety (WO 02/088172).

Exemplary auristatin embodiments include the N-terminus linkedmonomethylauristatin drug moieties DE and DF, disclosed in“Monomethylvaline Compounds Capable of Conjugation to Ligands,” U.S.Pat. No. 7,498,298, the disclosure of which is expressly incorporated byreference in its entirety. As used herein, the abbreviation “MMAE”refers to monomethyl auristatin E. As used herein the abbreviation“MMAF” refers to dovaline-valine-dolaisoleuine-dolaproine-phenylalanine.

Typically, peptide-based drug moieties can be prepared by forming apeptide bond between two or more amino acids and/or peptide fragments.Such peptide bonds can be prepared, for example, according to the liquidphase synthesis method (see E. Schroder and K. Lubke, “The Peptides,”volume 1, pp 76-136, 1965, Academic Press) that is well known in thefield of peptide chemistry. The auristatin/dolastatin drug moieties maybe prepared according to the methods of: U.S. Pat. No. 5,635,483; U.S.Pat. No. 5,780,588; Pettit et al. (1989) J. Am. Chem. Soc.111:5463-5465; Pettit et al. (1998) Anti-Cancer Drug Design 13:243-277;Pettit, G. R., et al. Synthesis, 1996, 719-725; and Pettit et al. (1996)J. Chem. Soc. Perkin Trans. 15:859-863. See also Doronina (2003) NatBiotechnol 21(7):778-784; “Monomethylvaline Compounds Capable ofConjugation to Ligands,” U.S. Pat. No. 7,498,298, filed Nov. 5, 2004,hereby incorporated by reference in its entirety (disclosing, e.g.,linkers and methods of preparing monomethylvaline compounds such as MMAEand MMAF conjugated to linkers). Biologically active organic compoundswhich act as cytotoxic agents, specifically pentapeptides, are disclosedin U.S. Pat. Nos. 6,884,869; 7,498,298; 7,098,308; 7,256,257; and7,423,116. Monoclonal antibodies linked with MMAE and MMAF as well asvarious derivatives of auristatins and methods of making them aredescribed in U.S. Pat. No. 7,964,566.

Examples of auristatins include MMAE and MMAF the structures of whichare shown below:

Maytansine and Maytansinoids

Maytansinoids are mitototic inhibitors which act by inhibiting tubulinpolymerization. Maytansine was first isolated from the east Africanshrub Maytenus serrata (U.S. Pat. No. 3,896,111). Subsequently, it wasdiscovered that certain microbes also produce maytansinoids, such asmaytansinol and C-3 maytansinol esters (U.S. Pat. No. 4,151,042). Highlycytotoxic maytansinoid drugs drugs can be prepared from ansamitocinprecursors produced by fermentation of microorganisms such asActinosynnema. Methods for isolating ansamitocins are described in U.S.Pat. No. 6,573,074. Synthetic maytansinol and derivatives and analoguesthereof are disclosed, for example, in U.S. Pat. Nos. 4,137,230;4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016;4,308,268; 4,308,269; 4,309,428; 4,313,946; 4,315,929; 4,317,821;4,322,348; 4,331,598; 4,361,650; 4,364,866; 4,424,219; 4,450,254;4,362,663; and 4,371,533.

Antibody-maytansinoid conjugates are prepared by chemically linking anantibody to a maytansinoid molecule without significantly diminishingthe biological activity of either the antibody or the maytansinoidmolecule. See, e.g., U.S. Pat. No. 5,208,020. An average of 3-4maytansinoid molecules conjugated per antibody molecule has shownefficacy in enhancing cytotoxicity of target cells without negativelyaffecting the function or solubility of the antibody, although even onemolecule of toxin/antibody would be expected to enhance cytotoxicityover the use of naked antibody. Maytansinoids are well known in the artand can be synthesized by known techniques or isolated from naturalsources. Suitable maytansinoids are disclosed, for example, in U.S. Pat.No. 5,208,020 and in the other patents and nonpatent publicationsreferred to hereinabove. Maytansinoids are maytansinol and maytansinolanalogues modified in the aromatic ring or at other positions of themaytansinol molecule, such as various maytansinol esters. Methods forpreparing matansinoids for linkage with antibodies are disclosed in U.S.Pat. Nos. 6,570,024 and 6,884,874.

Calicheamicin

The calicheamicin family of antibiotics is capable of producingdouble-stranded DNA breaks at sub-picomolar concentrations. For thepreparation of conjugates of the calicheamicin family, see U.S. Pat.Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710,5,773,001, 5,877,296 (all to American Cyanamid Company). Structuralanalogues of calicheamicin which may be used include, but are notlimited to, .gamma. 1I, .alpha.2I, .alpha.3I, N-acetyl-.gamma. 1I, PSAGand .theta.I1 (Hinman et al., Cancer Research 53:3336-3342 (1993), Lodeet al., Cancer Research 58:2925-2928 (1998) and the aforementioned U.S.patents to American Cyanamid). Another anti-tumor drug that the antibodycan be conjugated is QFA which is an antifolate. Both calicheamicin andQFA have intracellular sites of action and do not readily cross theplasma membrane. Therefore, cellular uptake of these agents throughantibody mediated internalization greatly enhances their cytotoxiceffects.

Other Cytotoxic Agents

Other antitumor agents that can be conjugated to the antibodies includeBCNU, streptozoicin, vincristine and 5-fluorouracil, the family ofagents known collectively LL-E33288 complex described in U.S. Pat. Nos.5,053,394, 5,770,710, as well as esperamicins (U.S. Pat. No. 5,877,296).

Enzymatically active toxins and fragments thereof which can be usedinclude diphtheria A chain, nonbinding active fragments of diphtheriatoxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain,abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordiiproteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII,and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonariaofficinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin,enomycin and the tricothecenes. See, for example, WO 93/21232 publishedOct. 28, 1993.

The present invention further contemplates an immunoconjugate formedbetween an antibody and a compound with nucleolytic activity (e.g., aribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

For selective destruction of the tumor, the antibody may comprise ahighly radioactive atom. A variety of radioactive isotopes are availablefor the production of radioconjugated antibodies. Examples includeAt211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 andradioactive isotopes of Lu. When the conjugate is used for detection, itmay comprise a radioactive atom for scintigraphic studies, for exampletc99m or 1123, or a spin label for nuclear magnetic resonance (NMR)imaging (also known as magnetic resonance imaging, mri), such asiodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13,nitrogen-15, oxygen-17, gadolinium, manganese or iron.

The radio- or other labels may be incorporated in the conjugate in knownways. For example, the peptide may be biosynthesized or may besynthesized by chemical amino acid synthesis using suitable amino acidprecursors involving, for example, fluorine-19 in place of hydrogen.Labels such as tc99m or 1123, Re186, Re188 and In111 can be attached viaa cysteine residue in the peptide. Yttrium-90 can be attached via alysine residue. The IODOGEN method (Fraker et al. (1978) Biochem.Biophys. Res. Commun. 80: 49-57) can be used to incorporate iodine-123.“Monoclonal Antibodies in Immunoscintigraphy” (Chatal, CRC Press 1989)describes other methods in detail.

Preparation of ADCs

In antibody drug conjugates, the antibody can be conjugated directly tothe cytotoxic agent or via a linker. Suitable linkers include, forexample, cleavable and non-cleavable linkers. A cleavable linker istypically susceptible to cleavage under intracellular conditions.Suitable cleavable linkers include, for example, a peptide linkercleavable by an intracellular protease, such as lysosomal protease or anendosomal protease. In exemplary embodiments, the linker can be adipeptide linker, such as a valine-citrulline (val-cit) or aphenylalanine-lysine (phe-lys) linker. Other suitable linkers includelinkers hydrolyzable at a pH of less than 5.5, such as a hydrazonelinker. Additional suitable cleavable linkers include disulfide linkers.

Bristol-Myers Squibb has described particular lysosomal enzyme-cleavableantitumor drug conjugates. See, for example, U.S. Pat. No. 6,214,345.Seattle Genetics has published applications U.S. Pat. Appl. 2003/0096743and U.S. Pat. Appl. 2003/0130189, which describe p-aminobenzylethers indrug delivery agents. The linkers described in these applications arelimited to aminobenzyl ether compositions.

Conjugates of the antigen binding protein and cytotoxic agent may bemade using a variety of bifunctional protein coupling agents such asN-succinimidyl-3-(2-pyridyldithio)propionate (SPDP),succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC),iminothiolane (IT), bifunctional derivatives of imidoesters (such asdimethyl adipimidate HCl), active esters (such as disuccinimidylsuberate), aldehydes (such as glutaraldehyde), bis-azido compounds (suchas bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (suchas bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astoluene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene).

Additionally the linker may be composed of one or more linkercomponents. Exemplary linker components include 6-maleimidocaproyl(“MC”), maleimidopropanoyl (“MP”), valine-citrulline (“val-cit”),alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl (“PAB”),N-Succinimidyl 4-(2-pyridylthio)pentanoate (“SPP”), N-Succinimidyl4-(N-maleimidomethyl)cyclohexane-1 carboxylate (“SMCC”), andN-Succinimidyl (4-iodo-acetyl)aminobenzoate (“SIAB”). Additional linkercomponents are known in the art and some are described herein. See also“Monomethylvaline Compounds Capable of Conjugation to Ligands,” U.S.Pat. No. 7,498,298, filed Nov. 5, 2004, the contents of which are herebyincorporated by reference in its entirety.

Linkers may also comprises amino acids and/or amino acid analogs. Aminoacid linker components include a dipeptide, a tripeptide, a tetrapeptideor a pentapeptide. Exemplary dipeptides include: valine-citrulline (vcor val-cit), alanine-phenylalanine (af or ala-phe).

Exemplary tripeptides include: glycine-valine-citrulline (gly-val-cit)and glycine-glycine-glycine (gly-gly-gly). Amino acid residues whichcomprise an amino acid linker component include those occurringnaturally, as well as minor amino acids and non-naturally occurringamino acid analogs, such as citrulline. Amino acid linker components canbe designed and optimized in their selectivity for enzymatic cleavage bya particular enzyme, for example, a tumor-associated protease, cathepsinB, C and D, or a plasmin protease.

Antigen binding proteins and antibodies may be made reactive forconjugation with linker reagents. Nucleophilic groups on antibodiesinclude, but are not limited to: (i) N-terminal amine groups, (ii) sidechain amine groups, e.g., lysine, (iii) side chain thiol groups, e.g.cysteine, and (iv) sugar hydroxyl or amino groups where the antibody isglycosylated. Amine, thiol, and hydroxyl groups are nucleophilic andcapable of reacting to form covalent bonds with electrophilic groups onlinker moieties and linker reagents including: (i) active esters such asNHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl andbenzyl halides such as haloacetamides; (iii) aldehydes, ketones,carboxyl, and maleimide groups. Certain antibodies have reducibleinterchain disulfides, i.e. cysteine bridges. Antibodies may be madereactive for conjugation with linker reagents by treatment with areducing agent such as DTT (dithiothreitol). Each cysteine bridge willthus form, theoretically, two reactive thiol nucleophiles. Additionalnucleophilic groups can be introduced into antibodies through thereaction of lysines with 2-iminothiolane (Traut's reagent) resulting inconversion of an amine into a thiol. Reactive thiol groups may beintroduced into the antibody (or fragment thereof) by introducing one,two, three, four, or more cysteine residues (e.g., preparing mutantantibodies comprising one or more non-native cysteine amino acidresidues).

Antigen binding proteins and antibodies may also be modified tointroduce electrophilic moieties, which can react with nucleophilicsubstituents on the linker reagent or drug. The sugars of glycosylatedantibodies may be oxidized, e.g. with periodate oxidizing reagents, toform aldehyde or ketone groups which may react with the amine group oflinker reagents or drug moieties. The resulting imine Schiff base groupsmay form a stable linkage, or may be reduced, e.g., by borohydridereagents to form stable amine linkages. In one embodiment, reaction ofthe carbohydrate portion of a glycosylated antibody with either glactoseoxidase or sodium meta-periodate may yield carbonyl (aldehyde andketone) groups in the protein that can react with appropriate groups onthe drug (Hermanson, Bioconjugate Techniques). In another embodiment,proteins containing N-terminal serine or threonine residues can reactwith sodium meta-periodate, resulting in production of an aldehyde inplace of the first amino acid (Geoghegan & Stroh, (1992) BioconjugateChem. 3:138-146; U.S. Pat. No. 5,362,852). Such aldehydes can be reactedwith a drug moiety or linker nucleophile.

Nucleophilic groups on a drug moiety include, but are not limited to:amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone,hydrazine carboxylate, and arylhydrazide groups capable of reacting toform covalent bonds with electrophilic groups on linker moieties andlinker reagents including: (i) active esters such as NHS esters, HOBtesters, haloformates, and acid halides; (ii) alkyl and benzyl halidessuch as haloacetamides; (iii) aldehydes, ketones, carboxyl, andmaleimide groups.

In some embodiments, the linker is cleavable by a cleaving agent that ispresent in the intracellular environment (e.g., within a lysosome orendosome or caveolea). The linker can be, e.g., a peptidyl linker thatis cleaved by an intracellular peptidase or protease enzyme, including,but not limited to, a lysosomal or endosomal protease. Typically, thepeptidyl linker is at least two amino acids long or at least three aminoacids long. Cleaving agents can include cathepsins B and D and plasmin,all of which are known to hydrolyze dipeptide drug derivatives resultingin the release of active drug inside target cells (see, e.g., Dubowchikand Walker, 1999, Pharm. Therapeutics 83:67-123). Peptidyl linkers maybe cleavable by enzymes that are present cells. For example, a peptidyllinker that is cleavable by the thiol-dependent protease cathepsin-B,which is highly expressed in cancerous tissue, can be used (e.g., aPhe-Leu or a Gly-Phe-Leu-Gly (SEQ ID NO:50) linker). Other such linkersare described, e.g., in U.S. Pat. No. 6,214,345. In specificembodiments, the peptidyl linker cleavable by an intracellular proteaseis a Val-Cit linker or a Phe-Lys linker (see, e.g., U.S. Pat. No.6,214,345, which describes the synthesis of doxorubicin with the val-citlinker). One advantage of using intracellular proteolytic release of thetherapeutic agent is that the agent is typically attenuated whenconjugated and the serum stabilities of the conjugates are typicallyhigh.

In other embodiments, the cleavable linker is pH-sensitive, i.e.,sensitive to hydrolysis at certain pH values. Typically, thepH-sensitive linker hydrolyzable under acidic conditions. For example,an acid-labile linker that is hydrolyzable in the lysosome (e.g., ahydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide,orthoester, acetal, ketal, or the like) can be used. (See, e.g., U.S.Pat. Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999,Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem.264:14653-14661.) Such linkers are relatively stable under neutral pHconditions, such as those in the blood, but are unstable at below pH 5.5or 5.0, the approximate pH of the lysosome. In certain embodiments, thehydrolyzable linker is a thioether linker (such as, e.g., a thioetherattached to the therapeutic agent via an acylhydrazone bond (see, e.g.,U.S. Pat. No. 5,622,929)).

In yet other embodiments, the linker is cleavable under reducingconditions (e.g., a disulfide linker). A variety of disulfide linkersare known in the art, including, for example, those that can be formedusing SATA (N-succinimidyl-5-acetylthioacetate), SPDP(N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB(N-succinimidyl-3-(2-pyridyldithio)butyrate) and SMPT(N-succinimidyl-oxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio)toluene)-,SPDB and SMPT (See, e.g., Thorpe et al., 1987, Cancer Res. 47:5924-5931;Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates inRadioimagery and Therapy of Cancer (C. W. Vogel ed., Oxford U. Press,1987. See also U.S. Pat. No. 4,880,935.)

In yet other specific embodiments, the linker is a malonate linker(Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimidobenzoyllinker (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1299-1304), or a3′-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1305-12).

Typically, the linker is not substantially sensitive to theextracellular environment. As used herein, “not substantially sensitiveto the extracellular environment,” in the context of a linker, meansthat no more than about 20%, typically no more than about 15%, moretypically no more than about 10%, and even more typically no more thanabout 5%, no more than about 3%, or no more than about 1% of thelinkers, in a sample of ADC or ADC derivative, are cleaved when the ADCor ADC derivative present in an extracellular environment (e.g., inplasma). Whether a linker is not substantially sensitive to theextracellular environment can be determined, for example, by incubatingindependently with plasma both (a) the ADC or ADC derivative (the “ADCsample”) and (b) an equal molar amount of unconjugated antibody ortherapeutic agent (the “control sample”) for a predetermined time period(e.g., 2, 4, 8, 16, or 24 hours) and then comparing the amount ofunconjugated antibody or therapeutic agent present in the ADC samplewith that present in control sample, as measured, for example, by highperformance liquid chromatography.

In other, non-mutually exclusive embodiments, the linker promotescellular internalization. In certain embodiments, the linker promotescellular internalization when conjugated to the therapeutic agent (i.e.,in the milieu of the linker-therapeutic agent moiety of the ADC or ADCderivate as described herein). In yet other embodiments, the linkerpromotes cellular internalization when conjugated to both thetherapeutic agent and the antigen binding protein or antibody orderivative thereof (i.e., in the milieu of the ADC or ADC derivative asdescribed herein).

A variety of linkers that can be used with the present compositions andmethods are described in WO 2004010957 entitled “Drug Conjugates andTheir Use for Treating Cancer, An Autoimmune Disease or an InfectiousDisease” filed Jul. 31, 2003, and U.S. Provisional Application No.60/400,403, entitled “Drug Conjugates and their use for treating cancer,an autoimmune disease or an infectious disease”, filed Jul. 31, 2002(the disclosure of which is incorporated by reference herein).

Alternatively, a fusion protein comprising the antigen binding proteinand cytotoxic agent may be made, e.g., by recombinant techniques orpeptide synthesis. The length of DNA may comprise respective regionsencoding the two portions of the conjugate either adjacent one anotheror separated by a region encoding a linker peptide which does notdestroy the desired properties of the conjugate.

In yet another embodiment, the antibody may be conjugated to a“receptor” (such as streptavidin) for utilization in tumor pre-targetingwherein the antibody-receptor conjugate is administered to the patient,followed by removal of unbound conjugate from the circulation using aclearing agent and then administration of a “ligand” (e.g., avidin)which is conjugated to a cytotoxic agent (e.g., a radionucleotide).

The term “Non Human antibody or antibody fragment thereof” as usedherein is meant to refer to antibodies or fragments thereof whichoriginate from any species other than human wherein human includeschimeric antibodies.

The term “donor antibody” refers to an antibody (monoclonal, and/orrecombinant) which contributes the amino acid sequences of its variabledomains, CDRs, or other functional fragments or analogs thereof to afirst immunoglobulin partner, so as to provide the alteredimmunoglobulin coding region and resulting expressed altered antibodywith the antigenic specificity and neutralizing activity characteristicof the donor antibody.

The term “acceptor antibody” refers to an antibody (monoclonal and/orrecombinant) heterologous to the donor antibody, which contributes all(or any portion, but preferably all) of the amino acid sequencesencoding its heavy and/or light chain framework regions and/or its heavyand/or light chain constant regions to the first immunoglobulin partner.The human antibody is the acceptor antibody.

The term “Human acceptor sequence” as used herein is meant to refer to aframework of an antibody or antibody fragment thereof comprising theamino acid sequence of a VH or VL framework derived from a humanantibody or antibody fragment thereof or a human consensus sequenceframework into which CDR's from a non-human species may be incorporated.

The term “incorporation” of CDR's or hypervariable regions as usedherein encompasses any means by which the non-human CDR's are situatedwith the human acceptor framework. It will be appreciated that this canbe achieved in various ways, for example, nucleic acids encoding thedesired amino acid sequence can be generated by mutating nucleic acidsencoding the non-human variable domain sequence so that the frameworkresidues thereof are changed to human acceptor framework residues, or bymutating nucleic acid encoding the human variable domain sequence sothat the CDR's are changed to non-human residues, or by synthesizingnucleic acids encoding the desired sequence. In one embodiment the finalsequence is generated in silico.

The present invention is now described by way of example only. Theappended claims may include a generalisation of one of more of thefollowing examples.

EXAMPLES Example 1 Monoclonal Antibody Generation and Selection 1.1Immunisation Strategies

The anti human BCMA mAb murine parental CA8 was identified fromhybridomas derived from mice immunized with full length human BCMA. ABALB/c mouse was immunized i.p. with 25 μg of recombinant (rBCMA)protein combined with CFA. The mouse was boosted three times atone-month intervals with 25 μg of full length rBCMA protein+10 μgmonophosphoryl lipid A-stable emulsion (MPL-SE) (Corixa Corporation,Seattle, Wash.) and given a pre-fusion boost of 30 μg rBCMA protein i.v.3 days prior to fusion. Hybridomas were either generated and clonedusing the ClonaCell-HY hybridoma cloning kit (StemCell Technologies,Vancouver, BC) or using a conventional method. In the conventionalmethod, B cells from the spleens of the immunized animals were fusedwith Sp2/0 myeloma cells in the presence of PEG (Sigma-Aldrich, St.Louis, Mo.). After overnight recovery, fused cells were plated atlimiting dilution in 96-well plates and subjected tohypoxanthine-aminopterin-thymidine selection. Hybridoma culturesupernatants were examined for the presence of anti-BCMA antibodies byELISA and flow cytometry

The anti human BCMA mAb murine parental S307118G03 was identified fromhybridomas derived from SJL mice immunized with recombinant humanBCMA/TNFRSF17-Fc chimera (R&D 193-Fc) using the RIMMS method (Rapidimmunisation multiple sites). At Day 0, 5 ug protein per mouse wasemulsified in AS02a adjuvant at 2 sites on back (over haunches and overshoulders) and subjacent to the major lymph nodes at 4 sites on front.On day 6 and day 11 2.5 ug protein per mouse in RIBI adjuvant wasinjected subjacent to the major lymph nodes at 4 sites on front. On day14 the animals were sacrificed. The lymph nodes and spleen were excised,disrupted and a PEG1500 induced somatic cell fusion performed using a3:1 ratio with mouse myeloma cells X63 AG8 653.GFP.Bcl-2.11 (BioCat112754; R17209/58). The fusion was plated out into 10×96 well plates andscreened directly from these. The anti human BCMA mAb murine parental5336105A07 was identified from hybridomas derived from identicalimmunisations. The lymph nodes and spleen were excised at day 14,disrupted, and a Cytopulse electrofusion was performed using a 1:1 ratiowith mouse myeloma cells X63 AG8 653.GFP.Bcl-2.11 (BioCat 112754;R17209/58). The fusion was plated out into omnitrays containing semisolid medium prior to picking into 10×96 well plates and was screeneddirectly from these 5 days later.

The anti human BCMA murine parental mAbs S332121F02 and S332126E04 wereidentified from hybridomas derived from SJL mice immunized withrecombinant Fc fusion of the extracellular domain of human BCMA (4-53)BCMA using the RIMMS method (Rapid immunisation). At Day 0, 5 ug proteinper mouse was emulsified in AS02a adjuvant at 2 sites on back (overhaunches and over shoulders) and subjacent to the major lymph nodes at 4sites on front. On day 6 5 ug recombinant cyno BCMA-Fc protein per mousein RIBI adjuvant was injected subjacent to the major lymph nodes at 4sites on front. On day 11 2.5 ug recombinant human BCMA-Fc and 2.5 ugrecombinant cyno BCMA-Fc per mouse in RIBI adjuvant was injectedsubjacent to the major lymph nodes at 4 sites on front. On day 14 theanimals were sacrificed and cells treated as for S307118G03.

The anti human BCMA murine parental mAb S322110D07 was identified fromhybridomas derived from SJL mice immunised with recombinant Fc fusion ofthe extracellular domain of human BCMA (4-53) in complex withrecombinant human April (R&D 5860-AP/CF) premixed at 1:1 molar ratio.The mice were immunized i.p. with 5 ug April/Cyno BCMA-Fc complex inPBS, suspended in RIBI adjuvant, 100 ul dose per mouse and boosted 3times at 3-4 week intervals with 2.5 ug April/Cyno BCMA-Fc complex inPBS, suspended in RIBI adjuvant, 100 ul dose per mouse injected viaintraperitoneal route and given a pre-fusion boost of the same immunogen1 day prior to fusion and treated as for S307118G03.

The anti human BCMA mAb murine parental S335115G01 and S335122F05 wereidentified from hybridomas derived from SJL mice immunized with amixture of recombinant Fc fusion of the extracellular domain of humanBCMA (4-53) and recombinant Fc fusion of the extracellular domain ofcyno BCMA (4-52) using the RIMMS method (Rapid immunisation multiplesites). At Day 0, 2, 5 ug of each protein per mouse was emulsified inAS02a adjuvant and injected at 2 sites on the back (over haunches andover shoulders) and subjacent to the major lymph nodes at 4 sites onfront. On day 6 and day 11 2.5 ug of each protein per mouse in RIBIadjuvant was injected subjacent to the major lymph nodes at 4 sites onfront. On day 14 the animals were sacrificed. The lymph nodes and spleenwere excised, disrupted and a Cytopulse electrofusion was performedusing a 1:1 ratio with mouse myeloma cells X63 AG8 653.GFP.Bcl-2.11(BioCat 112754; R17209/58). The fusion was plated out into omnitrayscontaining semi solid medium prior to picking into 32×96 well plates andwas screened directly from these 5 days later.

Example 2 Humanisation 2.1 Cloning of CA8 Hybridoma Variable Regions

Total RNA was extracted from CA8 hybridoma cells, heavy and lightvariable domain cDNA sequence was then generated by reversetranscription and polymerase chain reaction (RT-PCR). The forward primerfor RT-PCR was a mixture of degenerate primers specific for murineimmunoglobulin gene leader-sequences and the reverse primer was specificfor the antibody constant regions. Reverse primers specific for IgG,IgG2a and IgG2b were used in this case as the isotype was unknown. Todesign the primers, DNA multiple sequence alignments of the leadersequences of the mouse V_(H) and V_(k) genes were generated.

2.2 Cloning of Chimeric CA8 The DNA expression constructs encoding thechimeric antibody were prepared de novo by build-up of overlappingoligonucleotides including restriction sites for cloning into mammalianexpression vectors as well as a human signal sequence. HindIII and SpeIrestriction sites were introduced to frame the VH domain containing thesignal sequence for cloning into mammalian expression vectors containingthe human γ1 constant region. HindIII and BsiWI restriction sites wereintroduced to frame the VL domain containing the signal sequence forcloning into mammalian expression vector containing the human kappaconstant region.

2.3 Cloning of the Humanised CA8 Variants

The DNA expression constructs encoding the humanised antibody variantswere prepared de novo by build-up of overlapping oligonucleotidesincluding restriction sites for cloning into mammalian expressionvectors as well as a human signal sequence. HindIII and SpeI restrictionsites were introduced to frame the VH domain containing the signalsequence for cloning into mammalian expression vectors containing thehuman γ1 constant region. HindIII and BsiWI restriction sites wereintroduced to frame the VL domain containing the signal sequence forcloning into mammalian expression vector containing the human kappaconstant region.

2.4 Expression of the Recombinant CA8 Antibodies (Including AntibodyQuantification)

Expression plasmids encoding the heavy and light chains respectivelywere transiently co-transfected into HEK 293 6E cells and expressed atsmall scale to produce antibody. Antibodies were quantified by ELISA.ELISA plates were coated with anti human IgG (Sigma 13382) at 1 mg/mland blocked with blocking solution (4% BSA in Tris buffered saline).Various dilutions of the tissue culture supernatants were added and theplate was incubated for 1 hour at room temperature. Dilutions of a knownstandard antibody were also added to the plate. The plate was washed inTBST and binding was detected by the addition of a peroxidise labelledanti human kappa light chain antibody (Sigma A7164) at a dilution of1/1000 in blocking solution. The plate was incubated for 1 hour at roomtemp before washing in TBST. The plate was developed by addition of OPDsubstrate (Sigma P9187) and colour development stopped by addition of 2MH2SO4. Absorbance was measured at 490 nm and a standard curve plottedusing data for the known standard dilutions. The standard curve was usedto estimate the concentration of antibody in the tissue culturesupernatants. Larger scale antibody preparations were purified usingprotein A and concentrations were measured using a Nanodrop (ThermoScientific).

TABLE 1 Design of CA8 variable heavy and light humanised variantsHumanised Backmutations VH Template (Kabat#) J0 Straight graft of CA8 VHCDRs onto None IGHV1_69 + JH1 minigene J1 J0 G27Y, S30T J2 J1 A93T J3 J2A24G, K73T J4 J3 M48I, V67A, I69L J5 J3 N99D J6 J0 N99D J7 J1 N99D J8 J2N99D J9 J4 N99D M0 Straight graft of CA8 VL CDRs onto None IGKV1_39 +JK2 minigene M1 M0 F71Y M2 M1 M4L, K45E, L47V

2.5 Defucosylated Antibody Production

To generate defucosylated antibodies the heavy and light chainsrespectively were co-transfected into CHO DG44 MS705 BioWa cells andexpressed at scale to produce antibody. Briefly, 30 μg DNA waslinearised overnight with Not1, the DNA was ethanol precipitated andre-dissolved in TE buffer. From culture, 2.4×107 BioWa DG44 cells wereobtained and washed in 14 ml of warmed PBS-sucrose. The cells were spunand the pellet resuspended in 1.6 ml of PBS-sucrose. Half (0.8 ml) ofaforementioned cells, suspended in PBS-sucrose, were added to a BioRadcuvette with the 30 μg of linearised DNA (in 50 μl TE buffer). A BioRadGenePulser was programmed to 380V with a capacitance of 25 μF and thecuvette was entered for electroporation. The resulting 850 ul ofelectroporated cells and DNA were added to (80 ml) warmed SFM512 medium(including phenol red, 2×HT (nucleosides), glutamax and Gibcosupplement4). Finally, the resulting 80 ml of cell suspension wastransferred └ (150 μl/well) to each well of one of 4×96-well plates.After 48 hours, the medium was changed to nucleoside free by removingapproximately 130 μl of conditioned and replacing with 150 μl of freshselection medium SFM512 medium (including phenol red and glutamax).Every 3-4 days, 130-150 μl of conditioned medium was removed andreplaced with fresh, selection medium. Wells were monitored for colourchange and assayed for IgG concentration as discussed previously.

2.6 Additional Antibodies—Cloning of Hybridoma Variable Regions

Total RNA was extracted from S307118G03, S332121F02, S332126E04,S322110D07, S336105A07, S335115G01 and S335122F05 hybridoma cells. Heavyand light variable domain cDNA sequence was then generated by reversetranscription and polymerase chain reaction (RT-PCR). The forward primerfor RT-PCR was a mixture of degenerate primers specific for murineimmunoglobulin gene leader-sequences and the reverse primer was specificfor the antibody constant regions, in this case isotype IgG2a. Primerswere designed based on a strategy described by Jones and Bendig(Bio/Technology 9:88, 1991). RT-PCR was carried out for both V-regionsequences to enable subsequent verification of the correct V-regionsequences. DNA sequence data was obtained for the V-region productsgenerated by the RT-PCR.

2.7 Additional Antibodies—Cloning of the Chimeras

The DNA expression constructs encoding the chimeric antibodies wereprepared de novo by infusion advantage PCR cloning (Clonetech) of theV-gene PCR products into mammalian expression vectors. This cloningmethod enabled fusion the murine variable regions to human IgG1 H chainand kappa L chain constant regions.

2.8 S307118G03—Cloning of the Humanized Variants

Cloning was carried out as for paragraph 2.3.

2.9 S307118G03 Expression of the Recombinant Antibodies

Expression plasmids encoding the relevant heavy and light chains (listedin Table 8 below) were transiently co-transfected into HEK 293 6E cellsand expressed at small scale to produce antibody. The antibodies wereProtein A purified from the supernatants and quantified using theNanodrop spectrophotometer. 8 below) were transiently co-transfectedinto HEK 293 6E cells and expressed at small scale to produce antibody.The antibodies were Protein A purified from the supernatants andquantified using the Nanodrop spectrophotometer.

Example 3 Conjugation of Antibodies to vcMMAE and mcMMAF to FormAntibody Drug Conjugates (ADC)

TABLE B Chemical structures of drug-linkers

SGD-1006

SGD-1269

Gammabind Plus Protein G Sepharose (GE Healthcare) resin slurry (75 uL)was added to a each well of a deep well (2 mL capacity) filter plate.The antibodies to be conjugated were grouped by species and isotype andup to 0.5 mg of each antibody transferred to each well of the plate.Each antibody was transferred to two separate wells to facilitate thepreparation of two conjugates, with the drug-linkers SGD-1006 andSGD-1269. The filter plate was then shaken at 1200 RPM for 2 hours at 5°C. to bind the antibodies to the resin. The filter plate was thencentrifuged at 500×g for 3 minutes to ensure complete pulldown of allfluids and resin to the bottom of the each well.

The bound antibodies were then reduced by adding 500 uL of 10 mM TCEP in100 mM KPO4, 150 mM NaCl, pH 7, 1 mM EDTA and shaking for 30 minutes at22° C. Following reduction, the plate was again centrifuged to removethe TCEP solution and subsequently washed with PBS+1 mM EDTA, 1 mL perwell. The wash solution was removed by centrifugation and the processrepeated 3 times for a total of 4 washes. The bound and reducedantibodies were then conjugated using a mixture of NEM and drug linkerprepared in accordance with the mole fractions indicated in Table 2.

TABLE 2 Antibody Reducible SGD-1006 SGD-1269 (species/isotype)Disulfides mole fraction mole fraction Human IgG1* 4 0.675 0.688 MurineIgG1 5 0.500 0.586 Murine IgG2a 5 0.500 0.586 Murine IgG2b 6 0.463 0.481*also for murine/human IgG1 chimerics

Separate mixtures of NEM and drug linker were thus prepared for eachantibody species/isotype using 10 mM DMSO stock solutions of SGD-1006,SGD-1269 (See Table B) and NEM. When mixed at the appropriate ratio thetotal maleimide concentration was therefore still 10 mM, and this valuewas used to calculate the volume of maleimide solution to be added toeach well. For example for a murine IgG1 with 5 reducible disulfides (10available thiols when reduced) 0.5 mg of antibody at 150 kD is 3.33 nmolcorresponding to 33.3 nmol of thiol. A 3-fold excess is therefore 100nmol of total maleimide or 10 μL of the 10 mM drug linker/NEM mix. Forthe SGD-1269 conjugate this mix would then be prepared with 5.86 μL ofSGD-1269 and 4.14 μL of NEM. The maleimide mix would then be dilutedinto 500 μL of PBS prior to addition to the immobilized reducedantibody. In practice, since multiple antibodies of each isotype wereconjugated simultaneously a single SGD-1269/NEM mixed solution for eachisotype was prepared by multiplying the number of wells containing thatisotype by 10 μL per well then diluting into a volume of PBS equal to500 μL times the number of wells. In like fashion a total of eightdrug-linker/NEM mixes were prepared—four with SGD-1006 and four withSGD-1269—and diluted into PBS. These mixes were then added to thereduced antibodies (500 μL per well) and the plate was shaken for 30minutes at 22° C. The plate was then centrifuged as above to remove theexcess reaction solution, and subsequently washed 4 times with PBS asbefore.

The bound ADCs were then eluted by adding 200 μL of 50 mM glycine pH 2.5to each well and shaking the plate for 3 minutes at 1200 RPM. Whileshaking 20 μL of neutralization buffer (1M potassium phosphate, pH 7.4,500 mM NaCl, 0.2% Tween-20) was added to each well of a 1 mL collectionplate. The ADCs were then eluted into the collection plate by spinningat 1500×g for 6 minutes. The collection plate was then shaken briefly toensure complete mixing of the neutralization buffer.

The concentration of each ADC was then determined with an absorbanceplate reader by transferring the solutions into a UV assay plate (Costarmodel 3635, Corning) and measuring the optical density at 280 nm. Anaverage IgG extinction coefficient of 1.45 mL mg-1 cm-1 was used toprovide an adequate estimation of ADC concentration across the panel. Toconfirm successful conjugation, a reversed phase protein HPLC method(described below) was used to estimate the drug loading of the isotypecontrols. For the plate containing the humanization variants of CA8 thismethod was used to estimate the loading of all ADCs directly.

The reversed phase protein chromatography method for determining drugloading employs the PLRP-S polymeric stationary phase (AgilentTechnologies). Since the antibodies were fully reduced during theconjugation process all of the antibody subunits elute from the columnas single polypeptide chains allowing the subpopulations of light andheavy chain species with varying levels of drug loading to be evaluatedseparately. Thus, the analysis of these data allow for the calculationof the average light chain drug loading and the average heavy chain drugloading as independent factors which can then be combined to determineaverage antibody drug loading with the basic knowledge that eachantibody is comprised of two light and two heavy chains. Thechromatographic conditions were as follows: A PRLP-S column, 1000 Å,50×2.1 mm, 8 um particle size (Agilent Technologies) with water+0.05%TFA as mobile phase A and acetonitrile+0.01% TFA as mobile phase B;elution with a linear gradient of 27% B to 42% B in 12.5 minutes.

Anti-BCMA antibodies were conjugated with SGD-1006 and SGD-1269 in threeseparate batches over a period of seven months. In the first batch atotal of 29 antibodies were conjugated (resulting in 58 ADCs). The drugloading of each isotype control determined by PLRP chromatography andthe data are summarized in Table 3.

TABLE 3 SGD-1006 SGD-1269 Isotype loading loading cIgG1 (control P) 4.234.35 cIgG1 (control M) 4.42 4.41 mIgG1 4.26 4.04 mIgG2a 4.51 4.57 mIgG2b4.39 4.18

For the second batch an additional 25 antibodies were conjugated(resulting in 50 ADCs). The drug loading of each isotype control wasagain determined by PLRP chromatography and the data are summarized inTable 4.

TABLE 4 SGD-1006 SGD-1269 Isotype loading loading cIgG1 3.96 3.78 mIgG13.95 3.32 mIgG2a 4.53 3.60 mIgG2b 4.32 3.49

In the third batch 30 antibodies were conjugated (resulting in 60 ADCs),including 13 humanized variants of CA8. In this final batch, the drugloading of all ADCs were determined and are summarized in the followingtwo plate maps. (Table 5 & 6)

Mean drug loading and % CV are indicated for each isotype series at thebottom. An uncharacteristically large variability in drug loading wasobserved for the SGD-1269 ADCs prepared with mIgG2b antibodies; thereason for this is unclear. Also, the Fc-enhanced CA8 antibodies yieldedsomewhat lower drug loading levels than the other CA8 human variants; toaddress this, additional Fc-enhanced CA8 was conjugated in asolution-phase reaction to better match the drug loading achieved forthe other antibodies.

Example 4—Binding Data 4.1 FMAT Binding Assay to Show Binding ofChimeric CA8 to Cells Expressing Human or Cyno BCMA.

Cryopreserved transfected human, cyno BCMA and mock transfected HEK293cells were recovered from LN2 storage. Assay wells were prepared withhuman chimeric CA8 antibody, at a range of different concentrations,mixed with human BCMA HEK293, cyno BCMA HEK293 and mock transfectedcells respectively. Anti-human IgG FMAT Blue secondary conjugate wasadded for detection of human chimeric CA8. The assay plates were leftfor a minimum of 90 minutes before the result was read on the ABI8200(FMAT) plate reader. This showed that the CA8 antibody in chimeric formbinds well to both human and cyno BCMA proteins expressed on HEK293cells.

Results are shown in FIG. 1.

4.2 ELISA Experiment Showing Binding of Chimeric CA8 to Recombinant BCMAProtein

Chimeric CA8 antibodies were tested for binding to human BCMA and cynoBCMA expressed as Fc fusions. Human BCMA-Fc and cyno BCMA-Fc were coatedto ELISA plates and the plates were blocked using BSA to reduce nonspecific binding. CA8 chimeric antibodies were added in a concentrationrange from 5 ug/ml to 0.1 ug/ml to the human and cyno BCMA coated ELISAplates. Any bound human chimeric CA8 antibody was detected usinganti-human IgG HRP conjugated secondary antibody as appropriate. HRPsubstrate (TMB) was added to develop the ELISA. This showed that CA8antibody binds to recombinant human and cyno BCMA in an ELISA assay.

Results are shown in FIG. 2.

4.3 Biacore Experiment to Show CA8 Antibody Binding to BCMA and TACIProteins to Determine Cross Reactivity with TACI Protein.

CA8 chimera antibody was injected and captured on protein A. (A proteinA derivitised sensorchip was used). Residual protein A binding wasblocked with an injection of a high concentration of human IgG solution.BCMA-Fc, TACI-Fc or BAFF-R-Fc solutions were then tested for binding tothe antibody. The 3 proteins were injected in sequence and bindingevents were measured. The surface was regenerated between injection ofeach protein.

Sensorgrams were analysed in the Biaevaluation program. Double referencesubtraction was done to remove instrument noise and any non-specificbinding from the sensorgram curves.

This showed that CA8 was specific for binding to BCMA binding and not toTACI and BAFFR.

Binding of the CA8 antibody to BCMA-Fc, TACI-Fc and BAFF-R-Fc wasplotted out as shown in FIG. 3.

4.4 Cell Binding and Neutralisation Data 4.4.1 Binding of Murine AntiBCMA Antibodies to Multiple Myeloma Cells and BCMA Expressing Cells

Multiple myeloma cell line H929 and ARH77-hBCMA 10B5 BCMA expressingtransfectant cells were stained with murine S332211D07, S3332121F02 orS332126E04 or murine isotype control at 5 μg/mL. Multiple myeloma cellline H929 was stained with murine S307118G03. Cells were incubated for20 mins at room temperature (RT) and then washed with FACS buffer(PBS+0.5% BSA+0.1% sodium azide) to remove unbound antibody. Cells wereincubated with a secondary PE labelled anti-mouse IgG antibody for 15minutes at RT and then washed with FACS buffer to remove unboundantibody. Cells were analysed by FACS to detect antibody bound to thecells.

The results (FIG. 4) showed that all 4 murine antibodies bound to theH929 multiple myeloma cell line and the three antibodies tested on ARH77BCMA transfected cells bound to these.

4.4.2 Binding Curve of Chimeric CA8 to Multiple Myeloma Cells asDetermined by FACS

A panel of multiple myeloma cell lines were used to determine thebinding of chimeric CA8. Cell lines H929, OPM-2, JJN-3 and U266 werestained with either chimeric CA8 or irrelevant antibody (Synagis) atvarying concentrations for 20 minutes at RT. Cells were then washed withFACS buffer (PBS+0.5% BSA+0.1% sodium azide) to remove unbound antibody.Cells were incubated with a secondary PE labelled anti-human IgGantibody for 15 minutes at RT and then washed with FACS buffer to removeunbound antibody. Cells were analysed by FACS and mean fluorescenceintensity (MFI) values measured to determine binding.

Results: showed that chimeric CA8 bound to multiple myeloma cell linesH929, OPM-2, JJN-3 & U266 in a dose dependent manner (FIG. 5).

4.4.3 Binding of Humanised CA8 to BCMA Transfected Cells as Determinedby FACS

ARH77-hBCMA 10B5 BCMA expressing transfectant cells or H929 cells werestained with either chimeric CA8 or humanised variants of CA8 designatedJ6M0, J6M1, J6M2, J9M0, J9M1, J9M2 at varying concentrations for 20minutes at RT. Cells were then washed with FACS buffer (PBS+0.5%BSA+0.1% sodium azide) to remove unbound antibody. Cells were incubatedwith a secondary PE labelled anti-human IgG antibody for 15 minutes atRT and then washed with FACS buffer to remove unbound antibody. Cellswere analysed by FACS and mean fluorescence intensity (MFI) valuesmeasured to determine binding.

Results showed that chimeric CA8 and all antibodies tested apart fromJ9M2 bound to ARH77-hBCMA 10B5 BCMA expressing transfectant cells andH929 cells in a dose dependent manner (FIG. 6).

4.5 Demonstration of Ability of CA8 and the Humanised Version J6M0 toNeutralise Binding of BAFF or APRIL to Recombinant BCMA.

The aim of this assay was to assess the ability of antibody CA8, andhumanised version J6M0 in both wild type and afucosylated (Potelligent)form, at various concentrations, to neutralise the binding ability ofeither BCMA ligand, BAFF or APRIL.

96 well flat bottomed plates were coated overnight with 1 μg/mL solutionof recombinant human BCMA Fc 4-53 in PBS. Following a wash step using0.05% TWEEN20, plates were blocked with 2% Bovine Serum Albumin solutionin PBS for 1 hour at room temperature. Plates were washed as before and40 μL of each antibody (murine IgG, murine CA8, and chimeric CA8),starting at 10 μg/mL, titrated at 1 in 2 in duplicate was added to therelevant wells and incubated for 1 hour at room temperature. 40 μL of 2%BSA was added to the relevant control wells. 10 μL of either recombinanthuman BAFF (2149-BF/CF, R&D Systems) or recombinant human APRIL(5860-AP/CF, R&D Systems) was added at 30 ng/mL and 750 ng/mLrespectively, giving a final concentration of 6 ng/mL and 150 ng/mLrespectively in each well. Equivalent volume of 2% BSA was added to therelevant control wells. Plates were allowed to incubate for 2 hours atroom temperature, after which they were washed as before. Biotinylatedanti-human ligand (BAFF BAF124 or APRIL BAF884, R&D Systems) was addedto the relevant wells at 50 ng/mL and incubated for 1 hour. Following awash step, 50 μL of a 1:4000 dilution of Streptavidin-HRP (AmershamRPN4401) was added to each well and incubated for 30 minutes at roomtemperature. The wash process was repeated again followed by theaddition of 100 μL of Tetramethylbenzidine substrate solution (T8665,Sigma) into each well. Plates were incubated for 20-25 minutes at roomtemperature, wrapped in foil. The reaction was stopped with the additionof 100 μL of 1M H₂SO₄. Optical density was determined at 450 nm usingSpectromax reader. See FIGS. 7A and B.

In a plate based assay for neutralisation of binding of BAFF or APRIL toBCMA, the EC50 values calculated for chimeric CA8 were 0.695 μg/mL and0.773 μg/mL respectively. The values for the humanised J6M0 were 0.776ng/ml and 0.630 ng/ml. The values for the J6M0 potelligent version were0.748 and 0.616 ng/ml respectively.

4.6 Effect of Chimerised CA8 and Humanised J6M0 BCMA Antibody on BAFF orAPRIL Induced Phosphorylation of NFkB in H929 Cells.

In one set of experiments, H-929 cells were plated at 75,000 cells/wellin a 96 well plate in serum free medium. The chimeric CA8 antibody wasadded 24 hours later to give final well concentrations up to 200 ug/ml.Ten minutes later, BAFF or APRIL ligand were added to the cells to givefinal well concentrations of 0.6 or 0.3 ug/ml respectively. After 30minutes the cells were lysed and phosphorylated NfkappaB levels measuredusing a MSD pNFkappaB assay.

The chimeric BCMA antibody CA8 neutralised both BAFF and APRIL inducedNfkappaB cell signalling in H-929 cells. It was particularly potent atneutralising BAFF induced NfkappaB cell signalling in this cell typewith a mean IC50 of 10 nM, compared to 257 nM for APRIL induced NfkappaBcell signalling.

Meaned Data for 2 Experiments

IC50s were 10 nM for BAFF induced NfkappaB neutralisation and 257 nM forAPRIL induced NfkappaB neutralisation (mean of 2 independentexperiments) are shown in Table 7.

TABLE 7 BAFF APRIL induced induced IC50 IC50 ug/ml nM ug/ml nM BCMAantibody CA8 1.5 10 38.5 256.7

A further set of experiments were carried out to aim to understand whythere was such a discrepancy between the potency in neutralisation ofAPRIL and BAFF in the cell based system. Following the discovery of thesoluble form of BCMA the experimental design was changed to include astep where the H929 cells were washed prior to the assay to reduce theinterference from the antibody binding to soluble BCMA. H-929 cells werewashed 3 times to remove any sBCMA and resuspended in serum free medium.J6M0 potelligent antibody was added to a 96 well plate to give a finalwell concentrations up to 100 ug/ml along with BAFF or APRIL ligand togive a final well concentration of 0.6 or 0.2 ug/ml respectively. H-929cells were then plated at 7.5×104 cells/well in serum free medium. 30minutes later the cells were lysed and phosphorylated NFkappaB levelsmeasured using a MSD pNFkappaB assay. This is data from one experiment.Each data point is the mean/sd of two replicates. The data from thisexperiment is shown in FIG. 7c . The IC50s for inhibition of BAFF andAPRIL signalling were determined as 0.91 ug/ml and 2.43 ug/mlrespectively.

4.7 ProteOn Analysis of Anti-BCMA CA8 Chimeric and Humanised Constructs

The initial screen of CA8 chimeric and humanised variants was carriedout on the ProteOn XPR36 (Biorad). The method was as follows; Protein Awas immobilised on a GLC chip (Biorad, Cat No: 176-5011) by primaryamine coupling, CA8 variants were then captured on this surface andrecombinant human BCMA (in house or commercial US Biological, B0410)materials (run 2 only)) passed over at 256, 64, 16, 4, 1 nM with a 0 nMinjection (i.e. buffer alone) used to double reference the bindingcurves, the buffer used is the HBS-EP buffer. 50 mM NaOH was used toregenerate the capture surface. The data was fitted to the 1:1 modelusing the analysis software inherent to the ProteOn XPR36. Run 1corresponds to the first screen of humanised CA8 variants (JO to J5series) and run 2 to the second screen of humanised CA8 variants (J5 toJ9 series). Both runs were carried out at 25° C.

The data obtained from run 1 are set out in Table 8 and data from run 2are set in Table 9 Several molecules in the Run 2 (Table 09) failed togive affinity values measurable by ProteOn, this was due to the off-ratebeing beyond the sensitivity of the machine in this assay, this doeshowever indicate that all these molecules bind tightly to recombinanthuman BCMA. From Run 1 the data indicates that some constructs did notshow any binding to recombinant cyno BCMA.

TABLE 8 Run 1-Kinetics analyses of anti-BCMA molecules againstRecombinant Human BCMA Human in house BCMA Cyno in house BCMA KD KDSample name ka kd (nM) ka kd (nM) CA8 humanised J5M0 2.16E+05 1.88E−050.087 3.25E+05 8.14E−06 0.025 CA8 humanised J5M2 2.67E+05 3.21E−05 0.124.30E+05 4.70E−05 0.109 CA8 humanised J5M1 2.97E+05 4.32E−05 0.1454.81E+05 5.41E−05 0.112 CA8 humanised J4M1 2.54E+05 7.04E−05 0.2783.50E+05 7.10E−05 0.203 CA8 humanised J4M2 2.51E+05 7.06E−05 0.2813.44E+05 6.15E−05 0.179 CA8 humanised J0M2 2.25E+05 6.97E−05 0.313.26E+05 1.84E−04 0.563 CA8 humanised J3M2 2.66E+05 9.64E−05 0.3623.69E+05 5.87E−05 0.159 CA8 humanised J0M1 2.31E+05 8.60E−05 0.3733.32E+05 1.67E−04 0.503 CA8 humanised J0M0 2.45E+05 1.06E−04 0.4353.58E+05 2.32E−04 0.648 CA8 humanised J3M1 2.85E+05 1.25E−04 0.4384.04E+05 7.93E−05 0.196 CA8 humanised J2M2 2.05E+05 9.87E−05 0.4822.98E+05 3.17E−05 0.106 CA8 Chimera 2.41E+05 1.25E−04 0.519 3.82E+051.74E−04 0.457 CA8 humanised J2M1 2.04E+05 1.72E−04 0.842 2.96E+056.46E−05 0.218 CA8 humanised J4M0 2.42E+05 2.20E−04 0.906 3.34E+052.89E−04 0.866 CA8 humanised J1M2 2.15E+05 2.46E−04 1.14 3.19E+059.67E−05 0.303 CA8 humanised J3M0 2.08E+05 2.85E−04 1.37 2.93E+051.54E−04 0.526 CA8 humanised J1M1 2.27E+05 3.43E−04 1.51 3.33E+051.47E−04 0.442 CA8 humanised J2M0 1.95E+05 3.77E−04 1.94 2.81E+051.51E−04 0.538 CA8 humanised J1M0 1.78E+05 5.02E−04 2.82 2.47E+052.10E−04 0.849 S307118G03 Chimera 4.75E+05 1.95E−03 4.11 No AnalysableBinding S307118G03 humanised H3L1 4.69E+05 2.28E−03 4.86 No AnalysableBinding S307118G03 humanised H3L0 2.86E+05 1.52E−03 5.31 No AnalysableBinding S307118G03 humanised H2L0 3.78E+05 2.41E−03 6.36 No AnalysableBinding S307118G03 humanised H2L1 3.38E+05 2.15E−03 6.37 No AnalysableBinding S307118G03 humanised H4L1 No Analysable Binding No AnalysableBinding

TABLE 9 Run 2-Kinetics analyses of anti-BCMA molecules againstRecombinant Human BCMA Human in house BCMA commercial human BCMA Cyno inhouse BCMA KD KD KD Sample Name ka kd (nM) ka kd (nM) ka kd (nM) CA8Chimera 2.51E+05 1.03E−04 0.412 7.05E+05 9.79E−05 0.139 5.89E+041.21E−04 2.060 CA8 humanised J6M1 2.17E+05 2.70E−05 0.124 5.92E+053.75E−05 0.063 4.88E+04 2.58E−04 5.300 CA8 humanised J6M0 2.40E+057.40E−05 0.308 6.23E+05 5.37E−05 0.086 5.64E+04 3.18E−04 5.630 CA8humanised J6M2 2.01E+05 4.06E−05 0.202 5.63E+05 3.97E−05 0.071 4.41E+043.02E−04 6.860 S307118G03 H5L0 No Analysable Binding V weak signal NoAnalysable Binding S307118G03 H5L1 No Analysable Binding V weak signalNo Analysable Binding S307118G03Chimera 4.79E+05 1.65E−03 3.44 1.55E+061.48E−03 0.956 No Analysable Binding

For antibodies J8M0, J9M0, J8M1, J9M2, J7M2, J5M0, J7M1, J7M0, J8M2,J9M1, J5M2, J5M1 the off rate was beyond the sensitivity of the assayhence no data shown.

4.8 BIAcore Analysis of Anti-BCMA CA8 Chimeric and Humanised Constructs(J7 to J9 Series)

Protein A was immobilised on a CM5 chip (GE Healthcare, Cat No:BR-1005-30) by primary amine coupling and this surface was then used tocapture the antibody molecules. Recombinant human BCMA (US Biological,B0410) was used as analyte at 256 nM, 64 nM, 16 nM, 4 nM and 1 nM.Regeneration of the capture surface was carried out using 50 mM NaOH.All binding curves were double referenced with a buffer injection (i.e.0 nM) and the data was fitted to the using the 1:1 model inherent toT100 evaluation software. The run was carried out at 37° C., usingHBS-EP as the running buffer.

The results showed the molecules tested with the exception of J9M2 bindto recombinant human BCMA, with similar affinity as the chimericmolecule. Data generated from this experiment are presented in table 10.

TABLE 10 Kinetics analysis of anti-BCMA humanised molecules againstRecombinant Human BCMA Human commercial BCMA Cyno in house BCMA KD KDSample name ka kd (nM) ka kd (nM) CA8 humanised J9M1 1.96E+07 3.50E−040.018 6.77E+05 2.99E−04 0.442 CA8 humanised J9M0 4.95E+06 1.74E−04 0.0357.03E+05 3.24E−04 0.46 CA8 Chimera 3.27E+07 1.18E−03 0.036 1.15E+063.49E−04 0.305 CA8 humanised J8M1 2.66E+06 1.34E−04 0.05 2.82E+053.62E−04 1.284 CA8 humanised J8M0 2.44E+06 1.26E−04 0.052 3.89E+054.18E−04 1.076 CA8 humanised J7M1 2.35E+06 1.31E−04 0.056 3.70E+053.91E−04 1.057 CA8 humanised J8M2 2.63E+06 1.50E−04 0.057 3.83E+055.06E−04 1.324 CA8 humanised J7M2 2.37E+06 1.35E−04 0.057 3.46E+054.47E−04 1.293 CA8 humanised J7M0 2.36E+06 1.51E−04 0.064 3.21E+053.67E−04 1.143 CA8 humanised J9M2 No Analy sable Binding 4.88E+052.52E−04 0.515

4.9 BIAcore Analysis of Anti-BCMA CA8 Chimeric and Humanised ConstructsJ6M0 and J9M0

Protein A was immobilised on a CM5 chip (GE Healthcare, Cat No:BR-1005-30) by primary amine coupling and this surface was then used tocapture the antibody molecules.

Recombinant human BCMA (US Biological, B0410) was used as analyte at 256nM, 64 nM, 16 nM, 4 nM and 1 nM. Regeneration of the capture surface wascarried out using 50 mM NaOH. All binding curves were double referencedwith a buffer injection (i.e. 0 nM) the data was fitted to the using the1:1 model inherent to T100 evaluation software. The run was carried outat 25° C. and 37° C. for experiment 1 and only 37° C. for experiment 2using HBS-EP as the running buffer.

The both runs identified J9M0 as the best molecule in term of overallaffinity to human BCMA. Data generated from this experiment arepresented in table 11.

TABLE 11 Kinetics analyses of anti-BCMA humanised molecules againstHuman BCMA Human commercial BCMA 25° C. 37° C. Experiment 1 Experiment 1Experiment 2 KD KD KD Sample ka kd (nM) ka kd (nM) ka kd (nM) J9M01.59E+06 3.38E−05 0.021 3.75E+06 1.58E−04 0.042 3.62E+06 1.89E−04 0.052J6M0 1.01E+06 1.22E−04 0.121 2.12E+06 1.48E−03 0.698 3.78E+06 1.88E−030.498 Chimera CA8 1.88E+06 2.63E−04 0.140 1.72E+07 8.72E−04 0.0511.88E+07 1.04E−03 0.055

4.10. ProteOn Analysis of New Anti-BCMA Chimeric Constructs

The initial screen of the new chimeric variants from the second batch ofhybridomas was carried out on the ProteOn XPR36 (Biorad). The method wasas follows; Protein A was immobilised on a GLM chip (Biorad, Cat No:176-5012) by primary amine coupling, anti-BCMA variants were thencaptured on this surface and recombinant human BCMA (in house material)passed over at 256, 64, 16, 4, 1 nM with a 0 nM injection (i.e. bufferalone) used to double reference the binding curves, the buffer used isthe HBS-EP buffer. Regeneration of the capture surface was carried outusing 50 mM NaOH. The data was fitted to the 1:1 model using theanalysis software inherent to the ProteOn XPR36. The run was carried outat 25° C. Data generated from this experiment are presented in table 12.

TABLE 12 Kinetics analyses of anti-BCMA humanised molecules againstHuman BCMA In house human BCMA Sample KD name ka kd (nM) S332110D073.11E+05 3.77E−03 12.100 S332121F02 3.73E+05 6.45E−03 17.300

Example 5 Cell Killing Assays 5.1 ADCC Potencies of Chimeric CA8 andDefucosylated Chimeric CA8 Version in ARH77 Cells Expressing BCMA

Human natural killer (NK) cells were incubated with europium labelledARH77 BCMA transfected target cells (10B5) in the presence of varyingconcentrations of antibody at an E:T ratio of 5:1 for 2 hours. Europiumrelease from the target cells was measured and specific lysiscalculated.

Result: Chimeric CA8 and defucosylated chimeric CA8 killed BCMAexpressing target cells via ADCC. The defucosylated chimeric antibodyshowed more potent ADCC activity, as measured by a higher percent lysisachieved with all the target cells tested and a ten-fold lower EC₅₀ onthe high BCMA expressing target cell line 10B5, compared to the parentchimeric antibody. See FIGS. 8A and 8B.

5.2 ADCC Activity of CA8 Humanised Antibodies Using ARH77 BCMAExpressing Target Cells and PBMC as Effectors

Human PBMC were incubated with europium labelled ARH77 BCMA transfectedtarget cells (10B5) in the presence of varying concentrations ofhumanised versions of CA8 antibody (5 ug/ml to 0.005 ug/ml) at an E:Tratio of 5:1 for 2 hours. Europium release from the target cells wasmeasured and specific lysis calculated.

Result:

Result: All the J5, J6, J7 J8 & J9 series of humanised variants of CA8showed ADCC activity against the ARH77 high BCMA expressing cell line10B5 in a dose dependent manner. ADCC was at a similar level as thatfound in the experiments using chimeric CA8 molecule. See FIG. 9.

5.3 ADCC Potencies of Chimeric S322110F02, S322110D07 and S307118G03 andHumanised S307118G03 H3L0 Against ARH77 10B5 Cells Expressing BCMA withPurified NK Cells as Effector Cells

Human natural killer (NK) target cells were incubated with europiumlabelled ARH77 BCMA transfected target cells (10B5) in the presence ofvarying concentrations of antibody at an E:T ratio of 5:1 for 2 hours.Europium release from the target cells was measured and specific lysiscalculated.

Result: all 4 antibodies tested showed ADCC activity against ARH77 10B5cells. See FIG. 10.

5.4 Antibody-Drug Conjugate (ADC) Activity of Chimeric CA8 ADCs.

Measuring ADC activity of chimeric CA8 antibody, chimeric CA8-mcMMAFantibody drug conjugates and chimeric CA8-vcMMAE antibody drugconjugates against human multiple myeloma cell lines.

Multiple Myeloma cell lines were treated with chimeric CA8 antibody-drugconjugates to determine the ADC concentrations required for growthinhibition and death.

The antibody drug conjugates tested were added to wells containingmultiple myeloma cells at concentrations ranging from 1 ug/ml to 5ng/ml. The plates were incubated at 37° C. for 96 hours at which pointviable cells were quantitated using Cell titre Glo. The unconjugatedchimeric CA8 antibody showed no significant growth inhibitory activityat the antibody concentrations that were tested. The chimeric CA8-mcMMAFantibody-drug conjugate showed greater growth inhibitory activity thanthe chimeric CA8-vcMMAE antibody-drug conjugate in all 4 of the multiplemyeloma cell lines that were tested. See FIG. 11 and Table 13

TABLE 13 IC₅₀ values represented in ng/mL for the chimeric CA8-vcMMAEand the chimeric CA8-mcMMAF antibody-drug conjugates in 4 differentmultiple myeloma cell lines IC₅₀ (ng/mL) Multiple Myeloma CA8 chimera -CA8 chimera - cell lines vcMMAE mcMMAF NCI-H929 29.5 8.8 U266-B1 18.99.7 JJN3 21.8 12.4 OPM2 92.7 58.15.5 Measuring Cell Cycle Arrest Activity of Chimeric CA8 Antibody,Chimeric CA8-mcMMAF Antibody Drug Conjugates and Chimeric CA8-vcMMAEAntibody Drug Conjugates Against Human Multiple Myeloma Cell Line H929.

To determine the mechanism that chimeric CA8 Antibody Drug Conjugates(ADC's) cause growth inhibition in multiple myeloma cells, the cellcycle of NCI-H929 cells was monitored by measuring cellular DNA contentthrough fixed cell propidium iodide staining at multiple timepointsfollowing chimeric CA8 antibody and chimeric CA8 ADC treatment.

At the chimeric CA8 ADC concentration tested (50 ng/mL), the chimericCA8-mcMMAF ADC caused significant G2/M cell cycle arrest (4N DNAcontent) which peaked at 48 hours. At the later timepoints 48, 72 and 96hours, treatment with the chimeric CA8-mcMMAF ADC resulted inaccumulation of a cell population with sub-2N DNA content, which isrepresentative of cell death. At the 50 ng/mL concentration tested thechimeric CA8-vcMMAE ADC had no significant effect on G2/M cell cyclearrest or sub-G1 accumulation. See FIG. 12.

5.6 Phospho-Histone-H3 (Thr11) Staining as a Marker for ChimericCA8-mcMMAF Antibody Drug Conjugate and Chimeric CA8-vcMMAE Antibody DrugConjugate Induced Mitotic Arrest.

To determine if the accumulation of cells with 4N DNA content is aspecific result of mitotic arrest induced by the chimeric CA8 ADCsNCI-H929 cells were stained with an anti-phospho-Histone H3 antibodyfollowing treatment with increasing concentrations of unconjugatedchimeric CA8, chimeric CA8-vcMMAE or chimeric CA8-mcMMAFfor 48 hours.Treatment with chimeric CA8 ADCs resulted in a dose-dependentaccumulation of NCI-H929 cells that stained positive for83eroxidi-Histone H3 (Thr11), a specific marker of mitotic cells. Thechimeric CA8-mcMMAF ADC caused accumulation of 83eroxidi-Histone H3positive cells at lower concentrations than the chimeric CA8-vcMMAE ADC.See FIG. 13.

5.7 Measuring Apoptosis in NCI-H929 Cells in Response to Chimeric CA8ADCs by Staining for Annexin V.

To determine if the accumulation of cells with sub-2N DNA content is aspecific result of apoptosis induced by the chimeric CA8 ADCs, NCI-H929cells were stained with an anti-Annexin-V antibody following treatmentwith increasing concentrations of unconjugated chimeric CA8, chimericCA8-vcMMAE or chimeric CA8-mcMMAFfor 48 hours. Treatment with chimericCA8 ADCs resulted in a dose-dependent accumulation of NCI-H929 cellsthat stained positive for Annexin-V, a specific marker of apoptosis. Thechimeric CA8-mcMMAF ADC caused accumulation of Annexin-V positive cellsat lower concentrations than the chimeric CA8-vcMMAE ADC. See FIG. 14.

5.8 Antibody-Drug Conjugate (ADC) Activity of Humanised Variants of CA8Anti-BCMA Antibody-Drug Conjugates.

Cells were plated in 96-well plates (4,000 cells per well in 100 μL ofRPMI+10% FBS) Naked antibody or ADC was added 6 hours after cell seedingand plates were incubated for 144 hours. Growth inhibition in thepresence of the antibodies or ADCs was measured at 144 hours using CellTitre glo. Data points represent the mean of triplicate CellTiterGlomeasurements. Error bars represent standard error.

Multiple Myeloma cell lines NCI-H929 and OPM2 were treated withhumanized CA8 anti-BCMA antibody-drug conjugates to determine the ADCconcentrations required for growth inhibition and death. The mcMMAF andvcMMAE antibody-drug conjugate forms of these antibodies showedsignificant growth inhibitory activity comparable to that found with theCA8 chimera. Variant J6M0 showed higher potency than the chimera anddata is shown in FIG. 15 in H929 cells and OPM2 cells. The mcMMAFantibody-drug conjugate showed greater growth inhibitory activity thanthe vcMMAE antibody-drug conjugate for all antibodies in both cell linestested. Results for all humanized variants are shown in Table 14.

TABLE 14 IC₅₀ values represented in ng/mL for the anti BCMAantibody-drug conjugates in NCI-H929 and U266-B1 cells NCI-H929 OPM2mcMMAF vcMMAE mcMMAF vcMMAE Average Average Average Average IC50 IC50IC50 IC50 (ng/mL) (ng/mL) (ng/mL) (ng/mL) CA8 11.64 37.96 57.04 80.01chimera CA8 5.97 27.67 87.22 121.2 J6M0 CA8 14.6 51.89 205.6 239.9 J6M1CA8 9.5 39.71 112.9 144.7 J6M2 CA8 18.97 52.25 93.27 127.1 J7M0 CA817.87 43.97 95.35 107.5 J7M1 CA8 31.63 55.13 102.6 115.9 J7M2 CA8 15.6759.94 89.95 132 J8M0 CA8 17.04 46.55 82.96 115.8 J8M1 CA8 15.08 55.9872.63 124.5 J8M2 CA8 14.95 48.5 58.6 109.8 J9M0 CA8 15.19 55.1 55.88 115J9M1 CA8 20.87 55.77 80.35 111.7 J9M2

5.9 Antibody-Drug Conjugate (ADC) Activity of Other Murine Anti-BCMAAntibody-Drug Conjugates.

Cells were plated in 96-well plates (4,000 cells per well in 100 μL ofRPMI+10% FBS) Antibody or ADC was added 6 hours after cell seeding andplates were incubated for 144 hours. Growth inhibition in the presenceof the ADCs was measured at 144 hours using Cell Titre glo. The mean oftriplicate CellTiterGlo measurements are shown. Table 15a and 15b arefrom experiments carried out at different times on different series ofantibodies. Multiple Myeloma cell lines NCI-H929 and U266-B1 were usedfor antibodies in Table 15a.

The mcMMAF and vcMMAE antibody-drug conjugate forms of murine antibodiesS322110D07, S332121F02 and S332136E04 showed significant growthinhibitory activity. The mcMMAF antibody-drug conjugate showed greatergrowth inhibitory activity than the vcMMAE antibody-drug conjugate inall of the murine anti-BCMA antibodies tested where activity was seen.IC50 figures are shown in Table 15a. See FIG. 16 for dose responsecurves for these three antibodies and also S107118G03. Error barsrepresent standard error. NCI-H929, U266-B1, JJN3 and OPM2 cells forantibodies in Table 15b were treated with a different series of murineanti-BCMA antibody-drug conjugates to determine the ADC concentrationsrequired for growth inhibition and death. IC50 figures are shown inTable 15b. All 5 antibodies shown on the table had significant ADCactivity.

TABLE 15a IC₅₀ values represented in ng/mL for the anti BCMAantibody-drug conjugates in NCI-H929 and U266-B1 cells IC50 (ng/mL)NCI-H929 U226-B1 Antibody -vcMMAE -mcMMAF -vcMMAE -mcMMAF S322110D07mIgG1 28.4 6.7 53.3 33.3 S332121F02 mIgG1 24.5 7 2.3 2.5 S332126E04mIgG1 46.8 9.7 27.1 10.6

TABLE 15b IC₅₀ values represented in ng/mL for the anti BCMA antibody-drug conjugates in NCI-H929, U266-B1, JJN3 and OPM2 cells Average IC50NCI-H929 U266B1 JJN3 OPM2 (ng/mL) vcMMAE mcMMAF vcMMAE mcMMAF vcMMAEmcMMAF vcMMAE mcMMAF S335115G01 14.9 4.2 38.8 18.5 73.9 45.8 162.4 197.2S336105A07 17.8 5.1 21.4 9.3 54.2 23.2 95.5 73.7 S335122F05 10.9 4.221.1 14.1 29.5 25.5 98.4 128.7 S335106E08 19.2 7.9 36.8 32.6 189.8 214.1243.9 307.5 S335128A12 86.3 28.3 101.8 104.1 >500 >500 >500 >500

5.10 ADCC Potency of Conjugated, Afucosylated J6M0 (Potelligent)

Afucosylated J6M0 conjugated to MMAE or MMAF was tested in ADCC assaysusing BCMA transfectants to ensure that its ADCC activity was notcompromised by the conjugation.

Europium labelled ARH77-10B5 cells were incubated with various J6M0 WTand Potelligent BCMA antibodies at concentrations up to 10000 ng/ml for30 minutes prior to the addition of PBMCs (PBMC: target cell ratio50:1). Two hours later an aliquot of cell media was sampled and mixedwith enhancement solution. After 30 minutes on a plate shaker, europiumrelease was monitored on the Victor 2 1420 multi-label reader.Datapoints represent means of triplicate values. This data isrepresentative of 2 experiments.

There were no significant differences in ADCC potency between theunconjugated and ADC forms of J6M0 Potelligent. In the same experiment awild type version of J6M0 was included to show how the potency comparesto the afucosylated version. As expected, defucosylation resulted in alower EC50 and higher maximal lysis. No lysis was observed with the Fcdisabled form of J6M0. (FIG. 17)

5.11 ADCC Potency of Afucosylated J6M0 on MM Cell Lines

Human PBMC were incubated with multiple myeloma target cells at an E:Tratio of 50:1 in presence of varying concentrations of afucosylated(Potelligent) J6M0 The percentage of target cells remaining in theeffector+target cell mixture after 18 hours was measured by FACS using afluorescently labelled anti-CD138 antibody to detect the target cellsand the percent lysis calculated. This is representative of severalexperiments.

J6M0 Potelligent antibody showed ADCC activity against all five multiplemyeloma target cell lines tested. This was important to test sinceearlier studies were carried out using transfected cells. Results areshown in FIG. 18. Full dataset with multiple donors is shown in Table 16The potencies were all in a similar range as those found with thetransfectants. The ADCC activity was not directly related to BCMAsurface expression on these cell lines.

TABLE 16 EC₅₀ values generated on 13 independent assays using 11 donors(designated A-K) across the five multiple myeloma cell lines. EC₅₀(ng/mL) Donor H929 RPMI JJN-3 OPM-2 U266 A 1.43 NA 1.64 NA NA B 0.57 NANA NA NA C 0.73 NA 1.01 NA NA C 1.81 NA NA NA NA A 2.05 NA NA NA NA D NA4.09 NA NA NA E NA NA 14.4 NA NA F 2.18 NA NA NA NA G NA NA 26.3 NA NA H4.79 NA 111.3 NA NA I NA NA 40.1 NA NA J 2.19 20.4 4.89 NA NA K ND ND4.52 4.15 9.04

Example 6. Xenograft Data

6.1 Murine xenografts of human MM cell lines were tested to ensure thatantibody potency detected in vitro can also be demonstrated in vivo. Thecell line selected for xenograft studies was NCI-H929 which is sensitiveto ADC and ADCC killing in vitro. Studies were carried out inimmunocompromised CB.17 SCID mice which lack T and B cells but maintainNK cells to allow for ADCC activity. However it should be noted thatalthough human IgG1 can engage murine Fc receptors, the Potelligentenhancement does not improve the affinity as it does with human Fcreceptors.

6.2 Impact of Unconjugated and MMAE or MMAF Conjugated J6M0 on NCI-H929Tumour Growth.

In order to independently analyze both the ADCC and ADC activities ofJ6M0 we tested J6M0 antibody in the presence and absence of MMAF or MMAEconjugation. By testing the unconjugated J6M0, any anti-tumour effectscould be attributed to some combination of ADDC and functionalinhibitory activity.

Mice with NCI-H929 tumours that had reached a volume of 200 mm³ onaverage were treated with a human IgG1 control or the J6M0 antibody(unconjugated, MMAE or MMAF) twice weekly at a dose of 50 ug or 100 ug,for 2 weeks. Results from this study show that a 100 ug dose of theJ6M0-MMAF conjugate resulted in elimination of tumours in those micewhich have completed the dosing. The J6M0-MMAF mice were maintained for40 days after the last dose with no recurrence of tumour occurring.These results from this experiment demonstrate that MMAF conjugation hadincreased anti-tumour activity over both unconjugated J6M0 antibody andJ6M0-MMAE conjugate See FIG. 19.

Example 7 Evaluation of Soluble BCMA Levels from MM Patient Serum

7.1 It is currently unknown whether BCMA is present extracellularly andcan be detected in the blood. In this work, we determined the serumlevel of human BCMA from MM patients. Serum samples from 54 MM andplasma cell dyscrasia patients and 20 normal control samples wereanalyzed by ELISA. Human Subject Approval was obtained from WesternInstitutional Review Board.

7.2 Assessment of Serum Human BCMA Levels

Blood, from patients and normal controls in the clinic, were collectedin serum collection tubes. MM patient samples were from a variety ofstages (progressive disease, remission, relapsed, newly diagnosed, andothers). The Blood samples were spun at 10,000 rpm for 10 minutes andserum transferred into sterile micro-centrifuge plastic tubes.

A Human BCMA/TNFRSF17 ELISA kit from R& D Systems (catalog # DY193E)which measures soluble human BCMA levels was used to detect BCMAfollowing the standard protocol supplied with the kit.

Briefly, 96 well micro-plates were coated with 100 ul per well captureantibody and incubated overnight at 4° C. The plates were washed threetimes with wash buffer (0.05% Tween 20 in PBS, pH 7.2) and blocked with300 ul of 1% BSA in PBS at room temperature for 2 hours.

The plates were washed three times with washing buffer. 100 ul of serumsample or standard was added into each well and incubated for 2 hours atroom temperature. The plates were washed three times with washing bufferand then 100 ul of the detection antibody was added to each well andincubated 2 hours at room temperature. 100 ul of Streptavidin-HRP wasadded in each well after washing plates three times and incubated indark room for 20 minutes. The plates were washed three times and added50 ul stop solution and then determined by micro-plate reader with 570nM wavelength.

A series of assays were carried out in order to determine the serumdilution factor appropriate for the levels of BCMA which were present. Adilution factor of 1:500 was found to be suitable for the majority ofsamples and is the dilution factor used in the data shown in FIG. 20.The full data set is shown in Table 17.

Patient and normal control serum samples diluted and run in triplicateshad BCMA levels determined. The serum levels of BCMA were significantlyelevated in the sera from MM patients compared with normal controls inthis study. When the disease subset was divided further there was atrend towards elevated serum levels of BCMA in the sera from progressingMM patients compared with those in remission. This is the first reportidentifying serum BCMA in any human disease and suggests that theselevels may be a novel biomarker for monitoring disease status andtherapeutic response of MM patients and for other patients with plasmacell mediated diseases.

TABLE 17 Figures represent serum concentration of soluble BCMA in ng/mlcalculated from samples diluted at 1/50, 1/500 and 1/5000. P values werecalculated using the one tailed T-Test and 95% significance values arebelow the table. Myeloma: Myeloma: Myeloma: Myeloma: Other Plasma CellNormal Progressive Stable Remission Other MGUS Dyscrasias 1-5000 Mean14.130 500.804 154.762 151.201 94.457 84.912 22.838 1-500 TriplicateMean 15.901 215.877 81.135 43.294 97.584 53.894 22.838 1-500 Single Mean16.620 207.028 61.576 42.796 71.372 40.623 14.099 1-50 Trial 1 Mean25.568 129.544 41.983 40.507 65.120 42.067 51.650 1-50 Trial 2 Mean17.160 119.220 34.567 34.264 54.780 26.333 51.650 P−Values (One TailedT-Test, 95% Significance) ~1-500 Single Normal vs Progressive: p =.0010* Progressive vs Remission: p = .0146* ~1-500 Triplicate Normal vsProgressive: p = .0004* Progressive vs Remission: p = .0091* ~1-50 Trial1 Normal vs Progressive: p = .0171* Progressive vs Remission: p = .0777~1-50 Trial 2 Normal vs Progressive: p = .0184* Progressive vsRemission: p = .0876 *shows significance

Sequence Summary (Table C)

Amino acid Polynucleotide Description sequence sequence CA8 CDRH1SEQ.I.D.NO: 1 n/a CA8 CDRH2 SEQ.I.D.NO: 2 n/a CA8 CDRH3 SEQ.I.D.NO: 3n/a CA8 CDRL1 SEQ.I.D.NO: 4 n/a CA8 CDRL2 SEQ.I.D.NO: 5 n/a CA8 CDRL3SEQ.I.D.NO: 6 n/a CA8 V_(H) domain (murine) SEQ.I.D.NO: 7 SEQ.I.D.NO: 8CA8 V_(L) domain (murine) SEQ.I.D.NO: 9 SEQ.I.D.NO: 10 CA8 HumanisedV_(H) J0 SEQ.I.D.NO: 11 SEQ.I.D.NO: 12 CA8 Humanised V_(H) J1SEQ.I.D.NO: 13 SEQ.I.D.NO: 14 CA8 Humanised V_(H) J2 SEQ.I.D.NO: 15SEQ.I.D.NO: 16 CA8 Humanised V_(H) J3 SEQ.I.D.NO: 17 SEQ.I.D.NO: 18 CA8Humanised V_(H) J4 SEQ.I.D.NO: 19 SEQ.I.D.NO: 20 CA8 Humanised V_(H) J5SEQ.I.D.NO: 21 SEQ.I.D.NO: 22 CA8 Humanised V_(H) J6 SEQ.I.D.NO: 23SEQ.I.D.NO: 24 CA8 Humanised V_(H) J7 SEQ.I.D.NO: 25 SEQ.I.D.NO: 26 CA8Humanised V_(H) J8 SEQ.I.D.NO: 27 SEQ.I.D.NO: 28 CA8 Humanised V_(H) J9SEQ.I.D.NO: 29 SEQ.I.D.NO: 30 CA8 Humanised V_(L) M0 SEQ.I.D.NO: 31SEQ.I.D.NO: 32 CA8 Humanised V_(L) M1 SEQ.I.D.NO: 33 SEQ.I.D.NO: 34 CA8Humanised V_(L) M2 SEQ.I.D.NO: 35 SEQ.I.D.NO: 36 Human BCMA SEQ.I.D.NO:37 SEQ.I.D.NO: 38 CD33-hBCMA ECD (1-53) TEV-Fc Human BCMA SEQ.I.D.NO: 39SEQ.I.D.NO: 40 CD33-hBCMA ECD (4-53) TEV-Fc Cyno BCMA SEQ.I.D.NO: 41SEQ.I.D.NO: 42 CD33 cyno BCMA ECD (4-52) TEV-Fc CA8 J0 Humanised heavychain SEQ.I.D.NO: 43 SEQ.I.D.NO: 44 CA8 J1 Humanised heavy chainSEQ.I.D.NO: 45 SEQ.I.D.NO: 46 CA8 J2 Humanised heavy chain SEQ.I.D.NO:47 SEQ.I.D.NO: 48 CA8 J3 Humanised heavy chain SEQ.I.D.NO: 49SEQ.I.D.NO: 50 CA8 J4 Humanised heavy chain SEQ.I.D.NO: 51 SEQ.I.D.NO:52 CA8 J5 Humanised heavy chain SEQ.I.D.NO: 53 SEQ.I.D.NO: 54 CA8 J6Humanised heavy chain SEQ.I.D.NO: 55 SEQ.I.D.NO: 56 CA8 J7 Humanisedheavy chain SEQ.I.D.NO: 57 SEQ.I.D.NO: 58 CA8 J8 Humanised heavy chainSEQ.I.D.NO: 59 SEQ.I.D.NO: 60 CA8 J9 Humanised heavy chain SEQ.I.D.NO:61 SEQ.I.D.NO: 62 CA8 M0 Humanised light chain SEQ.I.D.NO: 63SEQ.I.D.NO: 64 CA8 M1 Humanised light chain SEQ.I.D.NO: 65 SEQ.I.D.NO:66 CA8 M2 Humanised light chain SEQ.I.D.NO: 67 SEQ.I.D.NO: 68 S307118G03V_(H) domain SEQ.I.D.NO: 69 SEQ.I.D.NO: 70 (murine) S307118G03 V_(L)domain SEQ.I.D.NO: 71 SEQ.I.D.NO: 72 (murine) S307118G03 heavy chainSEQ.I.D.NO: 73 SEQ.I.D.NO: 74 (chimeric) S307118G03 light chainSEQ.I.D.NO: 75 SEQ.I.D.NO: 76 (chimeric) S307118G03 Humanised V_(H) H0SEQ.I.D.NO: 77 SEQ.I.D.NO: 78 S307118G03 Humanised V_(H) H1 SEQ.I.D.NO:79 SEQ.I.D.NO: 80 S307118G03 humanised V_(H) H2 SEQ.I.D.NO: 81SEQ.I.D.NO: 82 S307118G03 humanised V_(H) H3 SEQ.I.D.NO: 83 SEQ.I.D.NO:84 S307118G03 humanised V_(H) H4 SEQ.I.D.NO: 85 SEQ.I.D.NO: 86S307118G03 humanised V_(H) H5 SEQ.I.D.NO: 87 SEQ.I.D.NO: 88 S307118G03humanised V_(L) L0 SEQ.I.D.NO: 89 SEQ.I.D.NO: 90 S307118G03 humanisedV_(L) L1 SEQ.I.D.NO: 91 SEQ.I.D.NO: 92 S307118G03 CDRH1 SEQ.I.D.NO: 93S307118G03 CDRH2 SEQ.I.D.NO: 94 S307118G03 CDRH3 SEQ.I.D.NO: 95S307118G03 CDRL1 SEQ.I.D.NO: 96 S307118G03 CDRL2 SEQ.I.D.NO: 97S307118G03 CDRL3 SEQ.I.D.NO: 98 S307118G03 humanised H5 SEQ.I.D.NO: 99CDRH3 S307118G03 H0 Humanised heavy SEQ.I.D.NO: 100 SEQ.I.D.NO: 101chain S307118G03 H1 humanised heavy SEQ.I.D.NO: 102 SEQ.I.D.NO: 103chain S307118G03 H2 humanised heavy SEQ.I.D.NO: 104 SEQ.I.D.NO: 105chain S307118G03 H3 humanised heavy SEQ.I.D.NO: 106 SEQ.I.D.NO: 107chain S307118G03 H4 humanised heavy SEQ.I.D.NO: 108 SEQ.I.D.NO: 109chain S307118G03 H5 humanised heavy SEQ.I.D.NO: 110 SEQ.I.D.NO: 111chain S307118G03 L0 humanised light SEQ.I.D.NO: 112 SEQ.I.D.NO: 113chain S307118G03 L1 humanised light SEQ.I.D.NO: 114 SEQ.I.D.NO: 115chain S332121F02 murine variable heavy SEQ.I.D.NO: 116 SEQ.I.D.NO: 117chain S332121F02 chimeric variable SEQ.I.D.NO: 118 SEQ.I.D.NO: 119 heavychain S332121F02 murine variable light SEQ.I.D.NO: 120 SEQ.I.D.NO: 121chain S332121F02 chimeric variable SEQ.I.D.NO: 122 SEQ.I.D.NO: 123 lightchain S322110D07 murine variable SEQ.I.D.NO: 124 SEQ.I.D.NO: 125 heavychain S322110D07 chimeric heavy chain SEQ.I.D.NO: 126 SEQ.I.D.NO: 127S322110D07 murine variable light SEQ.I.D.NO: 128 SEQ.I.D.NO: 129 chainS322110D07 chimeric light chain SEQ.I.D.NO: 130 SEQ.I.D.NO: 131S332126E04 murine variable SEQ.I.D.NO: 132 SEQ.I.D.NO: 133 heavy chainS332126E04 Chimeric heavy chain SEQ.I.D.NO: 134 SEQ.I.D.NO: 135S332126E04 murine variable light SEQ.I.D.NO: 136 SEQ.I.D.NO: 137 chainS332126E04 Chimeric light chain SEQ.I.D.NO: 138 SEQ.I.D.NO: 139S336105A07 murine variable SEQ.I.D.NO: 140 SEQ.I.D.NO: 141 heavy chainS336105A07 Chimeric heavy chain SEQ.I.D.NO: 142 SEQ.I.D.NO: 143S336105A07 murine variable light SEQ.I.D.NO: 144 SEQ.I.D.NO: 145 chainS336105A07 chimeric light chain SEQ.I.D.NO: 146 SEQ.I.D.NO: 147S335115G01 murine variable SEQ.I.D.NO: 148 SEQ.I.D.NO: 149 heavy chainS335115G01 Chimeric heavy chain SEQ.I.D.NO: 150 SEQ.I.D.NO: 151S335115G01 murine variable light SEQ.I.D.NO: 152 SEQ.I.D.NO: 153 chainS335115G01 Chimeric light chain SEQ.I.D.NO: 154 SEQ.I.D.NO: 155S335122F05 murine variable heavy SEQ.I.D.NO: 156 SEQ.I.D.NO: 158 chainS335122F05 Chimeric heavy chain SEQ.I.D.NO: 158 SEQ.I.D.NO: 159S335122F05 murine variable light SEQ.I.D.NO: 160 SEQ.I.D.NO: 161 chainS335122F05 Chimeric light chain SEQ.I.D.NO: 162 SEQ.I.D.NO: 163S332121F02 CDRH1 SEQ.I.D.NO: 164 S332121F02 CDRH2 SEQ.I.D.NO: 165S332121F02 CDRH3 SEQ.I.D.NO: 166 S332121F02 CDRL1 SEQ.I.D.NO: 167S332121F02 CDRL2 SEQ.I.D.NO: 168 S332121F02 CDRL3 SEQ.I.D.NO: 169S322110D07 CDRH1 SEQ.I.D.NO: 170 S322110D07 CDRH2 SEQ.I.D.NO: 171S322110D07 CDRH3 SEQ.I.D.NO: 172 S322110D07CDRL1 SEQ.I.D.NO: 173S322110D07 CDRL2 SEQ.I.D.NO: 174 S322110D07 CDRL3 SEQ.I.D.NO: 175S332126E04CDRH1 SEQ.I.D.NO: 176 S332126E04 CDRH2 SEQ.I.D.NO: 177S332126E04 CDRH3 SEQ.I.D.NO: 178 S332126E04 CDRL1 SEQ.I.D.NO: 179S332126E04 CDRL2 SEQ.I.D.NO: 180 S332126E04 CDRL3 SEQ.I.D.NO: 181S336105A07 CDRH1 SEQ.I.D.NO: 182 S336105A07 CDRH2 SEQ.I.D.NO: 183S336105A07 CDRH3 SEQ.I.D.NO: 184 S336105A07 CDRL1 SEQ.I.D.NO: 185S336105A07 CDRL2 SEQ.I.D.NO: 186 S336105A07 CDRL3 SEQ.I.D.NO: 187S335115G01 CDRH1 SEQ.I.D.NO: 188 S335115G01 CDRH2 SEQ.I.D.NO: 189S335115G01 CDRH3 SEQ.I.D.NO: 190 S335115G01 CDRL1 SEQ.I.D.NO: 191S335115G01 CDRL2 SEQ.I.D.NO: 192 S335115G01 CDRL3 SEQ.I.D.NO: 193S335122F05 CDRH1 SEQ.I.D.NO: 194 S335122F05 CDRH2 SEQ.I.D.NO: 195S335122F05 CDRH3 SEQ.I.D.NO: 196 S335122F05 CDRL1 SEQ.I.D.NO: 197S335122F05 CDRL2 SEQ.I.D.NO: 198 S335122F05 CDRL3 SEQ.I.D.NO: 199

SEQUENCE LISTING SEQ ID 1 - CA8 CDRH1 NYWMH SEQ ID 2 - CA8 CDRH2ATYRGHSDTYYNQKFKG SEQ ID 3 - CA8 CDRH3 GAIYNGYDVLDN SEQ ID 4 - CA8 CDRL1SASQDISNYLN SEQ ID 5 - CA8 CDRL2 YTSNLHS SEQ ID 6 - CA8 CDRL3 QQYRKLPWTSEQ ID 7 - CA8 V_(H) domain (murine)EVQLQQSGAVLARPGASVKMSCKGSGYTFTNYWMHWVKQRPGQGLEWIGATYRGHSDTYYNQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTRGAIYNGYDVLDN WGQGTLVTVSSSEQ ID 8 - CA8 V_(H) domain (murine) (Polynucleotide)GAGGTGCAGCTGCAGCAGAGCGGCGCCGTGCTGGCCAGGCCCGGAGCTAGCGTGAAGATGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAAACAGAGGCCCGGCCAGGGACTGGAGTGGATCGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCAAGGCCAAGCTGACCGCCGTGACCTCAACCAGCACCGCCTACATGGAACTGAGCAGCCTGACCAACGAGGACAGCGCCGTCTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAATTGGGGCCAGGGAACACTAGTGACCGTGTCCAGCSEQ ID 9 - CA8 V_(L) domain (murine)DIQLTQTTSSLSASLGDRVTISCSASQDISNYLNWYQQKPDGTVELVIYYTSNLHSGVPSRFSGSGSGTDYSLTIGYLEPEDVATYYCQQYRKLPWTFGGGSKLEIKRSEQ ID 10 - CA8 V_(L) domain (murine) (Polynucleotide)GATATCCAGCTGACCCAGACCACAAGCAGCCTGAGCGCCTCCCTGGGCGACAGGGTGACCATTAGCTGCAGCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGACGGCACCGTGGAGCTCGTGATCTACTACACCTCCAACCTGCACAGCGGCGTGCCCAGCAGGTTCTCTGGCAGCGGCAGCGGCACCGACTACAGCCTGACCATCGGCTATCTGGAGCCCGAGGACGTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTGCCCTGGACCTTCGGCGGAGGCTCTAAGCTGGAGATTAAGCGTSEQ ID 11 - CA8 Humanised V_(H) J0QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLD NWGQGTLVTVSSSEQ ID 12 - CA8 Humanised V_(H) J0 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 13 - CA8 Humanised V_(H) J1QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLD NWGQGTLVTVSSSEQ ID 14 - CA8 Humanised V_(H) J1 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 15 - CA8 Humanised V_(H) J2QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLD NWGQGTLVTVSSSEQ ID 16 - CA8 Humanised V_(H) J2 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 17 - CA8 Humanised V_(H) J3QVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADTSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLD NWGQGTLVTVSSSEQ ID 18 - CA8 Humanised V_(H) J3 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 19 - CA8 Humanised V_(H) J4QVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWIGATYRGHSDTYYNQKFKGRATLTADTSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLDN WGQGTLVTVSSSEQ ID 20 - CA8 Humanised V_(H) J4 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATCGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGCGACCCTCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 21 - CA8 Humanised V_(H) J5QVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADTSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLD NWGQGTLVTVSSSEQ ID 22 - CA8 Humanised V_(H) J5 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 23 - CA8 Humanised V_(H) J6QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLD NWGQGTLVTVSSSEQ ID 24 - CA8 Humanised V_(H) J6 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 25 - CA8 Humanised V_(H) J7QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLD NWGQGTLVTVSSSEQ ID 26 - CA8 Humanised V_(H) J7 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 27 - CA8 Humanised V_(H) J8QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLD NWGQGTLVTVSSSEQ ID 28 - CA8 Humanised V_(H) J8 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 29 - CA8 Humanised V_(H) J9QVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWIGATYRGHSDTYYNQKFKGRATLTADTSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLDN WGQGTLVTVSSSEQ ID 30 - CA8 Humanised V_(H) J9 (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATCGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGCGACCCTCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 31 - CA8 Humanised V_(L) M0DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRSEQ ID 32 - CA8 Humanised V_(L) M0 (Polynucleotide)GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTTCACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTSEQ ID 33 - CA8 Humanised V_(L) M1DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRSEQ ID 34 - CA8 Humanised V_(L) M1 (Polynucleotide)GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTACACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTSEQ ID 35 - CA8 Humanised V_(L) M2DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPELVIYYTSNLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRSEQ ID 36 - CA8 Humanised V_(L) M2 (Polynucleotide)GACATCCAGCTGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCGAGCTGGTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTACACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTSEQ ID 37 - Human BCMA CD33-hBCMA ECD (1-53) TEV-FcMPLLLLLPLLWAGALAMLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNSGENLYFQGDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 38 - Human BCMA CD33-hBCMA ECD (1-53) TEV-Fc (Polynucleotide)ATGCCGCTGCTGCTACTGCTGCCCCTGCTGTGGGCAGGGGCGCTAGCTATGCTGCAGATGGCCGGCCAGTGCAGCCAGAACGAGTACTTCGACAGCCTGCTGCACGCCTGCATCCCCTGCCAGCTGAGATGCAGCAGCAACACACCTCCTCTGACCTGCCAGAGATACTGCAACGCCAGCGTGACCAACAGCGTGAAGGGCACCAACTCCGGAGAGAACCTGTACTTCCAAGGGGATCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCC GGGTAAASEQ ID 39 - Human BCMA CD33-hBCMA ECD (4-53) TEV-FcMPLLLLLPLLWAGALAMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNSGENLYFQGDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ KSLSLSPGKSEQ ID 40 - Human BCMA CD33-hBCMA ECD (4-53) TEV-Fc (Polynucleotide)ATGCCGCTGCTGCTACTGCTGCCCCTGCTGTGGGCAGGGGCGCTAGCTATGGCCGGCCAGTGCAGCCAGAACGAGTACTTCGACAGCCTGCTGCACGCCTGCATCCCCTGCCAGCTGAGATGCAGCAGCAACACACCTCCTCTGACCTGCCAGAGATACTGCAACGCCAGCGTGACCAACAGCGTGAAGGGCACCAACTCCGGAGAGAACCTGTACTTCCAAGGGGATCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAASEQ ID 41 - Cynomolgous BCMA CD33 cyno BCMA ECD (4-52) TEV-FcMPLLLLLPLLWAGALAMARQCSQNEYFDSLLHDCKPCQLRCSSTPPLTCQRYCNASMTNSVKGMNSGENLYFQGDPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 42 - Cynomolgous BCMA CD33 cyno BCMA ECD (4-52) TEV-Fc(Polynucleotide) ATGCCGCTGCTGCTACTGCTGCCCCTGCTGTGGGCAGGGGCGCTAGCTATGGCCAGACAGTGCAGCCAGAACGAGTACTTCGACAGCCTGCTGCACGACTGCAAGCCCTGCCAGCTGAGATGCAGCAGCACACCTCCTCTGACCTGCCAGAGATACTGCAACGCCAGCATGACCAACAGCGTGAAGGGCATGAACTCCGGAGAGAACCTGTACTTCCAAGGGGATCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAA ASEQ ID 43 - CA8 J0 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 44 - CA8 J0 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 45 - CA8 J1 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYNGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 46 - CA8 J1 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 47 - CA8 J2 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 48 - CA8 J2 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 49 - CA8 J3 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADTSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 50 - CA8 J3 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 51 - CA8 J4 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWIGATYRGHSDTYYNQKFKGRATLTADTSTSTAYMELSSLRSEDTAVYYCTRGAIYNGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 52 - CA8 J4 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATCGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGCGACCCTCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACAACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 53 - CA8 J5 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADTSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 54 - CA8 J5 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 55 - CA8 J6 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 56 - CA8 J6 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCGGCACCTTCAGCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 57 - CA8 J7 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 58 - CA8 J7 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCGCCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 59 - CA8 J8 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG KSEQ ID 60 - CA8 J8 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATGGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGTGACCATCACCGCCGACAAGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 61 - CA8 J9 Humanised heavy chainQVQLVQSGAEVKKPGSSVKVSCKGSGYTFTNYWMHWVRQAPGQGLEWIGATYRGHSDTYYNQKFKGRATLTADTSTSTAYMELSSLRSEDTAVYYCTRGAIYDGYDVLDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 62 - CA8 J9 Humanised heavy chain (Polynucleotide)CAGGTGCAGCTGGTCCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCAGCTCCGTGAAAGTGAGCTGCAAGGGCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAGGCAGGCCCCCGGACAGGGCCTGGAGTGGATCGGCGCCACCTACAGGGGCCACAGCGACACCTACTACAACCAGAAGTTCAAGGGCCGGGCGACCCTCACCGCCGACACGAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTCAGGAGCGAGGACACCGCTGTGTATTACTGCACCAGGGGCGCCATCTACGACGGCTACGACGTGCTGGACAACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 63 - CA8 M0 Humanised light chainDIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 64 - CA8 M0 Humanised light chain (Polynucleotide)GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTTCACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 65 - CA8 M1 Humanised light chainDIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 66 - CA8 M1 Humanised light chain (Polynucleotide)GACATCCAGATGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTACACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 67 - CA8 M2 Humanised light chainDIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPELVIYYTSNLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 68 - CA8 M2 Humanised light chain (Polynucleotide)GACATCCAGCTGACCCAGAGCCCTAGCTCACTGAGCGCCAGCGTGGGCGACAGGGTGACCATTACCTGCTCCGCCAGCCAGGACATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCCGAGCTGGTGATCTACTACACCTCCAACCTGCACTCCGGCGTGCCCAGCAGGTTCAGCGGAAGCGGCAGCGGCACCGATTACACCCTGACCATCTCCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGGAAGCTCCCCTGGACTTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 69 - S307118G03 mouse variable heavyEVQLQQSGPELVKPGASVKISCKASGYTFTDYYMKWVKQSHGKSLEWIGEIYPNNGGITYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCANGYEFVYWGQGTLVT VSASEQ ID 70 - S307118G03 mouse variable heavy (DNA sequence)GAGGTCCAGTTGCAACAATCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGTAAGGCTTCTGGATACACATTCACTGACTACTACATGAAGTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGAGATTTATCCTAATAATGGTGGTATTACCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAATGGTTACGAGTTTGTTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA SEQ ID 71 - S307118G03 mouse variable lightDIQMTQTASSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPWTFGGGTKLEIKRSEQ ID 72 - S307118G03 mouse variable light (DNA sequence)GATATCCAGATGACACAGACTGCATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGTGCAAGTCAGGGCATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTATTACACATCAAGTTTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTATTCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGTCAGCAGTATAGTAAGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAACGGSEQ ID 73 - S307118G03 chimeric heavy chainEVQLQQSGPELVKPGASVKISCKASGYTFTDYYMKWVKQSHGKSLEWIGEIYPNNGGITYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCANGYEFVYWGQGTLVTVSAAKTTAPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 74 - S307118G03 chimeric heavy chain (DNA sequence)GAGGTCCAGTTGCAACAATCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGTAAGGCTTCTGGATACACATTCACTGACTACTACATGAAGTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGAGATTTATCCTAATAATGGTGGTATTACCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAATGGTTACGAGTTTGTTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAACAGCCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 75 - S307118G03 chimeric light chainDIQMTQTASSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQYSKLPWTFGGGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 76 - S307118G03 chimeric light chain (DNA sequence)GATATCCAGATGACACAGACTGCATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGTGCAAGTCAGGGCATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTATTACACATCAAGTTTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTATTCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGTCAGCAGTATAGTAAGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAGCTGAAACGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 77 - S307118G03 humanised H0 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYEFVYWGQGTL VTVSSSEQ ID 78 - S307118G03 humanised H0 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCGGCACCTTCAGCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 79 - S307118G03 humanised H1 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYEFVYWGQGTL VTVSSSEQ ID 80 - S307118G03 humanised H1 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 81 - S307118G03 humanised H2 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCANGYEFVYWGQGTL VTVSSSEQ ID 82 - S307118G03 humanised H2 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGC SEQ ID 83 - S307118G03 humanised H3 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGEIYPNNGGITYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCANGYEFVYWGQGTLV TVSSSEQ ID 84 - S307118G03 humanised H3 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATAGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGCGACCCTCACCGTCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGC SEQ ID 85 - S307118G03 humanised H4 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCADGYEFVYWGQGTL VTVSSSEQ ID 86 - S307118G03 humanised H4 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCGACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGC SEQ ID 87 - S307118G03 humanised H5 variable heavyQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGEIYPNNGGITYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCANGYEFDYWGQGTLV TVSSSEQ ID 88 - S307118G03 humanised H5 variable heavy (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATAGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGCGACCCTCACCGTCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGACTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 89 - S307118G03 humanised L0 variable lightDIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSKLPWTFGQGTKLEIKRSEQ ID 90 - S307118G03 humanised L0 variable light (DNA sequence)GACATCCAGATGACCCAGAGCCCCTCAAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACTATCACCTGCAGCGCCTCCCAGGGCATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCTAAGCTGCTGATCTACTACACCAGCAGCCTGCACAGCGGCGTGCCCAGCAGGTTCTCCGGCAGCGGCAGCGGAACCGACTTCACCCTGACCATTAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCAAGCTGCCCTGGACCTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTSEQ ID 91 - S307118G03 humanised L1 variable lightDIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPWTFGQGTKLEIKRSEQ ID 92 - S307118G03 humanised L1 variable light (DNA sequence)GACATCCAGATGACCCAGAGCCCCTCAAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACTATCACCTGCAGCGCCTCCCAGGGCATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCTAAGCTGCTGATCTACTACACCAGCAGCCTGCACAGCGGCGTGCCCAGCAGGTTCTCCGGCAGCGGCAGCGGAACCGACTACACCCTGACCATTAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCAAGCTGCCCTGGACCTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTSEQ ID 93 - S307118G03 CDRH1 DYYMK SEQ ID 94 - S307118G03 CDRH2EIYPNNGGITYNQKFKG SEQ ID 95 - S307118G03 CDRH3 GYEFVYSEQ ID 96 - S307118G03 CDRL1 SASQGISNYLN SEQ ID 97 - S307118G03 CDRL2YTSSLHS SEQ ID 98 - S307118G03 CDRL3 QQYSKLPWTSEQ ID 99 - S307118G03 humanised H5 CDRH3 GYEFDYSEQ ID 100 - S307118G03 humanised H0 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGGTFSDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYEFVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 101 - S307118G03 humanised H0 heavy chain (polynucleotide)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCGGCACCTTCAGCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 102 - S307118G03 humanised H1 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYEFVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 103 - S307118G03 humanised H1 heavy chain (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAGGGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 104 - S307118G03 humanised H2 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCANGYEFVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 105 - S307118G03 humanised H2 heavy chain (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 106 - S307118G03 humanised H3 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGEIYPNNGGITYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCANGYEFVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 107 - S307118G03 humanised H3 heavy chain (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATAGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGCGACCCTCACCGTCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 108 - S307118G03 humanised H4 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWMGEIYPNNGGITYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCADGYEFVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 109 - S307118G03 humanised H4 heavy chain (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATGGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGTGACCATCACCGCCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCGACGGCTACGAGTTCGTGTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 110 - S307118G03 humanised H5 heavy chainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGEIYPNNGGITYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCANGYEFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 111 - S307118G03 humanised H5 heavy chain (DNA sequence)CAGGTGCAGCTGGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCGGCTCCAGCGTGAAGGTGAGCTGCAAGGCTAGCGGCTACACCTTCACCGACTACTACATGAAGTGGGTGAGGCAGGCCCCCGGCCAGGGACTGGAGTGGATAGGCGAGATCTACCCCAACAACGGGGGCATCACCTACAACCAGAAGTTCAAGGGCAGGGCGACCCTCACCGTCGACAAAAGCACCAGCACCGCCTACATGGAACTGAGCAGCCTGAGGAGCGAGGACACCGCCGTGTACTACTGCGCCAACGGCTACGAGTTCGACTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 112 - S307118G03 humanised L0 light chainDIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 113 - S307118G03 humanised L0 light chain (DNA sequence)GACATCCAGATGACCCAGAGCCCCTCAAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACTATCACCTGCAGCGCCTCCCAGGGCATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCTAAGCTGCTGATCTACTACACCAGCAGCCTGCACAGCGGCGTGCCCAGCAGGTTCTCCGGCAGCGGCAGCGGAACCGACTTCACCCTGACCATTAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCAAGCTGCCCTGGACCTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 114 - S307118G03 humanised L1 light chainDIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAPKLLIYYTSSLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 115 - S307118G03 humanised L1 light chain (DNA sequence)GACATCCAGATGACCCAGAGCCCCTCAAGCCTGAGCGCCAGCGTGGGCGACAGGGTGACTATCACCTGCAGCGCCTCCCAGGGCATCAGCAACTACCTGAACTGGTACCAGCAGAAGCCCGGCAAGGCCCCTAAGCTGCTGATCTACTACACCAGCAGCCTGCACAGCGGCGTGCCCAGCAGGTTCTCCGGCAGCGGCAGCGGAACCGACTACACCCTGACCATTAGCAGCCTCCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGTACAGCAAGCTGCCCTGGACCTTCGGCCAGGGCACCAAACTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 116 - S332121F02 murine variable heavy chainEVQLQQSGPVLVKPGASVKMSCEASGYTFTDYYMNWVKQSHGKTLEWIGVINPYNGGTDYNQKFKGKATLTVDKSSSTAYMELNSLTSEDSAVYYCARSVYDYPFDYWGQ GTLVTVSSSEQ ID 117 S332121F02 murine variable heavy chain (DNA sequence)GAGGTGCAGCTGCAGCAGAGCGGCCCCGTGCTGGTGAAGCCTGGAGCCAGCGTGAAAATGAGCTGCGAAGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGAAGCAGAGCCACGGCAAGACCCTGGAGTGGATCGGCGTGATCAACCCCTACAACGGGGGCACCGACTACAACCAGAAGTTCAAGGGCAAGGCCACTCTGACCGTGGACAAGAGCTCCAGCACCGCCTACATGGAACTGAACAGCCTCACCTCTGAGGACAGCGCCGTCTATTACTGCGCCAGGAGCGTGTACGACTACCCCTTCGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 118 - S332121F02 chimeric heavy chainEVQLQQSGPVLVKPGASVKMSCEASGYTFTDYYMNWVKQSHGKTLEWIGVINPYNGGTDYNQKFKGKATLTVDKSSSTAYMELNSLTSEDSAVYYCARSVYDYPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 119 - S332121F02 chimeric heavy chain (DNA sequence)GAGGTGCAGCTGCAGCAGAGCGGCCCCGTGCTGGTGAAGCCTGGAGCCAGCGTGAAAATGAGCTGCGAAGCCAGCGGCTACACCTTCACCGACTACTACATGAACTGGGTGAAGCAGAGCCACGGCAAGACCCTGGAGTGGATCGGCGTGATCAACCCCTACAACGGGGGCACCGACTACAACCAGAAGTTCAAGGGCAAGGCCACTCTGACCGTGGACAAGAGCTCCAGCACCGCCTACATGGAACTGAACAGCCTCACCTCTGAGGACAGCGCCGTCTATTACTGCGCCAGGAGCGTGTACGACTACCCCTTCGACTACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 120 - S332121F02 murine variable light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPRTFGGGTKLEIKSEQ ID 121 - S332121F02 murine variable light chain (DNA sequence)GACATCGTCCTGACCCAGAGCCCCGCCAGCCTGGCCGTGAGCCTGGGCCAGAGGGCCACAATCAGCTGCAGGGCCTCTGAGTCCGTGAGCATCCACGGCACCCACCTGATGCACTGGTATCAGCAGAAGCCCGGCCAGCCTCCCAAGCTGCTGATCTACGCCGCCAGCAACCTGGAGAGCGGCGTGCCCGCTAGGTTCAGCGGAAGCGGCAGCGAGACCGACTTCACCCTGAACATCCACCCCGTGGAGGAGGAAGACGCCGCCACCTACTTCTGCCAGCAGAGCATCGAGGACCCCAGGACCTTCGGCGGGGGCACCAAGCTC GAGATTAAGCGTSEQ ID 122 - S332121F02 chimeric light chainMGWSCIILFLVATATGVHSDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPRTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGECSEQ ID 123 - S332121F02 chimeric light chain (DNA sequence)ATGGGCTGGTCCTGCATCATCCTGTTTCTGGTGGCCACCGCCACCGGCGTGCACAGCGACATCGTCCTGACCCAGAGCCCCGCCAGCCTGGCCGTGAGCCTGGGCCAGAGGGCCACAATCAGCTGCAGGGCCTCTGAGTCCGTGAGCATCCACGGCACCCACCTGATGCACTGGTATCAGCAGAAGCCCGGCCAGCCTCCCAAGCTGCTGATCTACGCCGCCAGCAACCTGGAGAGCGGCGTGCCCGCTAGGTTCAGCGGAAGCGGCAGCGAGACCGACTTCACCCTGAACATCCACCCCGTGGAGGAGGAAGACGCCGCCACCTACTTCTGCCAGCAGAGCATCGAGGACCCCAGGACCTTCGGCGGGGGCACCAAGCTCGAGATTAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGG GCGAGTGCSEQ ID 124 - S322110D07 murine variable heavy chainEVQLQQSGPELVKPGTSVKIPCKTSGYIFTDYSIDWVKQSHGKSLEWIGDIDPNYGDPIYNHKFKGKATLTVDRSSSTAYMELRSLTSEDTAVYFCARRATGTDWFAFWGQGTL VTVSSSEQ ID 125 - S322110D07 murine variable heavy chain (DNA sequence)GAGGTGCAGCTGCAGCAGAGCGGCCCCGAGCTGGTGAAACCCGGCACCAGCGTGAAGATCCCCTGCAAGACCTCTGGCTACATCTTCACCGACTACAGCATCGACTGGGTGAAGCAGAGCCACGGCAAGTCTCTGGAGTGGATTGGGGACATCGACCCCAACTACGGCGACCCCATCTACAACCACAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACAGGAGCAGCAGCACCGCCTACATGGAACTCAGGAGCCTGACCAGCGAGGACACCGCCGTGTATTTTTGCGCCAGGAGGGCCACCGGCACTGATTGGTTCGCCTTCTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 126 - S322110D07 chimeric heavy chainEVQLQQSGPELVKPGTSVKIPCKTSGYIFTDYSIDWVKQSHGKSLEWIGDIDPNYGDPIYNHKFKGKATLTVDRSSSTAYMELRSLTSEDTAVYFCARRATGTDWFAFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 127 - S322110D07 chimeric heavy chain (DNA sequence)GAGGTGCAGCTGCAGCAGAGCGGCCCCGAGCTGGTGAAACCCGGCACCAGCGTGAAGATCCCCTGCAAGACCTCTGGCTACATCTTCACCGACTACAGCATCGACTGGGTGAAGCAGAGCCACGGCAAGTCTCTGGAGTGGATTGGGGACATCGACCCCAACTACGGCGACCCCATCTACAACCACAAGTTCAAGGGCAAGGCCACCCTGACCGTGGACAGGAGCAGCAGCACCGCCTACATGGAACTCAGGAGCCTGACCAGCGAGGACACCGCCGTGTATTTTTGCGCCAGGAGGGCCACCGGCACTGATTGGTTCGCCTTCTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 128 - S322110D07 murine variable light chainDIQMTQSPASLSVSVGETVTITCRASENIYNNLAWYQQKQGKSPQLLVYAATILADGVPSRFSGSGSGTQYSLKINSLQSGDFGTYYCQHFWGTPLTFGAGTKLELKRSEQ ID 129 - S322110D07 murine variable light chain (DNA sequence)GACATCCAGATGACCCAGAGCCCCGCTAGCCTCAGCGTGTCCGTCGGCGAGACCGTGACCATCACCTGCAGGGCCAGCGAGAACATCTACAACAACCTGGCCTGGTATCAGCAGAAGCAGGGCAAAAGCCCCCAGCTGCTGGTGTACGCCGCCACCATTCTGGCCGACGGCGTGCCCAGCAGGTTCTCTGGAAGCGGCAGCGGCACCCAGTACAGCCTGAAGATCAACAGCCTGCAGAGCGGGGACTTCGGCACCTACTACTGCCAGCACTTCTGGGGCACTCCCCTGACCTTCGGAGCCGGCACCAAGCTGGAGCTGAAGCGTSEQ ID 130 - S322110D07 chimeric light chainDIQMTQSPASLSVSVGETVTITCRASENIYNNLAWYQQKQGKSPQLLVYAATILADGVPSRFSGSGSGTQYSLKINSLQSGDFGTYYCQHFWGTPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 131 - S322110D07 chimeric light chain (DNA sequence)GACATCCAGATGACCCAGAGCCCCGCTAGCCTCAGCGTGTCCGTCGGCGAGACCGTGACCATCACCTGCAGGGCCAGCGAGAACATCTACAACAACCTGGCCTGGTATCAGCAGAAGCAGGGCAAAAGCCCCCAGCTGCTGGTGTACGCCGCCACCATTCTGGCCGACGGCGTGCCCAGCAGGTTCTCTGGAAGCGGCAGCGGCACCCAGTACAGCCTGAAGATCAACAGCCTGCAGAGCGGGGACTTCGGCACCTACTACTGCCAGCACTTCTGGGGCACTCCCCTGACCTTCGGAGCCGGCACCAAGCTGGAGCTGAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 132 - S332126E04 murine variable heavy chainQVQLQQPGAELVKPGASVKLSCKASGYTFTNYWMHWVKQRPGQGLEWIGIIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGIYDYPFAYWGQG TLVTVSSSEQ ID 133 - S332126E04 murine variable heavy chain (DNA sequence)CAGGTGCAGCTCCAGCAGCCCGGAGCCGAACTGGTGAAGCCCGGAGCCAGCGTCAAACTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCATCATCCACCCCAACAGCGGGAGCACCAACTACAACGAGAAGTTCAAGAGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACTGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCTGTGTACTACTGCGCCAGGGGCATCTACGACTACCCCTTCGCCTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCSEQ ID 134 - S332126E04 Chimeric heavy chainQVQLQQPGAELVKPGASVKLSCKASGYTFTNYWMHWVKQRPGQGLEWIGIIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGIYDYPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 135 - S332126E04 Chimeric heavy chain (DNA sequence)CAGGTGCAGCTCCAGCAGCCCGGAGCCGAACTGGTGAAGCCCGGAGCCAGCGTCAAACTGTCCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCATCATCCACCCCAACAGCGGGAGCACCAACTACAACGAGAAGTTCAAGAGCAAGGCCACCCTGACCGTGGACAAGAGCAGCAGCACTGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCTGTGTACTACTGCGCCAGGGGCATCTACGACTACCCCTTCGCCTATTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 136 - S332126E04 murine variable light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPYTFGGGTKLEIKRSEQ ID 137 - S332126E04 murine variable light chain (DNA sequence)GACATCGTGCTGACCCAGTCTCCCGCTAGCCTGGCCGTGTCTCTGGGCCAGAGGGCCACAATCAGCTGCAGGGCCAGCGAGAGCGTCAGCATTCACGGCACCCACCTGATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCCAAGCTCCTGATCTACGCCGCCAGCAACCTGGAAAGCGGAGTGCCCGCCAGGTTCAGCGGCAGCGGCTCCGAGACCGACTTCACCCTGAACATCCACCCCGTGGAGGAGGAGGACGCCGCCACCTACTTCTGCCAGCAGAGCATCGAGGACCCCTACACCTTCGGCGGCGGCACCAAGCTGGA GATCAAGCGTSEQ ID 138 - S332126E04 Chimeric light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 139 - S332126E04 Chimeric light chain (DNA sequence)GACATCGTGCTGACCCAGTCTCCCGCTAGCCTGGCCGTGTCTCTGGGCCAGAGGGCCACAATCAGCTGCAGGGCCAGCGAGAGCGTCAGCATTCACGGCACCCACCTGATGCACTGGTACCAGCAGAAGCCCGGCCAGCCTCCCAAGCTCCTGATCTACGCCGCCAGCAACCTGGAAAGCGGAGTGCCCGCCAGGTTCAGCGGCAGCGGCTCCGAGACCGACTTCACCCTGAACATCCACCCCGTGGAGGAGGAGGACGCCGCCACCTACTTCTGCCAGCAGAGCATCGAGGACCCCTACACCTTCGGCGGCGGCACCAAGCTGGAGATCAAGCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGA GTGCSEQ ID 140 - S336105A07 murine variable heavy chainEVKLLQSGGGLVQPGGSLKLSCAASGIDFSRYWMSWVRRAPGKGLEWIGEINPDRSTINYAPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCAVFYYDYEGAMDYWGQ GTSVTVSSSEQ ID 141 - S336105A07 murine variable heavy chain (DNA sequence)GAGGTGAAGCTTCTCCAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGTGCAGCCTCAGGAATCGATTTTAGTAGATACTGGATGAGTTGGGTTCGGCGGGCTCCAGGGAAAGGACTAGAATGGATTGGAGAAATTAATCCAGATAGGAGTACAATCAACTATGCACCATCTCTAAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGAGCAAAGTGAGATCTGAGGACACAGCCCTTTATTACTGTGCAGTTTTCTACTATGATTACGAGGGTGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCASEQ ID 142 - S336105A07 Chimeric heavy chainEVKLLQSGGGLVQPGGSLKLSCAASGIDFSRYWMSWVRRAPGKGLEWIGEINPDRSTINYAPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCAVFYYDYEGAMDYWGQGTSVTVSSAKTTAPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 143 - S336105A07 Chimeric heavy chain (DNA sequence)GAGGTGAAGCTTCTCCAGTCTGGAGGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGTGCAGCCTCAGGAATCGATTTTAGTAGATACTGGATGAGTTGGGTTCGGCGGGCTCCAGGGAAAGGACTAGAATGGATTGGAGAAATTAATCCAGATAGGAGTACAATCAACTATGCACCATCTCTAAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGAGCAAAGTGAGATCTGAGGACACAGCCCTTTATTACTGTGCAGTTTTCTACTATGATTACGAGGGTGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACAGCCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 144 - S336105A07 murine varaible light chainDIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRFSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSFPFTFGSGTKLEIKRSEQ ID 145 - S336105A07 murine variable light chain (DNA sequence)GACATTGTGATGACCCAGTCTCAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGATACTAATGTAGCCTGGTATCAACAAAAACCAGGGCAATCTCCTAAAGCACTGATTTACTCGGCATCCTACCGGTTCAGTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTATTTCTGTCAGCAATATAACAGCTTTCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAACGTSEQ ID 146 - S336105A07 chimeric light chainDIVMTQSQKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPKALIYSASYRFSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSFPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 147 - S336105A07 chimeric light chain (DNA sequence)GACATTGTGATGACCCAGTCTCAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGATACTAATGTAGCCTGGTATCAACAAAAACCAGGGCAATCTCCTAAAGCACTGATTTACTCGGCATCCTACCGGTTCAGTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTATTTCTGTCAGCAATATAACAGCTTTCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAACGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGCSEQ ID 148 - S335115G01 murine variable heavy chainPVQLQQPGTELVRPGTSVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGVIDPSDSYTNYNQKFKGKATLTVDTSSSTAYMQLSSLTSEDSAVYYCARQVFDYPMDYWGQG TSVTVSSSEQID 149 - S335115G01 murine variable heavy chain (DNA sequence)CCGGTCCAACTGCAGCAGCCTGGGACTGAGCTGGTGAGGCCTGGGACTTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCTACTGGATGCACTGGGTAAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATCGGAGTGATTGATCCTTCTGATAGTTATACTAACTACAATCAAAAGTTCAAGGGCAAGGCCACATTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGACAGGTGTTTGACTATCCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA SEQ ID 150 - S335115G01 Chimeric heavy chainPVQLQQPGTELVRPGTSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGVIDPSDSYTNYNQKFKGKATLTVDTSSSTAYMQLSSLTSEDSAVYYCARQVFDYPMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 151 - S335115G01 Chimeric heavy chain (DNA sequence)CCGGTCCAACTGCAGCAGCCTGGGACTGAGCTGGTGAGGCCTGGGACTTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAGCCACTGGATGCACTGGGTAAAGCAGAGGCCTGGACAAGGCCTTGAGTGGATCGGAGTGATTGATCCTTCTGATAGTTATACTAACTACAATCAAAAGTTCAAGGGCAAGGCCACATTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGACAGGTGTTTGACTATCCTATGGACTACTGGGGTCAAGGAACACTAGTGACCGTGTCCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 152 - S335115G01 murine variable light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPWTFGGGTKLEIKRSEQ ID 153 - S335115G01 murine variable light chain (DNA sequence)GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGTGAAAGTGTCAGTATTCATGGTACTCATTTAATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCTAGAATCTGGAGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGAGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTTCTGTCAGCAAAGTATTGAGGATCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAA ATCAAACGTSEQ ID 154 - S335115G01 Chimeric light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSETDFTLNIHPVEEEDAATYFCQQSIEDPWTFGGGTKLEINRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 155 - S335115G01 Chimeric light chain (DNA sequence)GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGTGAAAGTGTCAGTATTCATGGTACTCATTTAATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCTAGAATCTGGAGTCCCTGCCAGGTTCAGTGGCAGTGGGTCTGAGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTTCTGTCAGCAAAGTATTGAGGATCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAATCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGA GTGCSEQ ID 156 - S335122F05 murine variable heavy chainQVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTRSIYDYYFDYWGQGT TLTVSSSEQ ID 157 - S335122F05 murine variable heavy chain (DNA sequence)CAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGGGTGAAGCAGACACCTGTGCATGGCCTGGAATGGATTGGAGCTATTGATCCTGAAACTGGTGGTACTGCCTACAATCAGAAGTTCAAGGGCAAGGCCATACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACAAGATCGATTTATGATTACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA SEQ ID 158 - S335122F05 Chimeric heavy chainQVQLQQSGAELVRPGASVTLSCKASGYTFTDYEMHWVKQTPVHGLEWIGAIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTRSIYDYYFDYWGQGTTLTVSSAKTTPPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEQ ID 159 - S335122F05 Chimeric heavy chain (DNA sequence)CAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGCTTCAGTGACGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGGGTGAAGCAGACACCTGTGCATGGCCTGGAATGGATTGGAGCTATTGATCCTGAAACTGGTGGTACTGCCTACAATCAGAAGTTCAAGGGCAAGGCCATACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACAAGATCGATTTATGATTACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACGACACCCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGCAAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACCGTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGGTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGCAGCAGGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAGSEQ ID 160 - S335122F05 murine variable light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGGGSETDFTLNIHPVEEEDGATYFCQQSIEYPRTFGGGTKLEINRSEQ ID 161 - S335122F05 murine variable light chain (DNA sequence)GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGTGAAAGTGTCAGTATTCATGGTACTCATTTAATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCTAGAATCTGGAGTCCCTGCCAGGTTCAGTGGCGGTGGGTCTGAGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGGTGCAACCTATTTCTGTCAGCAAAGTATTGAGTATCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAA ATCAATCGTSEQ ID 162 - S335122F05 Chimeric light chainDIVLTQSPASLAVSLGQRATISCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGGGSETDFTLNIHPVEEEDGATYFCQQSIEYPRTFGGGTKLEINRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECSEQ ID 163 - S335122F05 Chimeric light chain (DNA sequence)GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGCAGAGCCAGTGAAAGTGTCAGTATTCATGGTACTCATTTAATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTCATCTATGCTGCATCCAACCTAGAATCTGGAGTCCCTGCCAGGTTCAGTGGCGGTGGGTCTGAGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGGTGCAACCTATTTCTGTCAGCAAAGTATTGAGTATCCTCGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAATCGTACGGTGGCCGCCCCCAGCGTGTTCATCTTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGA GTGCSEQ. I. D. NO: 164 - S332121F02 CDRH1 DYYNMSEQ. I. D. NO: 165 - S332121F02 CDRH2 VINPYNGGTDYNQKFGSEQ. I. D. NO: 166 - S332121F02 CDRH3 SVYDYPFDYSEQ. I. D. NO: 167 - S332121F02 CDRL1 RASESVSIHGTHLMHSEQ. I. D. NO: 168 - S332121F02 CDRL2 AASNLESSEQ. I. D. NO: 169 - S332121F02 CDRL3 QQSIEDPRTSEQ. I. D. NO: 170 - S322110D07 CDRH1 DYSIDSEQ. I. D. NO: 171 - S322110D07 CDRH2 DIDPNYGDPIYNHKFKGSEQ. I. D. NO: 172 - S322110D07 CDRH3 RATGTDWFAFSEQ. I. D. NO: 173 - S322110D07CDRL1 RASENIYNNLASEQ. I. D. NO: 174 - S322110D07 CDRL2 AATILADSEQ. I. D. NO: 175 - S322110D07 CDRL3 QHFWGTPLTSEQ. I. D. NO: 176 - S332126E04CDRH1 NYWMHSEQ. I. D. NO: 177 - S332126E04 CDRH2 IIHPNSGSTNYNEKFKSSEQ. I. D. NO: 178 - S332126E04 CDRH3 GIYDYPFAYSEQ. I. D. NO: 179 - S332126E04 CDRL1 RASESVSIHGTHLMHSEQ. I. D. NO: 180 - S332126E04 CDRL2 AASNLESSEQ. I. D. NO: 181 - S332126E04 CDRL3 QQSIEDPYTSEQ. I. D. NO: 182 - S336105A07 CDRH1 RYWMSSEQ. I. D. NO: 183 - S336105A07 CDRH2 EINPDRSTINYAPSLKDSEQ. I. D. NO: 184 - S336105A07 CDRH3 FYYDYEGAMDYSEQ. I. D. NO: 185 - S336105A07 CDRL1 KASQNVDTNVASEQ. I. D. NO: 186 - S336105A07 CDRL2 SASYRFSSEQ. I. D. NO: 187 - S336105A07 CDRL3 QQYNSFPFTSEQ. I. D. NO: 188 - S335115G01 CDRH1 SYWMHSEQ. I. D. NO: 189 - S335115G01 CDRH2 VIDPSDSYTNYNQKFKGSEQ. I. D. NO: 190 - S335115G01 CDRH3 QVFDYPMDYSEQ. I. D. NO: 191 - S335115G01 CDRL1 RASESVSIHGTHLMHSEQ. I. D. NO: 192 - S335115G01 CDRL2 AASNLESSEQ. I. D. NO: 193 - S335115G01 CDRL3 QQSIEDPWTSEQ. I. D. NO: 194 - S335122F05 CDRH1 DYEMHSEQ. I. D. NO: 195 - S335122F05 CDRH2 AIDPETGGTAYNQKFKGSEQ. I. D. NO: 196 - S335122F05 CDRH3 SIYDYYFDYSEQ. I. D. NO: 197 - S335122F05 CDRL1 RASESVSIHGTHLMHSEQ. I. D. NO: 198 - S335122F05 CDRL2 AASNLESSEQ. I. D. NO: 199 - S335122F05 CDRL3 QQSIEYPRT

1. An immunoconjugate comprising an anti-BCMA antibody and a cytotoxicagent, wherein the cytotoxic agent is a maytansinoid.
 2. Theimmunoconjugate of claim 1, wherein the maytansinoid is DM-1 or DM-4. 3.The immunoconjugate of claim 1, wherein the antibody is conjugated tothe cytotoxic agent via a linker.
 4. The immunoconjugate of claim 3,wherein the linker is selected from the group consisting of6-maleimidocaproyl (“MC”), maleimidopropanoyl (“MP”), valine-citrulline(“val-cit”), alanine-phenylalanine (“ala-phe”), p-aminobenzyloxycarbonyl(“PAB”), N-Succinimidyl 4-(2-pyridylthio)pentanoate (“SPP”),N-Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1 carboxylate (“SMCC”),and N-Succinimidyl (4-iodo-acetyl)aminobenzoate (“SIAB”).
 5. Theimmunoconjugate of claim 3, wherein the linker is N-Succinimidyl4-(N-maleimidomethyl) cyclohexane-1 carboxylate (“SMCC”).
 6. Theimmunoconjugate of claim 1, wherein the antibody is humanized.
 7. Theimmunoconjugate of claim 1, wherein the antibody is human.
 8. Theimmunoconjugate of claim 1, wherein the antibody is a monoclonalantibody.
 9. The immunoconjugate of claim 1, wherein the antibody is achimeric antibody.
 10. The immunoconjugate of claim 1, wherein theantibody is an IgG1 antibody.
 11. The immunoconjugate of claim 1,wherein the antibody inhibits the binding of BAFF and/or APRIL to BCMA.12. The immunoconjugate of claim 1, wherein the antibody binds to humanBCMA and neutralizes the binding of the ligands BAFF and/or APRIL toBCMA in a cell neutralization assay wherein the antibody has an IC₅₀ ofbetween about 1 nM and about 500 nM.
 13. The immunoconjugate of claim 1,wherein the antibody does not bind to Taci or BAFF-R.
 14. Theimmunoconjugate of claim 1, wherein the antibody binds to human BCMAwith an affinity of 5 nM or less, 1000 pM or less, 500 pM or less, 400pM or less, 300 pM or less, or 150 pm or less.
 15. A pharmaceuticalcomposition comprising the immunoconjugate of claim 1 and apharmaceutically acceptable carrier.
 16. A method of treating a humanpatient afflicted with a B cell mediated disease or disorder comprisingadministering to a patient a therapeutically effective amount of theimmunoconjugate of claim
 1. 17. The method of claim 16, wherein theB-cell mediated disease or disorder is B-cell lymphoma, non-hodgkinslymphoma (NHL), Multiple myeloma (MM), Chronic Lymphocytic Leukaemia(CLL), diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. 18.The method of claim 16, wherein the B cell related disorder or diseaseis multiple myeloma.